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ABSTRACT 
Osteoarthritis (OA) and Diabetes Mellitus (DM), especially type 2, are age-related 
diseases with increasing prevalence. Several epidemiological and experimental data 
support a strong relation between DM and the development and progression of OA 
which leads to the concept of Diabetes–associated OA. Understanding the underlying 
mechanisms is essential for developing prevention strategies and targeted therapies 
that are urgently needed to stop the growing incidence of OA and its huge socio-
economic costs. 
Hyperglycemia, as a hallmark of DM, is by hypothesis a major trigger of joint 
degradation in this concept of DM-associated OA. In this context, this work aimed to 
contribute to elucidate how extracellular glucose levels are sensed by human 
chondrocytes, in particular by determining the role of potassium channels in this 
process, and to further understand the mechanisms by which hyperglycemia induces 
cartilage damage, unraveling possible pathological mechanisms and potential 
pharmacological targets of DM-associated OA. Moreover, molecules, of plant origin, 
were studied to assess their anti-inflammatory and chondroprotective activities that can 
be explored for development of new drugs with disease-modifying osteoarthritis 
properties. 
In general, the results obtained show that: 
 Human chondrocytes of any OA grade present heterogeneous K(ATP) 
channels, with Kir6.2 and SUR2B being the major subunits expressed. 
 The activity of K(ATP) channels influences the abundance of the major glucose 
transporters, GLUT-1 and GLUT-3, in normal chondrocytes, but did not affected 
glucose transport, suggesting that these channels participate in a glucose-
sensing apparatus that regulates GLUT levels which, by themselves, are not 
sufficient to adjust glucose transport capacity. 
 Chondrocytes of increasing OA grade are less responsive to changes in K(ATP) 
channel activity.  
 Exposure of human chondrocytes to high, hyperglycemia-like glucose 
concentrations induces the expression of pro-inflammatory mediators, 
namely IL-1β, TNF-α and iNOS, accompanied by increased NO production, in a 
mechanism, at least partially, mediated by NF-κB. 
 Insulin, not only does not prevent the pro-inflammatory effects of hyperglycemia 
in human chondrocytes, as, in supraphysiologic concentrations, can induce NF-
κB activation by itself. 
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 The essential oils of Lavandula luisieri and Eryngium duriae subsp. juresianum 
display important anti-inflammatory properties, namely, significant inhibition of 
IL-1β-induced iNOS expression, NO production and NF-κB activation in human 
chondrocytes. Likewise, these essential oils may be of great value in the 
development of new therapies or as sources of active compounds for the 
treatment of chronic inflammatory diseases, like OA. 
 (+)-α-pinene, showed the most potent chondroprotective and anti-inflammatory 
activities among its isomers, enantiomers and other naturally occurring 
compounds derived from the pinane nucleus, by significantly inhibiting IL-1β-
induced inflammatory and catabolic pathways, namely, NF-κB and JNK 
activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and 
-13) genes. 
 Limonene and myrcene, natural compounds found in the essential oils of 
Eryngium duriae subsp. juresianum and Lavandula luisieri, showed interesting 
anti-inflammatory and anti-catabolic properties, namely inhibition of IL-1β-
induced NF-κB and p38 MAPK activation and expression of pro-inflammatory 
and catabolic mediators, namely NO, iNOS and MMP-1 and -13. 
 Myrcene further inhibits the phosphorylation of JNK and ERK1/2 MAPKs, which 
possibly contributes to the inhibition of pro-inflammatory, pro-catabolic and 
chondrocyte dedifferentiation genes, namely collagen type I, as well as to 
relieve the inhibition of TIMP-1 and -3 expression caused by IL-1β. 
In summary, a comprehensive view of the results suggests that if, on one hand, altered 
glucose sensing mechanisms and high glucose exposure lead to an increased 
expression of inflammatory mediators and pathways in chondrocytes, establishing a 
new link between DM and OA and supporting the existence of a DM-induced OA 
phenotype, on the other hand, those inflammatory and catabolic mediators and 
signalling pathways are major targets for the development of new drugs with disease-
modifying OA properties. Myrcene is an interesting lead compound for the treatment of 
this disease. 
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RESUMO 
A Osteoartrite (OA) e a Diabetes Mellitus (DM), especialmente tipo 2, são doenças 
relacionadas com o envelhecimento e, por isso, cada vez mais prevalentes. Estudos 
epidemiológicos e experimentais suportam a forte relação entre a DM e o 
desenvolvimento e progressão da OA, conduzindo ao aparecimento do conceito de OA 
associada à diabetes. A compreensão dos mecanismos subjacentes é essencial para 
o desenvolvimento de estratégias preventivas e terapêuticas específicas que são 
urgentemente necessárias para travar a crescente incidência da OA e os seus 
enormes custos socioeconómicos. 
A hiperglicémia, como característica fundamental da DM, é por hipótese um importante 
promotor da degradação da articulação, neste conceito de OA associada à diabetes. 
Neste contexto, o principal objectivo deste trabalho foi contribuir para o esclarecimento 
dos mecanismos pelos quais os níveis extracelulares de glucose são detectados pelos 
condrócitos, em particular a clarificação do papel dos canais de potássio dependentes 
de ATP [K(ATP)] neste processo e compreender os mecanismos através dos quais a 
hiperglicemia induz dano nos condrócitos. Compreender estes processos é essencial 
para evidenciar possíveis mecanismos patológicos e potenciais alvos farmacológicos 
para a OA associada à DM. Adicionalmente procurou-se identificar compostos com 
propriedades anti-inflamatórias e anti-catabólicas que justifiquem a sua exploração 
para o desenvolvimento de novos fármacos anti-osteoartríticos. Como fontes dos 
compostos a estudar, utilizaram-se extractos de plantas, a maioria constituintes da 
flora endémica da Península Ibérica, de modo a contribuir também para a valorização 
do nosso património biológico. 
Em geral, os resultados obtidos mostram que: 
 Condrócitos humanos de todos os graus de OA apresentam canais de potássio 
ATP dependentes [K(ATP)] heterogéneos, com múltiplas combinações de 
subunidades possíveis, mas parecendo a Kir6.2 e a SUR2B as subunidades 
mais expressas. 
 A actividade dos canais K(ATP) influencia a abundância dos principais 
transportadores de glucose, GLUT-1 e -3, nos condrócitos normais, mas não 
afecta o transporte de glucose. Isto sugere que estes canais participam num 
mecanismo sensor de glucose que regula os níveis dos GLUT, mas a 
modulação da sua actividade isoladamente não é suficiente para ajustar a 
capacidade de transporte de glucose em condrócitos. 
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 Os condrócitos de graus de OA mais elevados, isto é, em que a degradação da 
cartilagem é progressivamente mais extensa, respondem menos eficazmente 
ou não respondem a alterações na actividade dos canais K(ATP). 
 A exposição dos condrócitos a concentrações elevadas de glucose induz a 
expressão de mediadores pro-inflamatórios, nomeadamente a IL-1β, o TNF-α e 
a iNOS, acompanhada pelo aumento da produção de NO, através de um 
mecanismo, pelo menos parcialmente, mediado pelo NF-κB.  
 A insulina não só não previne os efeitos pro-inflamatórios da hiperglicemia nos 
condrócitos humanos mas ainda, em concentrações supra-fisiológicas, induz 
por si só a activação do NF-κB. 
 Os óleos essenciais de Lavandula luisieri e Eryngium duriaei subsp. juresianum 
apresentam importantes actividades anti-inflamatórias, nomeadamente a 
inibição significativa da expressão da iNOS, da produção de NO e da activação 
do NF-κB induzidos pela IL-1β. Assim, estes óleos podem ser de grande valor 
no desenvolvimento de novas terapias ou como fonte de compostos activos 
para o tratamento da OA 
 O (+)-α-pinene apresenta o maior potencial condroprotector e anti-inflamatório 
de entre os seus isómeros, enantiomeros e outros compostos naturais de 
núcleo pinano por inibir significativamente a activação de vias de sinalização 
inflamatórias e catabólicas induzidas pela IL-1β, nomeadamente a activação do 
NF-κB e da JNK e a expressão de genes inflamatórios (iNOS) e catabólicos 
(MMP-1 e -13). 
 O mirceno e o limoneno, compostos naturais encontrados nos óleos essenciais 
de Eryngium duriaei subsp. juresianum e Lavandula luisieri, mostraram 
interessantes propriedades anti-inflamatórias e anti-catabólicas, 
nomeadamente a inibição da expressão de mediadores pro-inflamatórios e 
catabólicos como o NO, iNOS, MMP-1 e -13 e da activação de vias de 
sinalização como a do NF-κB e a da p38MAPK. 
 Adicionalmente, o mirceno ainda inibe a fosforilação das MAPK, JNK e 
ERK1/2, o que possivelmente contribui para a inibição da expressão de genes 
pro-inflamatórios, pro-catabólicos e de desdiferenciação do condrócito, 
nomeadamente o colagénio I, e atenua a inibição da expressão dos genes anti-
catabólicos TIMP-1 e -3 causadas pela IL-1β. 
Em resumo, uma visão geral dos resultados sugere por um lado, que a alteração dos 
mecanismos de sensibilidade à glucose e a exposição a concentrações de glucose 
elevada conduzem a um aumento da expressão de mediadores e vias de sinalização 
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inflamatórias nos condrócitos, estabelecendo uma nova ligação entre a OA e a DM e 
suportando a existência de um fenótipo específico de OA induzida pela DM. Por outro 
lado, estes mediadores e vias de sinalização inflamatórios e catabólicos são alvos 
importantes para o desenvolvimento de novos fármacos com capacidade de modificar 
o curso da doença. O mirceno aparece como um composto lead interessante a ser 
explorado para o desenvolvimento de novas terapêuticas para a OA 
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CHAPTER 1.  
INTRODUCTION
 
 
Rheumatic and musculoskeletal conditions comprise over 150 diseases and 
syndromes which are usually progressive and associated with pain. The World Health 
Organization (WHO) classifies them as conditions that mostly affect joints, bones, 
cartilage, tendons, ligaments and muscles yielding a reduction of the range of motion in 
one or more areas of the musculoskeletal system. Included in this group are joint 
diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA); back and neck pain; 
osteoporosis and fragility fractures; soft tissue rheumatologic diseases as bursitis and 
tendinitis; injuries due to trauma (sports, accidents) and autoimmune diseases as 
Lupus erythematosus. Rheumatic diseases associated with age, like OA, are leading 
causes of morbidity and disability, yielding a great socio-economic burden whose 
prevalence continues to increase. Recent epidemiologic data [Arden and Nevitt, 2006; 
Neogi and Zhang, 2013; Zhang and Jordan, 2010] indicate that OA is the most 
common joint disorder in the world. According to the WHO, by 2050 people aged over 
60 will account for more than 20% of the world’s population. Of these 20%, it is 
estimated that about 15% will have symptomatic OA, and one-third of these people will 
be severely disabled. This means that by 2050, 130 million people will suffer from OA 
worldwide, of whom 40 million will be severely disabled by the disease [Goldring, 2006; 
Heidari, 2011; Kaplan et al., 2013]. 
The diagnosis and definition of OA are complicated; especially due to the discrepancy 
between the symptomatic and the radiographic evidences of the disease which are the 
major factors considered for diagnosis. For instance, 50% of subjects in the general 
population with radiographic evidence of knee OA do not have pain and 50% of 
subjects who complain of knee pain, and who are at or above the age when 
osteoarthritis starts to become common(about 55 years), have no definite radiographic 
evidence of OA [Heidari, 2011; Neogi and Zhang, 2013].  
In 1986, the American College of Rheumatology defined OA as “a heterogeneous 
group of conditions that lead to joint symptoms and signs, which are associated with 
defective integrity of articular cartilage, in addition to related changes in the underlying 
bone at the joint margins” [Altman et al., 1986]. 
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Since then, there was consensus that OA is usually a progressive disease affecting the 
whole synovial joint [Lane et al., 2011] and generally it can be characterized by a local 
chronic inflammation, pain, cartilage destruction and loss of joint function. 
Traditionally, OA was thought to be a normal consequence of mechanical use and 
ageing. With age it is unequivocal the accumulation of changes in the joint tissue 
composition and structure, reason why it is considered a primary risk factor for OA. 
Despite its importance, there are also elderly people that do not develop OA, so the 
recent paradigm for disease definition considers that, more than just an “age-related” 
and “wear and tear” disease, OA results from an interplay of multiple factors, including 
trauma, genetic pre-disposition, local inflammation, congenital malalignement of joints 
and cellular and biochemical insults resulting from metabolic conditions [Goldring and 
Goldring, 2007; Lane et al., 2011].  
Generally, OA is subdivided by aetiology into either, idiopathic, if no identifiable cause 
exists for development of the disease, which corresponds to the majority of the cases 
and does not affect people under 40 years old, or secondary, when it is caused or 
associated with an identifiable underlying condition that promotes joint vulnerability and 
development of OA lesions at younger age. In children or younger adults, trauma or 
joint insults resulting from sports practice or accidents as well as congenital 
malalignement of joints and consequent biomechanical instability are strongly 
implicated in the initiation of OA. Also hereditary predisposition, and metabolic and 
inflammatory disorders, as obesity and gout, can result in an earlier onset of the 
disease and be considered causes of secondary OA [Buckwalter and Martin, 2006; 
Goldring, 2006]. 
It is likely however, that for idiopathic OA, several risk factors contribute to the initiation 
and progression of the disease, including ageing, hereditary predisposition, mechanical 
factors (joint malalignement and overuse, trauma, etc.), gender, obesity and other 
metabolic factors as malnutrition and Diabetes Mellitus [Buckwalter and Martin, 2006; 
Goldring and Goldring, 2007; Katz et al., 2010].  
Even though the clinical manifestations and symptoms [Goldring and Goldring, 2007] 
are common to the multiple OA aetiologies, it is reasonable that each risk factor 
influences the joint in a particular way and increases the susceptibility to the disease 
and its progression through a variety of mechanisms [Felson, 2010; Kerkhof et al., 
2010]. This complexity and variability of OA aetiologies suggests the need of identifying 
risk factors, establishing distinct phenotypes and understanding in each way they 
contribute to the initiation and progression of the disease. Uncovering the molecular or 
biomechanical processes affected in the joint and the mechanisms underlying the 
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primary trigger are critical for the development of new treatments and new preventing 
strategies for OA [Berenbaum, 2008; Felson, 2010; Kerkhof et al., 2010; Wenham and 
Conaghan, 2013]. 
The factors that initiate OA likely vary depending on the joint site [Lane et al., 2011]. 
They can affect a single joint, a few joints or be generalized. The most commonly 
affected joints are the knees, hips, spine and hands [Goldring and Marcu, 2009]. 
Although most tissues of the joint, including subchondral bone, synovial membrane, 
joint capsule, periarticular muscles and tendons, are definitely involved in and may be 
affected by the disease pathogenesis [Attur et al., 2010; Brandt et al., 2006; Goldring 
and Goldring, 2010; Hulejova et al., 2007; Stone et al., 2013], it is the cartilage that is 
affected to the major extent and its alterations are the most “visible” face of the 
disease. 
In the first part of this chapter, we will make a brief overview to the anatomy and 
physiology of the synovial joint by presenting the structure and composition of the 
articular cartilage and the role of chondrocytes, the only cell type in the articular 
cartilage, in the maintenance of the tissue homeostasis. Then, the known OA risk 
factors and specific phenotypes already identified were also briefly described. Special 
emphasis will be given to Diabetes Mellitus (DM) and particularly to glucose 
physiological and pathological effects and its sensing and transporting mechanisms. 
Then, the major cartilage changes observed in OA will also be addressed, as well as 
the function and regulation of the catabolic and anabolic processes involved in OA 
pathology. 
Finally, we will make a short description of the current OA therapies, including the 
currently available treatments and the current investigation on drugs with capacity to 
stop OA progression. 
The second part of this chapter will be dedicated to presenting the objectives that 
determined this work, as well as the content and organization of this thesis. 
 
 
1.1 SYNOVIAL JOINTS AND ARTICULAR CARTILAGE 
 
Synovial joints allow movement at the point of contact of articulating bones. Joints of 
the knees, hips and hands are general examples of synovial joints that are the most 
affected in OA. These joints, as represented in figure 1.1, are characterized by the 
presence of a joint cavity surrounded by a capsule around the bone extremities, 
covered inside by the synovial membrane, and by the presence of a lubricating 
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synovial fluid. The bones extremities in a synovial joint are covered by a layer of 
hyaline cartilage, the articular cartilage, which is a stiff but at the same time flexible and 
elastic tissue. 
 
 
Figure 1.1 Schematic representation of the major structures of a synovial joint 
 
1.1.1 Structure and Composition of Articular Cartilage 
 
Articular cartilage is a specialized connective tissue that covers the bony surface of 
synovial joints. It is avascular and aneural and serves as a viscoelastic, load-bearing 
support tissue that absorbs impacts, resists to compression and provides a smooth 
surface with almost no friction during joint movement, without losing its original shape 
[Martel-Pelletier et al., 2008]. These unique biomechanical properties are given by its 
extracellular matrix composition and structure, namely by the collagen and 
proteoglycan network [Goldring, 2006]. 
The chondrocyte is the only cell type found in mature articular cartilage, thus it is 
responsible for the homeostatic process involving the synthesis and degradation of the 
cartilage matrix components and consequently for its biomechanical properties. The 
physical function of joints is critically dependent on the integrity of the matrix and so 
dependents on normal chondrocyte function. 
Proteoglycans and collagens are the most abundant macromolecules of the 
extracellular cartilage matrix and are ordered in distinct layers from the superficial to 
the deepest zones of the cartilage, reflecting different proportions, structural 
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organization and function. The superficial layer is the thinnest and consists of fine 
collagen fibrils with tangential orientation and low proteoglycan content. This zone is in 
contact with synovial fluid, and is responsible for most of the tensile properties of 
cartilage. The middle zone represents 40–60% of the total cartilage height. It is formed 
by proteoglycans and thicker collagen fibrils organized into radial layers. The deep 
zone contains the largest collagen fibrils in a radial disposition, and the highest 
aggrecan content. Finally, the calcified cartilage is divided from the other zones by the 
tidemark, and separates – physically and mechanically – the hyaline cartilage from the 
subchondral bone [Martel-Pelletier et al., 2008]. 
Despite the importance of collagen, proteoglycans and other supporting glycoproteins, 
they only represent 20% of the tissue wet weight. Chondrocytes represent 5% and the 
remaining is water and inorganic salts. This enormous water content, almost all 
associated with proteoglycans, is extremely important for the mechanical properties, 
especially elasticity and capacity to resist to compressive forces, but also for the 
nutrition and lubrication of the tissue [Martel-Pelletier et al., 2008; Mobasheri, 1998; 
Muir, 1995]. 
 
1.1.1.1 Collagens and Proteoglycans 
 
The collagen network provides the shape and form of the articular cartilage and is 
composed by several types of collagens, including collagen type II, which represents 
the major collagen type in the tissue (90-98% of total collagen), and collagens type XI, 
type IX and type XXVII. Collagen type VI, characteristic of the connective tissue is also 
present in a small percentage [Eyre, 2002; Goldring and Marcu, 2009]. It constitutes 
the collagen network close to the cells in the so-called territorial matrix and acts as an 
interface between the rigid interterritorial cartilage matrix and the chondrocyte. It is also 
involved in cell anchoring, as well as in matrix-cell signalling [Soder et al., 2002]. 
The collagen type II macromolecule is composed of 3 identical polypeptide chains – α1 
(II) chains – interconnected to form a triple helix, as represented in figure 1.2. Those 
helixes do not exist in an isolated form, but as fibrils resulting from the association of 
adjacent collagen molecules within the extracellular matrix and stabilized by crosslinks 
between the N-terminal telopeptide of one collagen molecule and the triple helix of 
another [Eyre, 2002]. Collagens type XI and type IX are also associated with the 
collagen type II fibrils, the first lying within the fibril and the second integrated in the 
fibril surface, providing protection to collagen type II and enabling interactions with the 
other non-collagen elements of the matrix, especially proteoglycans [Eyre et al., 2006]. 
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Figure 1.2 Schematic diagram of collagen type II fiber structure. Adapted from [Eyre, 
2002] 
 
The major non-collageneous components of the cartilage matrix are proteoglycans, in 
particular aggrecan which represents about 5% of the cartilage wet weight. It can be 
found in association with the polysaccharide, hyaluronic acid (HA), forming large 
aggregates stabilized by a small link protein through non-covalent bonds. [Hardingham 
and Fosang, 1995; Heinegard, 2009; Kiani et al., 2002]. 
Proteoglycans are a family of glycoconjugates formed by a central core protein around 
which several sulphated glycosaminoglycan (GAG) chains attach, as represented in 
figure 1.3 [Kiani et al., 2002]. Two types of GAG can link to the central core protein. 
The most abundant is chondroitin sulphate wherein 100 molecules can link to the core 
protein. The other is keratan sulphate, smaller and less abundant than chondroitin 
sulphate. Up to 30 molecules of keratan sulphate can link to the core protein. 
[Hardingham and Fosang, 1995; Heinegard, 2009]. 
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Figure 1.3 Schematic representation of proteoglycans linked to Hyaluronic acid. 
Adapted from [Hardingham and Fosang, 1995] 
 
At high concentrations, proteoglycans, and in particular the aggregates formed with 
HA, create a large osmotic swelling pressure that draws water into the cartilage. This 
osmotic pressure occurs because all of the negatively charged sulphated groups of 
chondroitin and keratan sulphates on the GAG chains of aggrecan carry with them 
positive ions such as Na+, generating a huge difference in ion concentration between 
the cartilage and surrounding milieu. The osmotic imbalance generated is responsible 
for water to flow and to be retained within the cartilage. The addition of water causes 
the aggrecan-rich matrix to swell and expand which is essential to the biomechanical 
properties of cartilage, namely its visco-elastic properties that allow the impact loading 
without permanent deformation [Hardingham and Fosang, 1995; Kiani et al., 2002]. In 
an exclusively biophysic perspective of the process, when the cartilage is submitted to 
a compressive force, an amount of the water retained in the tissue is released, in 
proportion to the load applied [Kiani et al., 2002]. Moreover, some authors also 
postulate that aggrecan, through the chondroitin sulphate chains, can protect collagen 
type II fibrils from degradation by collagenases, possibly via direct blocking of their 
binding sites [Hedlund et al., 1999].  
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Small amounts of other non-collagen molecules, including biglycan, decorin, 
fibromodulin, the matrilins and cartilage oligomeric matrix protein (COMP), are also 
present in the matrix. COMP acts as a catalyst in the formation of the collagen fibrils. 
Interactions between type IX collagen and COMP or matrilin-3 are essential for proper 
formation and maintenance of the articular cartilage matrix [Shakibaei et al., 2008]. 
The collagen/aggrecan network is a resilient, viscoelastic load-bearing structure that 
allows smooth movement and distributes loads applied to the joint. The type II collagen 
network gives cartilage its shape and tensile strength and provides a framework to 
resist the swelling pressure of aggrecan. On its hand, aggrecan resists to any fluid flow 
and is able to efficiently distribute water. Proteolysis of any of the components of the 
cartilage not followed by its respective resynthesis will imbalance the network 
compromising the tissue biomechanical properties [Eyre, 2002; Goldring and Marcu, 
2009; Hedlund et al., 1999; Kiani et al., 2002; Martel-Pelletier et al., 2008]. 
 
1.1.1.2 Chondrocyte 
 
Similarly to the other cartilage components, chondrocytes are distributed unevenly 
throughout the cartilage depth, being in general more abundant at the surface. 
Differences in the morphology and organization of chondrocytes can be a reflex of the 
mechanical environment given by the collagen architecture in the interterritorial matrix, 
and can be the reason for the different matrix compositions found along the tissue. 
Chondrocytes in the superficial zone (SZ) are small and flattened; those of the middle 
zone (MZ) are rounded with no organized orientation while those of the deep zone (DZ) 
are grouped in columns or clusters, as represented in figure 1.4. These cell distribution 
patterns are thought to derive from the formation and specific organization of the 
Extracellular Matrix (ECM) during joint development and maturation [Lotz et al., 2010]. 
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Figure 1.4 Schematic Representation of the different cartilage zones and chondrocytes 
distribution. Adapted from [Lotz et al., 2010] 
 
Due to the avascular nature of the articular cartilage, chondrocytes receive oxygen and 
nutrients mainly by diffusion form the synovial fluid and from the subchondral bone 
[Levick and McDonald, 1995; Zhou et al., 2004b]. For the same reason, chondrocytes 
live in a hypoxic environment when compared to most other tissues, with an average of 
5 to 6% oxygen tension in the cartilage surface and 2 to 3% at the interface with the 
bone [Henrotin et al., 2005; Zhou et al., 2004b]. The chondrocytes adapt to these 
conditions by using glycolysis as their main energy source [Lee and Urban, 1997; 
Rajpurohit et al., 1996] and give preference to it even when exposed to higher oxygen 
tensions [Schneider et al., 2007]. 
How chondrocytes maintain cartilage homeostasis remains somehow unknown, since 
under physiological conditions, they do not divide, have a low cartilage matrix protein 
turnover rate and the matrix structure only admits a few chondrocytes adjacent to each 
other which limits their interactions [Lotz et al., 2010]. However, in order to maintain 
this homeostasis, chondrocytes have to be able to sense matrix alterations and also to 
integrate and to be sensible to stimuli addressed to the cartilage. To achieve that, 
chondrocytes have to be sensible to: 1) direct interaction with the ECM components via 
different surface receptors, as those of integrin and annexin families, the hyaluronan 
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receptor, CD44, or the Discoidin Domain receptor 2 (DDR2) which binds collagen II 
when proteoglycans are depleted [van der Kraan et al., 2002; Xu et al., 2007]; 2) 
soluble mediators produced by the chondrocytes themselves or by any other articular 
or non-articular tissue, and, finally, 3) to mechanical stimuli, [Goldring and Marcu, 2009; 
Shakibaei et al., 2008; van der Kraan et al., 2002].  
Moreover, several studies indicate that although chondrocytes are normally quiescent, 
in response to any injury or abnormal stimulus they can shift to an activated form and 
enter on a remodelling program that includes catabolic (destructive) and anabolic 
(synthetic) processes. The normal function of chondrocytes and consequently the 
integrity of the cartilage are dependent on a variety of signals including mechanical 
forces and chemical mediators (cytokines, growth factors, hormones), and on the 
capacity of chondrocytes to integrate those signals without disrupting the homeostatic 
balance of the tissue [Goldring and Marcu, 2009; Martel-Pelletier et al., 2008]. 
 
1.2 OSTEOARTHRITIS RISK FACTORS AND SPECIFIC PHENOTYPES 
 
Epidemiological studies have been transforming the way how OA is seen. Firstly saw 
as an age-related and a “wear and tear” disease of the cartilage, OA is now considered 
a multifactorial disease affecting the whole joint where the identification of several risk 
factors, both endogenous and exogenous, played an unquestionable role [Michael et 
al., 2010].  
No longer misconceived as a uniform disease, OA is an heterogeneous disease with 
the failure of the joint function as the major outcome [Goldring and Goldring, 2007]. 
Different pathophysiological aetiologies resulting in the final common consequence of 
cartilage destruction have driven the division of OA into different phenotypes according 
to the respective major related risk factor. The definition of a phenotype should be 
confined to those factors that have a primary effect on disease biology and aetiology, 
and that can be significant to treatment and prevention [Felson, 2010]. Traditional risk 
factors for OA, namely age, trauma, genetic predisposition and obesity by inducing 
direct effects on cartilage destruction, through destabilizing catabolic and anabolic 
homeostasis and creating a low grade inflammatory environment, have already been 
associated with specific OA phenotypes [Neogi and Zhang, 2013]. Although they can 
be seen as independent, most of the times OA onset and progression does not depend 
on an individual risk factor alone but on a synergy of multiple factors. Genetics, for 
instance, plays an indubitable role in OA development and progression [Spector et al., 
1996]. However, its role is more likely due to an interaction among multiple genes, in 
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combination with further risk factors, as ageing. Moreover, the effects of obesity on the 
joint have been admitted, historically, as simply resulting from excessive mechanical 
loading. However, there is increasing evidence of multifactorial, systemic links between 
obesity and OA, since non-loading joints, as elbows and hands, are also affected by 
OA in obese patients [Sowers and Karvonen-Gutierrez, 2010]. 
The evidence of systemic factors involved in obesity related-OA also contributed to the 
definition of a metabolic-induced OA. This phenotype shares several similar 
biochemical and inflammatory features with the metabolic syndrome. Hypertension, 
dyslipidemias and conditions with altered glucose metabolism, as diabetes mellitus 
(DM), and their major characteristics, increased expression of adipokines, varying 
glucose concentrations and hormonal imbalance characterize the metabolic syndrome. 
When OA is also present it has been described as metabolic-OA. These characteristics 
have already been, either directly or indirectly, related with the mechanisms of OA 
pathology [Zhuo et al., 2012].  
Besides its relationship with obesity and the metabolic syndrome, DM is increasingly 
recognized as an independent risk factor for OA development and progression. Thus, it 
can define a new specific OA phenotype [Berenbaum, 2011]. Recent epidemiologic 
data further demonstrate a higher OA prevalence with an earlier onset and more 
severe manifestations in diabetic vs. non-diabetic patients [King et al., 2013; Martinez-
Huedo et al., 2013; Nieves-Plaza et al., 2013; Schett et al., 2012a]. Moreover, several 
experimental evidences show that hyperglycemia, one of the features of DM, can 
trigger events that can be related to cartilage destruction, as Reactive Oxygen Species 
(ROS) production and a low grade systemic inflammation further linking DM and 
hyperglycemia to OA incidence [Berenbaum, 2011]. 
 
1.2.1 Diabetes Mellitus and Osteoarthritis: Role of Extracellular glucose 
concentrations 
 
Diabetes mellitus (DM) is a group of chronic diseases characterized generally by high 
blood glucose levels that result from defects in the body’s ability to produce and/or use 
insulin efficiently. Together with OA, DM type 2 is one of the most important causes of 
mortality and morbidity in older individuals [Kaplan et al., 2013]. Injurious effects 
induced by DM can be related with several factors, including insulin or other pancreatic 
hormone levels, but hyperglycemia is probably the most significant [Yan and Li, 2013]. 
At normal physiological conditions, due to the avascular nature of cartilage, 
chondrocytes are under a particular environment where nutrients and oxygen only 
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arrive by diffusion from the synovial fluid and subchondral bone. Consequently 
chondrocytes must have the capacity to survive in an extracellular matrix with limited 
nutrients and low oxygen tensions. Several studies showed that these particular 
conditions of low oxygen tension are important for the normal synthesis of matrix 
components and to the maintenance of the differentiated chondrocytic phenotype [Das 
et al., 2010; McNulty et al., 2005] and that their disruption results on negative 
outcomes, namely contributing to the altered synthesis of structural and regulatory 
proteins [Das et al., 2010; Grimshaw and Mason, 2000; Grimshaw and Mason, 2001]. 
In terms of energetic needs, chondrocytes adapted to this limited availability of oxygen 
by using the glycolytic pathway as their major energetic source [Lee and Urban, 1997] 
and they use it even in the presence of high oxygen tensions [Lee and Urban, 1997; 
Schneider et al., 2007]. However, glucose serves not only as the major energy source, 
but also as an essential precursor for glycosaminoglycan synthesis. Thus, a stable 
supply of glucose is important for the tissue homeostasis [Goldring, 2006].  
In pathological conditions, glucose and oxygen supply may be affected by different 
factors. For example, studies of Otte and Hernvann (1992) relate the importance of 
glucose as a metabolic substrate and also emphasize the fact that glucose uptake is 
stimulated by catabolic cytokines in chondrocytes in the concentrations easily found in 
OA joints [Hernvann et al., 1992; Otte, 1991]. In addition, since chondrocytes receive 
glucose especially from the synovial fluid whose glucose concentrations reflect, in the 
majority of cases, the plasma concentrations, conditions like DM that affect glycemia 
will probably also affect the availability of glucose to articular chondrocytes [Brannan 
and Jerrard, 2006].  
Despite these observations, the role of the extracellular glucose concentrations on the 
chondrocyte functions is still largely unknown. From the in vitro and in vivo data 
available, however, it is possible to understand that both hypo- and hyperglycemic 
conditions may contribute to cartilage homeostasis breakdown and thus to OA onset 
and progression. Glucose deprivation has been shown to increase the expression of 
the Matrix Metalloproteinase 2 (MMP-2) [Richardson et al., 2003], that participates in 
cartilage degradation in late OA, and was associated with decreased expression of 
collagen type II and proteoglycans [Yang et al., 2005]. The effects of hyperglycemia in 
cartilage have been associated with the formation of advanced glycation end products 
(AGEs) [Verzijl et al., 2003], as mediators of matrix stiffness, subchondral bone 
destruction and chondrocyte dysfunction. Chronic hyperglycemia increases the 
occurrence of non-enzymatic glycation reactions, which are associated with oxidative 
stress, as illustrated in patients with diabetes [Gillery, 2006]. AGEs have been shown to 
CHAPTER 1 
29 
 
accumulate within the cartilage in amounts that increase with age [Verzijl et al., 2001]. 
Hiraiwa and Nah [2011] showed that AGEs mediate the expression of matrix-degrading 
enzymes and pro-inflammatory and catabolic mediators (MMP-1, MMP-13, COX-2; 
NO) [Hiraiwa et al., 2011; Nah et al., 2008; Nah et al., 2007] and DeGroot [2001 and 
1999] showed that they decrease collagen type II and proteoglycan expression in 
bovine chondrocytes. 
Notwithstanding the importance of AGEs on OA pathogenesis, it is important to note 
that the development of OA with aging is not inevitable, even though changes in the 
composition and structure of the cartilage matrix are. So, studies focused only on older 
individuals and in AGEs, generated in increased amounts during aging, would not 
completely explain the role of hyperglycemia in OA development [DeGroot et al., 1999; 
Goldring and Goldring, 2007; Verzijl et al., 2003]. 
Recent studies have focused on the direct effects of high glucose on the chondrocyte 
functions. Those studies clearly show that direct exposure of chondrocytes to high 
glucose affects the cartilage homeostasis, namely by interfering with the synthesis of 
ECM components. In one study, hypo- and hyperglycemia-like conditions induced 
resistance to Insulin-like Growth factor (IGF-1), an important anabolic factor in 
chondrocytes, thus contributing to decreased proteoglycan synthesis [Kelley et al., 
1999] and in another, exposure of human chondrocytes to high glucose concentrations, 
was shown to decrease dehydroascorbate transport, which can compromise the 
synthesis of collagen type II [McNulty et al., 2005]. On the other hand, another study 
from our group showed that collagen II mRNA was similarly increased in normal and 
OA chondrocytes, exposed to hyperglycemia-like conditions, but the increase lasted 
longer in the OA group [Rosa et al., 2011b]. Moreover, this study also showed that that 
exposure to high glucose (30 mM) increased the mRNA levels of matrix-degrading 
enzymes in OA chondrocytes, whereas in normal ones only MMP-1 was increased. 
Furthermore, exposure of human chondrocytes to high glucose also prevented anti-
catabolic effects of TGF-β both in normal and OA chondrocytes [Rosa et al., 2011b]. 
Finally, culture of chondrocytes under high glucose elicited a increase in ROS 
production. In OA chondrocytes the increase in ROS production was sustained for a 
longer period than in normal ones [Rosa et al., 2009]. Since ROS are involved in the 
pathophysiology of OA, high glucose-induced ROS production is likely to directly 
contribute to high-glucose induced cartilage damage. In vivo data corroborate these 
findings. Indeed, diabetic rats were associated with major alterations in matrix 
composition in the cartilage of the knee joints, namely with decreased expression of 
proteoglycans and collagen type II, the main structural component of the articular 
CHAPTER 1 
 
30 
 
cartilage, and increased expression of collagen type XI, that is not normally present in 
articular cartilage and is a marker of chondrocyte progression to hypertrophy and 
subsequent calcification [Atayde et al., 2012]. This finding may contribute to 
understanding the functional limitations of diabetic patients and the association of DM 
with OA. Although these observations of glucose effects on chondrocytes and cartilage 
may contribute to establish a correlation between DM and OA, strengthening the 
existence of a specific DM-induced OA phenotype, more studies are needed to 
understand how DM affects the development and progression of OA. Finally, a better 
knowledge of the specificities of a DM-induced OA phenotype should allow a targeted 
approach for the development of preventive and curative treatments for OA 
[Berenbaum, 2011]. 
 
1.2.1.1 Glucose sensing and transport 
 
As glycolytic cells, chondrocytes must be able to sense the quantities of oxygen and 
glucose available to them in the extracellular matrix and respond appropriately by 
adjusting cellular metabolism [Mobasheri et al., 2005]. As the concentrations of glucose 
available may vary, depending for instance on the pathological conditions, immobility 
and age, glucose transport becomes a critical step on the utilization and on the effects 
of this nutrient on chondrocyte functions [Mobasheri et al., 2002b; Shikhman et al., 
2001]. 
Glucose consumption seems to be dependent on the extracellular glucose 
concentrations [Schneider et al., 2007], suggesting that chondrocytes may adjust 
glucose transport and increase glucose storage, glycolysis, and production of 
proteoglycans [Lee and Urban, 1997] to the extracellular glucose concentration. 
Several reports show that high, hyperglycemia-like glucose concentrations play an 
important role in the development of diabetic complications. High glucose can induce 
the release of pro-inflammatory cytokines as Interleukin-1β (IL-1β), Interleukin-6 (IL-6), 
Tumor necrosis factor –α (TNF-α), and interleukin-18 (IL-18) [Asakawa et al., 1997; 
Esposito et al., 2002; Jiang et al., 2012] and other pro-inflammatory mediators, as Nitric 
Oxide (NO) [Askwith et al., 2011; Jia et al., 2013], in different cell types, activate pro-
inflammatory and pro-catabolic signalling pathways, as those of Nuclear Factor κB (NF-
κB) and p38 Mitogen Activated Protein Kinase (MAPK) [Igarashi et al., 1999; Yerneni et 
al., 1999], and induce the production of ROS [Busik et al., 2008; Yao and Brownlee, 
2010] and AGEs [Brownlee, 2005]. Chondrocytes express multiple isoforms of the 
facilitative glucose or solute carrier (GLUT/SLC2A) family of glucose/polyol transporters 
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[Mobasheri et al., 2008], including GLUT-1, GLUT-3, GLUT-5, GLUT-9, GLUT-10 and 
GLUT-11 which are responsible for the majority of the glucose transport capacity of 
these cells [Mobasheri et al., 2008]. Among those, GLUT-1 and GLUT-3, constitutively 
expressed in chondrocytes, are the isoforms better characterized, and both have high 
glucose affinity [Colville et al., 1993]. GLUT-1 seems to be regulated by anabolic and 
catabolic stimuli, while GLUT-3, is less affected by [Mobasheri et al., 2008; 
Peansukmanee et al., 2009; Shikhman et al., 2001]. Specifically, GLUT-1 was found to 
be increased in equine articular chondrocytes stimulated with TNF-α, IL-1β, IGF-I, 
TGF-β and insulin, while GLUT-3 was only upregulated by IGF-I [Phillips et al., 2005; 
Richardson et al., 2003]. GLUT-1 and GLUT-3 together with hypoxia-inducible factor 
alpha (HIF-1alpha) were proposed as potential components of the glucose and oxygen 
sensing apparatus in chondrocytes by promoting anaerobic glycolysis and favoring 
oxidative phosphorylation, which allow chondrocytes to survive in the adverse 
conditions of low glucose and oxygen supply [Mobasheri et al., 2008; Mobasheri et al., 
2005]. However, how human chondrocytes sense and modulate glucose transport, in 
health and disease and in the presence of different extracellular glucose 
concentrations, remains unclear. 
Recent studies showed that normal human chondrocytes respond to high extracellular 
glucose concentrations by decreasing glucose uptake, which occurs through 
downregulation of GLUT-1 content [Rosa et al., 2009]. This mechanism seems to 
protect the cells against excessive intracellular glucose accumulation. Moreover, this 
study showed that a different effect occurs in OA chondrocytes, which when exposed 
to high glucose concentrations were unable to downregulate GLUT-1 and glucose 
transport, leading to increased glucose accumulation and prolonged ROS production 
[Rosa et al., 2009]. Increased ROS production and, thus oxidative stress, are seen as a 
major deleterious mechanism in OA pathogenesis by mediating inflammatory and 
catabolic responses in chondrocytes [Grishko et al., 2009; Mendes et al., 2003a; 
Mendes et al., 2003b]. Moreover, these observations establish another link between 
DM and OA development since OA chondrocytes seem to be susceptible to 
hyperglycemic episodes as those occurring in DM patients, and thus particularly 
subjected to the deleterious effects of high glucose. 
Further research is needed to expand our understanding of glucosensing and glucose 
signalling in chondrocytes, and other joint tissues, in health and disease. 
Understanding how human chondrocytes sense extracellular glucose and adjust its 
uptake to match the cell’s needs and whether such mechanisms remain functional in 
OA chondrocytes is critical to elucidate the mechanisms by which conditions 
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associated with impaired glucose metabolism contribute to the development and/or 
progression of OA, and for further development of new therapies and identification of 
new therapeutic targets for treating this joint disorder. 
 
1.3 CARTILAGE CHANGES IN OSTEOARTHRITIS 
 
Cartilage degradation and loss, one of the OA hallmarks, occurs due to a disturbance 
of the balance between the reparative and degradative processes of the cartilage. The 
initiation and progression of OA, however, appear to be enclosed in a cyclic evolution 
plan where it becomes virtually impossible to understand which are the causes and/or 
the consequences, i.e., any factor that disturbs the tissue can contribute to the 
deregulation of the cell’s functions and to tissue alterations, which in turn will lead to 
more cell dysfunction and more ECM alterations. As an example, abnormal mechanical 
stress induces chondrocytes to produce Matrix Metalloproteinases (MMPs), which 
degrade matrix components, destroying the cartilage, while the ECM protein fragments 
generated interact with different receptors to induce the production of inflammatory 
cytokines, chemokines and more MMPs, expanding further matrix destruction [Fichter 
et al., 2006; Pulai et al., 2005]. 
Chondrocytes, because of their location and function, play a central role in OA 
pathogenesis which can be described as a result of their failure to maintain the 
homeostatic process, so that the rate of loss of collagens and proteoglycans from the 
matrix exceeds the rate of deposition of new molecules. This, in turn, involves multiple 
interactions between local and systemic factors [Buckwalter and Martin, 2006; Goldring 
and Goldring, 2007; Martel-Pelletier et al., 2008] and even though the aetiology of the 
disease is still largely unknown, the fact is that several risk factors, lead to the OA 
phenotype. The similarities observed in the pathological progression of the disease, 
even when the initiating models are different, indicate that common molecular 
sequences may underlie OA onset and progression [Castaneda et al., 2013].  
Regardless the nature of the factors that initiate the pathology, its progression follows a 
consistent pattern which includes chondrocyte phenotype alterations, increased 
general synthetic activity, increased expression of ECM degradative proteinases, 
gradual loss of proteoglycans and collagen type II, fibrillation and formation of 
fibrocartilage and osteophytes [Fosang and Beier, 2011]. In non-pathological 
conditions, the normally quiescent chondrocytes have a very low turnover, which is 
enough to ensure the replacement of long-lived ECM proteins, like aggrecan with a 
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half-life of 3-24 years [Maroudas et al., 1998] and collagen whose half-life is even 
greater of 100 years or more [Verzijl et al., 2000]. 
In the initial pathological conditions, mechanical stress, cytokines, matrix degradation 
products, age-related AGEs or any other factor that can disrupt the cartilage 
homeostasis [Hiraiwa et al., 2011] lead chondrocytes to a changed phenotype where 
they become “activated”, proliferate and form clusters and suffer an inappropriate 
hypertrophy-like maturation [Lotz et al., 2010]. Hypertrophic chondrocytes undergo a 
stress response associated with ECM remodelling in what can be seen as an attempt 
to repair the damages. In this active remodelling, however, the quality of the ECM is 
compromised due to the abnormal quick turnover rate, and to the atypical composition 
of the newly synthesized ECM proteins. In this period, there is expression of non-
cartilage specific collagens, like type X, normally confined to the cartilage-calcified 
zones close to the subchondral bone and only produced by hypertrophic chondrocytes, 
and collagen type I typically present in fibrocartilage and structurally different from type 
II. [Boos et al., 1999; Eyre et al., 2006; Lahm et al., 2010; Miosge et al., 2004]. Both 
collagen types have less capacity to interact with non-collagen cartilage molecules as 
proteoglycans and contribute to the formation of fibrocartilage, biomechanically less 
effective than the original one. In the late phases of the disease, this fibrocartilage 
contributes to further cartilage matrix degradation and loss [Lorenzo et al., 2004; 
Martel-Pelletier et al., 2008].  
Associated with this abnormal renovation, there is decreased expression and higher 
degradation of the naturally-occurring articular components, namely types IX, XI and II 
collagens and proteoglycans. It has been shown that there is a significant 
downregulation of aggrecan gene expression at the onset of OA in a rat model [Nam et 
al., 2011] and this finding agrees with markedly low proteoglycan synthesis observed in 
human cartilage samples from an early phase of the disease process, even before a 
clear fibrillation of the tissue is evident [Lorenzo et al., 2004]. 
Evidence suggests that the degradative process of the cartilage starts most of the 
times at its surface. The local loss of collagen type II results in an increased water 
content and loss of the tensile strength which is often observed in the early phases of 
the disease. Later, the combination of aggrecan and collagen loss leads to the 
increased overall stiffness of the tissue. A relationship between this degradation and 
the increased expression of proteinases, namely those responsible for the degradation 
of collagen type II and aggrecans, as MMPs (MMP-1, MMP-3 and MMP-13), and the 
aggrecanases, A Desintegrin And Metalloproteinase with ThromboSpondin motif 
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(ADAMTS)-4 and -5, was established [Bau et al., 2002; Okada et al., 1992; Shinmei et 
al., 1990; Yoshihara et al., 2000]  
An increasing number of evidences suggest that an important inflammatory process 
characterized by deregulated cytokine activities that can be triggered by any 
mechanical, biomechanical or molecular  factor involved in OA pathogenesis, yield 
alterations of chondrocyte functions that are likely to contribute to the described 
disruption of that balance between the anabolism and catabolism in OA [Goldring and 
Berenbaum, 2004]. 
 
1.3.1 Regulation of Catabolic and Anabolic Pathways 
 
1.3.1.1 Matrix Metalloproteinases and Aggrecanases 
 
Degradation of the cartilage ECM is a feature of arthritic diseases and a consequence 
of the upregulated catabolic process. The destruction seems to be driven by both 
Matrix Metalloproteinases (MMPs) and aggrecanases, which degrade the two major 
structural components of the cartilage extracellular matrix, the proteoglycan, aggrecan, 
and type II collagen. 
Several members of the ADAMTs family of enzymes (ADAMTS 1, 4, 5, 8, 9, and 15) 
have been identified in articular cartilage [Bau et al., 2002] and are known to be 
capable of cleaving aggrecan in different sites [Troeberg and Nagase, 2012]. 
ADAMTS4 and ADAMTS5 (aggrecanase-1 and aggrecanase-2, respectively) seem to 
be the most active aggrecanases and their depletion [Song et al., 2007] was 
associated with lower proteoglycan degradation and slower OA progression [Majumdar 
et al., 2007]. 
Along with aggrecan breakdown, degradation of collagen is a central feature of OA, in 
a process that is extensively mediated by MMPs. These are a family of zinc-dependent 
proteinases and although they can, similarly to ADAMTs, participate in the degradation 
of all the ECM proteins, collagen is their main target [Burrage et al., 2006; Cawston and 
Wilson, 2006; Patwari et al., 2005]. They can be categorized in different groups 
according to their preferable substrate and tissue location: the collagenases (MMP-1, -
8, -13), which degrade the fibrillated collagens (types I, II and III), the gelatinases 
(MMP-2, -9), which target denaturated polypeptide chains of types IV and II collagen 
and, finally, the stromelysins (MMP-3, -10, -11) and the membrane-type MMPs (MMP-
14, -15, -16, -17, -24, -25) which degrade non-collagen matrix proteins, as aggrecans, 
fibronectin and elastin and participate in the activation of other MMPs [Burrage et al., 
CHAPTER 1 
35 
 
2006]. Generally, the collagenases (MMP-1, -8 and -13) cleave the collagen type II 
triple helix allowing further degradation of the released chains by gelatinases (MMP-2 
and -9). Even though all the collagenases were able to effectively cleave the triple 
helix, they seem to have a substrate preference, with MMP-13 being the most 
expressed in chondrocytes and preferably cleaving collagen type II. Although MMP-1 
preferentially cleaves collagen III, it also effectively cleaves type II collagen and both 
MMPs were found to be overexpressed in OA joints [Bau et al., 2002; Konttinen et al., 
1999; Troeberg and Nagase, 2012; Yoshihara et al., 2000]. 
Additionally, MMPs participate in other processes that indirectly contribute to further 
cartilage breakdown, as is the case of MMP-3 that seems to be involved in the 
activation of MMP-1 and MMP-13 [Troeberg and Nagase, 2012; van Meurs et al., 
1999]. 
Given the destructive potential of MMPs and their abnormal high levels in OA, 
abolishing or even just reducing their pathologic levels are interesting strategies for 
development of new disease-modifying OA drugs. 
Several factors and mechanisms have been associated with increased expression of 
the matrix-degrading enzymes observed in OA cartilage. The primary one is probably 
the abnormal mechanical loading. In vivo studies showed that immobilization leads to 
joint damage by upregulating MMP-3 and ADAMTS-5, while mechanical stimulation of 
moderate intensity has the opposite effect, increasing aggrecan and decreasing MMP-
3 [Leong et al., 2010a; Leong et al., 2010b]. Nevertheless, abnormal mechanical stress 
can be sensed by chondrocytes resulting in an increased stimulation of matrix-
degrading proteins [Fujisawa et al., 1999]. 
In addition, several other studies showed that activation of mechanical receptors is not 
the only cause of the upregulated expression of these proteinases. The stronger 
evidence rests on the role of pro-inflammatory mediators, namely, cytokines (IL-1β and 
TNF-α) [Fernandes et al., 2002; Kapoor et al., 2011], chemokines [Lotz et al., 1992], 
prostaglandins [Mohamed-Ali, 1995] and Nitric Oxide (NO) [Abramson, 2008]. 
Chondrocytes in OA cartilage express receptors that respond to those mediators, 
produced by chondrocytes themselves or by the synovium and other periarticular joint 
tissues, resulting in an increased expression of MMP-1,-3, -9 and -13 [Burrage et al., 
2006]. Moreover also integrins and matrix proteins fragments (collagen and fibronectin) 
have been associated with cartilage damage through the production MMPs and 
aggrecanases and through an amplification feedback by induction of the production of 
pro-inflammatory cytokines [Fichter et al., 2006; Loeser et al., 2003]. 
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The synthesis of MMPs is highly regulated at the transcriptional level [Burrage et al., 
2006; Murphy and Lee, 2005] and regardless of the mechanism that triggers their 
overexpression, the same signalling pathways seem to be involved. Several evidences 
showed that, among others, signalling pathways of Activator Protein-1 (AP-1) and NF-
κB transcription factors together with those of MAPKs are key pieces on the regulation 
of the expression of the matrix-degrading enzymes in human chondrocytes 
[Barchowsky et al., 2000; Mengshol et al., 2000]. At a post-transcriptional level, MMPs 
are regulated by the Tissue Inhibitors of the Metalloproteinases (TIMPs) [Cawston and 
Wilson, 2006]. The inhibition of MMP activity by TIMPs involves non-covalent binding in 
a 1:1 stoichiometry to the active site of the target MMP [Burrage et al., 2006]. 
Generally, TIMPs-1 to -4 can inhibit all MMPs, but are also effective in inhibiting 
aggrecanases. For example, TIMP-3 blocks all the MMPs [Burrage et al., 2006] and 
also ADAM-17 [Amour et al., 2000] and ADAMTS-4 and -5 [Burrage et al., 2006; 
Kashiwagi et al., 2004].  
Regardless of the natural role of MMPs in cartilage homeostasis, in the pathologic 
environment of an arthritic joint, their elevated levels usually exceed those of TIMPs 
[Dean et al., 1989] which contributes to cartilage degradation in OA [Martel-Pelletier et 
al., 1994]. 
 
1.3.2 Inflammatory Process in OA 
 
OA is not considered a classical inflammatory disease, especially due to the 
intermittent influx of inflammatory cells into the joint and the sparse characteristic signs 
of inflammation, such as redness and swelling with heat during the course of the 
disease when compared to other inflammatory arthritic diseases, namely, rheumatoid 
arthritis (RA). However, several reports have demonstrated the overproduction and 
expression of proinflammatory mediators including NO, inducible nitric oxide synthase 
(iNOS), Cycloxigenase 2 (COX-2), IL-1β, TNF-α, IL-6, and IL-8 in OA cartilage. This 
inflammatory response, seen as a chronic low-grade inflammation and so called 
“molecular inflammation”, even though not reflected by clinical signs of inflammation, 
leads to an imbalance of cartilage homeostasis that results in progressive breakdown 
[Attur et al., 2000; Fernandes et al., 2002; Sokolove and Lepus, 2013]. It is now 
significantly clear that inflammation is present in OA joints well before the development 
of significant radiographic changes, suggesting that the cartilage damage in OA can be 
driven by an articular inflammatory process [Attur et al., 2000; Ayral, 2005; Fernandes 
et al., 2002; Haywood et al., 2003; Ishii et al., 2002]. So, any factor that triggers the 
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excessive production of proinflammatory mediators can contribute to the initiation and 
progression of this pathology. 
Although the mechanism by which production of inflammatory mediators is initiated is 
unclear, several factors, including mechanical and metabolic, have been related with 
the induction of cytokines and chemokines, ROS, in particular NO, as well as 
inflammation-related enzymes, like COX-2, and iNOS in the joint tissues and, 
particularly, in cartilage. Evidences from in vivo and in vitro studies indicate that 
chondrocytes can produce and/or respond to a number of cytokines and chemokines 
that are present in OA joint tissues and fluids [Berenbaum, 2004; Berenbaum, 2013; 
Goldring and Goldring, 2007]. Synovial inflammation for instance is a factor that likely 
contributes to deregulation of chondrocyte functions with the levels of catabolic 
enzymes and inflammatory mediators, such as prostaglandins and NO, and the levels 
of IL-1β and TNF-α in OA synovial fluids and joint tissue favoring the imbalance 
between the catabolic and anabolic activities of the chondrocyte [Loeser, 2006; Loeser 
et al., 2012]. 
The major role of the inflammatory mediators in OA pathogenesis is related with their 
activity on the catabolic and anabolic programs of the chondrocyte [Berenbaum, 2013]. 
The upregulation of the proinflammatory genes generally results in increased levels of 
catabolic enzymes, as MMPs and aggrecanases, decreased synthesis of ECM 
proteins, as collagen type II and aggrecan, and anti-catabolic mediators, as TIMPs 
contributing, in this way, to the progressive cartilage degradation [Clancy et al., 2004; 
Goldring and Goldring, 2007; Marcu et al., 2010]. These processes involve the 
activation of different transcription factors and signalling pathways, in particular those 
of NF-κB and MAPK. 
 
1.3.2.1 Regulation and Function of Inflammatory Mediators in Osteoarthritis 
 
1.3.2.1.1 Cytokines 
 
Pro-inflammatory cytokines were found to be highly expressed in the synovial fluid, 
synovial membrane, subchondral bone and cartilage of the joints affected by OA and 
can be produced not only by chondrocytes, but also by other joint tissue cells 
[Berenbaum, 2013; Kapoor et al., 2011; Kobayashi et al., 2005; Loeser et al., 2012; 
Meats et al., 1980]. 
In OA, pro-inflammatory cytokines are known to induce the catabolic and inhibit the 
anabolic programs. This translates into an increase of inflammatory mediators and 
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proteolytic enzymes, and decreased synthesis of matrix components and TIMPs. 
Additionally, those cytokines also promote the induction of cell death, mainly by 
apoptosis, at least in part mediated by inflammatory mediators such as NO [Abramson, 
2008; Blanco et al., 1995; Fernandes et al., 2002; Kapoor et al., 2011]. These 
mechanisms make them critical mediators of cartilage breakdown and of disease 
amplification and progression [Kapoor et al., 2011] 
Although several cytokines (i.e. IL-15, IL-17, IL-18) [Fernandes et al., 2002; Kapoor et 
al., 2011] have been shown to be upregulated in OA joints and definitely contribute to 
the pathology establishment [Goldring and Goldring, 2007; Melas et al., 2014], both in 
vitro and in vivo studies evidence that, IL-1β and at a lower extent TNF-α are  major 
players [Kapoor et al., 2011], by deregulating chondrocyte anabolic and catabolic 
responses. The deleterious effects of IL-1β and TNF-α are mainly associated with the 
upregulation of proteolytic enzymes. In response to these cytokines, OA chondrocytes 
produce a variety of matrix degrading enzymes, including MMP-1, MMP-3, MMP-8, 
MMP-13 and aggrecanases, as ADAMTS-4 and ADAMTS-5 [Lefebvre et al., 1990; 
Liacini et al., 2003; Reboul et al., 1996][Maldonado and Nam, 2013; Pelletier et al., 
1995; Tetlow et al., 2001] On the other hand, the synthesis and expression of the 
natural MMPs inhibitors, TIMPs [Dean et al., 1989; Lefebvre et al., 1990], is inhibited, 
further promoting the degradative process. Moreover, other matrix-degrading enzymes 
are activated by IL-β in chondrocytes, namely glucosidases, responsible for GAG’s 
degradation, which increases the spectrum of degradation sites activated by this 
cytokine and that contributes to further damage [Shikhman et al., 2000].  
Moreover, the negative effects of IL-1β and TNF-α are also felt in the ECM protein 
synthesis. TNF-α has been shown to suppress the synthesis of proteoglycans, link 
protein and collagen type II in chondrocytes [Saklatvala, 1986; Seguin and Bernier, 
2003], while the expression of collagens type II and type IX and aggrecan is 
downregulated in IL-1β-treated chondrocytes from different species [Chadjichristos et 
al., 2003; Goldring et al., 1988; Nietfeld et al., 1990a; Nietfeld et al., 1990b; Shakibaei 
et al., 2005; Stove et al., 2000]. At the same time, IL-1β upregulates the expression of 
the non-cartilage specific collagens type I and type III in human chondrocytes [Goldring 
et al., 1988].  
IL-1β and TNF-α further promote the perpetuation of the disease by inducing the 
expression of pro-inflammatory cytokines, including their own and IL-17, IL-18 [Kapoor 
et al., 2011] and IL-6 [Reboul et al., 1996], and chemokines, as IL-8 [Lotz et al., 1992]. 
Additionally, IL-1β is responsible for the upregulated gene expression and production of 
other inflammatory mediators implicated in cartilage degradation in OA. Prostaglandin 
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E2 (PGE2) [Kojima et al., 2004] and NO result from the IL-1β-upregulated expression 
and activity of COX-2 and iNOS, respectively [Goldring and Goldring, 2007; Taskiran et 
al., 1994]. 
Whichever the factor considered that drives OA, the mechanisms underlying its 
pathogenesis and onset have been linked to the presence or to the production of IL-1β 
and, to a lower extent, of TNF-α (Figure 1.5). For instance in age-related OA, cell 
senescence is associated with a high secretory capacity, in a process called 
senescence-associated secretory phenotype (SASP), that includes the secretion of 
inflammatory mediators, in particular IL-1β [Coppe et al., 2010; Loeser, 2013]. Also, 
post-menopausal- [Richette et al., 2007], mechanical- or post-traumatic- and obesity- 
[Issa and Griffin, 2012] triggered OA subtypes have been associated with the 
upregulated expression of IL-1β in human chondrocytes.  
All these evidences make pro-inflammatory cytokines and the subsequent events they 
initiate important basis of study in OA. How is the disease triggered and what events, 
factors and mechanisms can contribute to trigger the inflammatory process that results 
in structural damage of cartilage are questions of primary importance in order to 
discover disease-modifying OA drugs capable of stopping the progression of the 
disease and/or reverse the degradative process. 
Figure 1.5 Schematic representation of the cytokine role on the OA pathogenesis. Risk 
factors contribute to the upregulated levels of the pro-inflammatory cytokines, as IL-1β 
and TNF-α in the OA joint. Those cytokines contribute to the pathogenesis through 
several mechanisms including downregulation of anabolic events and upregulation of 
CHAPTER 1 
 
40 
 
catabolic and anabolic responses, effects that lead to the homeostatic imbalance that 
result on structural damage of the OA joint 
 
1.3.2.1.2 Nitric Oxide 
 
Among the inflammatory mediators upregulated in OA chondrocytes, NO seems to 
have a prominent role. Several studies suggest that it can have different functions in 
normal and pathological joint conditions that appear to depend on the concentrations of 
NO found. In the cartilage of the OA joint, NO production is increased, and this 
excessive amount of NO has been mainly considered a catabolic factor that may be 
responsible for perpetuating the release of pro-inflammatory cytokines and other 
catabolic processes involved in OA process [Abramson, 2008]. 
Nitric oxide synthesis is catalyzed by one of the three isoforms of the nitric oxide 
synthase (NOS), iNOS, eNOS and nNOS. The inducible isoform, iNOS, is upregulated 
in OA chondrocytes, as result for example of mechanical stress, induced by abnormal 
compressive and shear forces [Fermor et al., 2001; Lee et al., 2003], pro-inflammatory 
cytokines, like TNF-α, IL-1β and IL-17 [Mendes et al., 2002a; Pacquelet et al., 2002; 
Palmer et al., 1993] or even as result of the presence of collagen [Chowdhury et al., 
2010] and fibronectin fragments [Yasuda et al., 2004]. The upregulation of iNOS results 
in the overproduction of NO in OA joints [Melchiorri et al., 1998]. NO itself plays a role 
in perpetuating the release of inflammatory cytokines and other catabolic factors 
contributing to the positive loop on the inflammatory process found in OA joints. For 
instance NO is, in part, responsible for the synthesis of caspase 1 or Interleukin-1-
coverting enzyme [Boileau et al., 2002], the enzyme responsible for the activation of IL-
1β and IL-18 and for downregulation of its natural inhibitor, the protease inhibitor 9 
(PI9), thus sustaining the inflammatory response by promoting the maturation of 
inflammatory cytokines [Boileau et al., 2002]. It also participates in the activation of the 
AP-1 [Mendes et al., 2002c] and NF-κB [Abramson, 2008], transcription factors that 
critically mediate the gene expression of inflammatory mediators, like IL-1β, TNF-α and 
iNOS itself, and catabolic factors, as MMPs [Boileau et al., 2002; Sasaki et al., 1998; 
Xie et al., 1994]. 
Apart from its role in sustaining the inflammatory process in OA, NO also participates in 
the modulation of proteoglycan, collagen and MMPs expression. It has been shown 
that NO mediates IL-1β-induced suppression of proteoglycans and collagen synthesis 
in human chondrocytes [Taskiran et al., 1994], increases the gene expression of MMP-
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1, -2, -3 and -9 in rabbit articular chondrocytes [Sasaki et al., 1998] and suppresses the 
endogenous activity of TIMP-1 in human chondrocytes [Ridnour et al., 2007]. 
On the other hand, several other studies, in part, counteract the observations above 
showing that NO also have an important role on the maintenance of normal joint 
conditions. In human chondrocytes, it was shown that the IL-17- induced NO 
production suppresses the matrix synthesis and protects cartilage from matrix 
breakdown [Cai et al., 2002]. It also seems to promote procollagen synthesis in tendon 
cells [Xia et al., 2006]. It is also contradictory the information regarding the pro-
inflammatory activity and the cartilage protection yield by NO. Henrotin (1998) showed 
that, in human chondrocytes, NO reduces the synthesis of PGE2, IL-6 and IL-8 
[Henrotin et al., 1998] and Rosa (2008) showed that NO can also help to downregulate 
NF-κB activity [Rosa et al., 2008]. Moreover, in an animal model of OA where the iNOS 
gene was silenced, the inflammatory symptoms were exacerbated, as well as cartilage 
degradation [McInnes et al., 1998; Veihelmann et al., 2001].  
Given the variety of catabolic but also protective effects of NO in the chondrocytes, its 
production, as a potential target for disease-modifying therapy for OA must be carefully 
managed. Both the inhibition of iNOS, for inhibition of the high amounts of NO 
associated with catabolic events and the NO donation might have benefits on OA 
treatment [Abramson, 2008].  
 
1.3.2.1.3 Nuclear Factor – κB (NF-κB) 
The upregulation by IL-1β and TNF-α of COX-2, MMP-13, iNOS and other central 
molecules of the osteoarthritic process is mediated by the induction and activation of 
transcription factors and signalling pathways including NF-κB and AP-1 which are 
involved generally in stress and inflammation-induced signalling [Goldring and 
Goldring, 2007]. Among the signalling pathways involved in the initiation and 
amplification of inflammatory responses and tissue destruction, the transcription factor 
NF-κB is regarded as its primary regulator [Tak and Firestein, 2001]. NF-κB represents 
a family of proteins sharing a Rel homology domain in their N-terminus that include NF-
κB1 (p50 and its precursor p105) and NF-κB2 (p52 and its precursor p100) Rel A (p65), 
Rel B, c-Rel (REL). This Rel domain is responsible for homo- and heterodimer 
formation, for the interaction with inhibitory molecules and for binding to the promoter 
sequences of target genes [Ge et al., 2011; Hayden and Ghosh, 2008a; Oeckinghaus 
and Ghosh, 2009]. This transcription factor takes part of the normal physiology of cells; 
however, the inappropriate regulation of its activity has been implicated in the 
pathogenesis of diverse pathologies [Marcu et al., 2010] with several studies showing 
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that NF-kB dimers are abundant in arthritic joints, especially in those affected by OA [Li 
et al., 2012; Rosa et al., 2008]. 
 
Figure 1.6 Schematic representation of the canonical NF-κB activation in response to 
pro-inflammatory cytokines. Adapted from [Hayden and Ghosh, 2008a] 
 
NF-κB belongs to a family of “fast-acting” primary transcription factors, i.e., transcription 
factors that are present in the cells in an inactive state and that do not require new 
protein synthesis to become activated. In resting cells, the NF-κB dimers are 
sequestered by a family of inhibitors, called IκBs, of which IκB-α is the most studied. 
When bound to NF-κB, these inhibitors function by masking the nuclear localization 
sequence (NLS) in one of the subunits of the heterodimer, allowing it to cycle between 
the nucleus and the cytoplasm without binding to DNA [Ghosh and Karin, 2002; 
Hayden and Ghosh, 2008a]. 
The canonical NF-κB pathway, as represented in figure 1.6 has been closely related to 
the inflammatory response. This classical NF-κB activation pathway requires the 
phosphorylation and subsequent proteossomal degradation of the inhibitory IκB-α, 
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which releases NF-κB dimers, commonly made of p65 (or RelA) and p50 proteins 
[Hayden and Ghosh, 2008a; O'Dea and Hoffmann, 2009]. Free dimers translocate to 
the nucleus to activate the transcription of target genes, particularly those of pro-
inflammatory cytokines (e.g. IL-1β, TNF-α), chemokines (e.g. CXCL-8) and 
inflammation-associated enzymes (iNOS and COX-2) [Hayden and Ghosh, 2008b].  
In the context of OA, NF-κB can be triggered by several distinct factors and 
mechanisms generated or not within the cartilage. Mechanical stress [Agarwal et al., 
2004; Ferretti et al., 2006; Knobloch et al., 2008], pro-inflammatory mediators, in 
particular IL-1β and TNF-α [Frank et al., 2013; Hayden and Ghosh, 2008a], iNOS 
[Aktan, 2004] or even ECM protein fragments [Chowdhury et al., 2010; Pulai et al., 
2005] are known to activate this transcription factor [Uwe, 2008; Yasuda, 2011]. Either 
acting by itself or in coordination with other mediators or signalling cascades, NF-κB 
induces additional expression of inflammatory genes, impairs the anabolic activity and 
directly enhances the secretion of several matrix-degrading proteinases [Fan et al., 
2006; Ge et al., 2011; Mengshol et al., 2000; Stove et al., 2000]. More specifically, NF-
κB seems to be involved in every step of the cartilage change that occurs in OA. In the 
OA cartilage, the responses induced by the chondrocytes with a degradative 
phenotype were NF-κB mediated and included the production of MMP-1, MMP-3, 
MMP-8, MMP-13, ADAMTS-4 and ADMATS-5 [Liacini et al., 2003; Liacini et al., 2002], 
increased expression of COX-2 and PGE2, iNOS and its product, NO, IL-1β, IL-6, TNF-
α and type X collagen, thus directly contributing to the increased cartilage degradation 
and further chondrocyte hypertrophy [Goldring and Marcu, 2009]. Thus, it is clear that 
in OA, NF-κB is part of a positive loop, resulting in a sustained activation of this 
transcription factor and, in additional expression of inflammatory genes and catabolic 
mediators further contributing to cartilage degradation. 
Moreover, NF-κB activation also results on the expression of other regulatory factors, 
including E74-like factor 3 (ELF3), hypoxia-inducible factor-2alpha (HIF-2), runt-related 
transcription factor 2 (RUNX2) and Bone morphogenic protein-2 (BMP-2), which further 
trigger the hyperthrophic state of the chondrocyte [Goldring, 2012]. 
Regarding its pivotal role in OA onset and progression, NF-κB is regarded as an 
important therapeutic target. However, given its importance for cell survival and 
maintenance, targeted strategies have to be weighted in order to not cause unwanted 
side effects due to complete inhibition [Uwe, 2008]. Targeting specifically the canonical 
activation of NF-κB, namely IκB-α phosphorylation and the upstream events may 
prevent the high activation of this transcription factor that contributes to cartilage 
degeneration in OA pathology [Marcu et al., 2010] 
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1.3.2.1.4 Mitogen Activated Protein Kinases (MAPK) 
 
Together with NF-κB, MAPKs pathways are key regulators of the chondrocyte 
functions, both during development and in adult cartilage [Thalhamer et al., 2008]. 
MAPK are a family of Ser/Thr kinases formed by 4 subfamilies of kinases with different 
isoforms, including c-Jun NH2- terminal kinase (JNK), p38 and extracellular signal-
regulated kinase (ERK), each presenting isoforms [Johnson and Lapadat, 2002]. 
MAPK are activated by phosphorylation of specific Thr and Tyr residues by MAPK 
kinases (MKKs). Such phosphorylation can be triggered by a great range of factors, 
namely cytokines, growth factors and/or integrin-mediated signals which activate 
downstream events that result on the activation of one or more MAPK. Once activated, 
the MAPK in turn, activate other protein kinases and several transcription regulatory 
proteins, including ERK activation of Elk-1 and c-Myc, p38 activation of ATF-2 and 
MEF2, and JNK activation of c-Jun (figure 1.7). These transcription factors regulate the 
expression of a set of genes relevant to OA, namely some involved in the inflammatory 
response, regulation of cell proliferation, and production of matrix-degrading enzymes 
[Berenbaum, 2004; Loeser et al., 2008]. JNK may be particularly relevant due to its role 
in the activation of c-jun [Han et al., 2001; Johnson and Nakamura, 2007; Kristof et al., 
2001], a key AP-1 component essential for the expression of MMPs and pro-
inflammatory cytokines, such as TNF-α and IL-1β [Loeser et al., 2008] and other pro-
inflammatory mediators, as iNOS and NO [Kristof et al., 2001; Mendes et al., 2003b] 
CHAPTER 1 
45 
 
 
Figure 1.7 Several receptors, including growth factor, cytokine, and integrin receptors, 
activate signalling pathways which lead to the activation of the MAP kinase pathways. 
MAP kinase kinase kinases (MAPKKKs) activate MAP kinase kinases (MKKs; MAP 
and ERK kinase or MEK), which in turn activate the MAP kinases (p38, ERK1/2, and 
JNK). The MAP kinases activate other kinases, such as p90RSK, and transcription 
factors that regulate gene transcription, including Elk-1, MEF2, ATF2, c-Myc, Ets-1, 
and c-Jun. In this way, all three MAP kinases are involved in the expression of matrix 
metalloproteinases (MMPs) and other mediators involved in the development of OA. 
Adapted from [Loeser et al., 2008] 
 
Several evidences attest the activity of all three MAPK in OA. Levels of phosphorylated 
JNK [Clancy et al., 2001] and p38 [Fan et al., 2007] are higher in human OA cartilage 
compared to normal cartilage. The higher activation of MAPK has been mainly 
associated with increased expression of MMPs and aggrecanases, but also with 
modulation of anabolic activities in the cartilage of several species [Fan et al., 2006; 
Liacini et al., 2003; Liacini et al., 2002; Liacini et al., 2005; Sylvester et al., 2012]. As 
examples of the deleterious MAPKs’ activity in the cartilage, IL-1β- and TNF-α-induced 
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expression of MMP-1, MMP-13 and aggrecanase 1 and downregulation of collagen 
type II in chondrocytes requires JNK and p38 activation [Fan et al., 2006; Liacini et al., 
2003; Liacini et al., 2002; Liacini et al., 2005; Sylvester et al., 2012], and the 
modulation of anabolic and catabolic activities by collagen type II and fibronectin 
fragments is mediated by MAPK activation [Chowdhury et al., 2010; Loeser et al., 
2003; Mengshol et al., 2000; Sondergaard et al.]  
All three MAPK are involved in the expression of MMPs and other factors involved in 
the development of OA. In the majority of cases, the mediation of cartilage destruction 
did not address a specific MAPK, but two MAPK or the three MAPK signalling 
pathways. Contrariwise, the inhibition of a single MAPK seems to be, in most cases, 
enough to inhibit the increased expression of MMPs or aggrecanases. For example, IL-
1β stimulation of MMP-13 production requires the activation of both JNK and p38 
[Mengshol et al., 2000] and fibronectin fragments activate ERK1/2, p38 and JNK1/2, 
but inhibition of one of the three MAPK is enough to inhibit the fibronectin fragments-
stimulated MMP-13 expression [Loeser et al., 2003]. 
Besides the role of MAPK in mediating the catabolic function of chondrocytes, several 
studies also showed that they take part on deregulated anabolic processes observed in 
OA. Activation of ERK and p38 was associated with inhibition of aggrecan expression 
[Masuko et al., 2007] and the LPS-inhibited synthesis of proteoglycans in chondrocytes 
can be partially reversed by inhibition of p38 [Bobacz et al., 2007]. 
 
 
1.4 OA TREATMENT 
 
According to the World Health Organization, OA is among the high burden diseases, in 
Europe particularly, for which the currently available treatment is inadequate. OA is 
highly common and is increasing not only in the elderly but also among the general 
population, and available treatment is ineffective in stopping or reversing disease 
progression [Kaplan et al., 2013; Wieland et al., 2005]. 
Most of the times, the major disease outcomes, as pain, loss of the joint function and 
disability [Wieland et al., 2005], are only distinctly observed in late stages of OA, being 
difficult to establish a correlation between symptoms and pathology in early stages of 
the disease, which together with the limited biological markers make an early 
intervention in the disease difficult [Rousseau and Garnero, 2012]. 
Regarding these difficulties, OA pain and functional impairment of the patient, as the 
major OA burden on individuals, have been the main focus of OA therapy. In addition 
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to the first-line non-pharmacological measures, such as weight loss and physical 
exercise, OA therapy includes pharmacological symptomatic treatment with analgesics, 
classical non-steroidal anti-inflammatory agents and COX-2 selective inhibitors 
(NSAIDs and COXIBs), glucosamine and chondroitin sulphate supplements and/or 
intra-articular administration of steroids or hyaluronic acid, all of them with limited 
efficacy and/or adverse side effects, especially in the long-term utilization that the 
disease requires [Wieland et al., 2005]. To date, the approved treatments directed at 
reducing the symptoms of OA have not been shown to prevent or reverse joint 
structural damage so, in severe cases, joint replacement surgery is the last choice 
effective in relieving the painful and debilitating effects of the disease. 
Consequently, there is an urgent need for OA disease-modifying therapies which also 
improve symptoms and are safe for clinical use over long periods of time. 
As we described before, OA is not considered only an age-related or a “wear and tear” 
disease, but a multiplicity of factors and conditions can influence and lead to OA onset 
and progression. The complexity and variability of OA aetiology is believed to have a 
further impact in the response to treatment. Thus, a better understanding of particular 
pathophysiological mechanisms involved in each particular OA phenotype together with 
an individual evaluation of the patient’s co-morbidities and with the evaluation of 
specific biomarkers of joint destruction [Poole, 2003] is necessary to found better 
targeted and effective therapies with capacity to prevent the degenerative joint process 
and reverse the already established damage, without underestimate the pain [Goldring 
and Goldring, 2007; Lane et al., 2011; Mobasheri, 2013]. 
 
1.4.1 Currently Available Treatment 
 
Current treatment options for OA patients are focused on relief from pain and 
improvement of joint function. Not surprisingly, since these medical interventions do not 
consider the full OA illness, they have little effect, if any at all, on the structural 
degradation of the joint tissue. Because of that, many patients have surgery as the only 
option to improve quality of life [McAlindon et al., 2014]. 
General recommendations by the European League Against Rheumatism (EULAR), 
the American College of Rheumatology (ACR) and the Osteoarthritis Research Society 
International (OARSI) for the management of OA include a combination of non-
pharmacological interventions and pharmacological treatments (figure 1.8) [Hochberg 
et al., 2012; McAlindon et al., 2014; Zhang and Doherty, 2006; Zhang et al., 2008]. 
OARSI has specifically developed guidelines for the non-surgical treatment of OA that 
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are based on the stratification of patients into four groups: patients with knee-only OA 
and no comorbidities, patients with knee-only OA with comorbidities, patients with 
multi-joint OA and no comorbidities, and patients with multi-joint OA with comorbidities. 
These comorbidities included diabetes, hypertension, cardiovascular disease, renal 
failure, gastrointestinal bleeding, depression, or a physical impairment limiting activity, 
like obesity, and were taken into account based on that those co-morbidities might 
influence treatment choices for OA [McAlindon et al., 2014].  
From the classes of medications currently used to treat OA of the knee we can refer: 
analgesics/ anti-inflammatory agents, glucocorticoids, opioids and slow-acting drugs for 
osteoarthritis (SYSADOA). 
Acetaminophen (paracetamol) is recommended for initial management of OA, as it is 
generally safe and particularly good for treatment of mild pain, being the first line 
therapy for knee OA [Hochberg et al., 2012; Towheed et al., 2006]. Oral and topical 
non-steroidal inflammatory drugs (NSAIDs) are considered when patients do not 
respond to acetaminophen. NSAIDs are the most common treatment for rheumatologic 
conditions, including OA, rheumatoid arthritis (RA) and gout. They present analgesic, 
antipyretic and anti-inflammatory effects and act mostly through inhibition of the 2 
isoforms of COX-1 and COX-2 enzymes, leading to the inhibition of prostaglandin 
synthesis that is directly related with pain and inflammation [Wieland et al., 2005]. Most 
conventional NSAIDs inhibit both COX isoforms which is directly related to their 
gastrointestinal adverse side effects. More recently, these drugs have also been 
associated with significant cardiovascular side-effects that warrant caution in patients 
at higher risk [Soubrier et al., 2013]. Selective COX-2 inhibitors were developed in 
order to avoid those side effects as this isoform is supposed to be induced at the site of 
inflammation and not on the gastrointestinal system; however, they are not devoid of 
side effects, as nephrotoxicity and hypertension, which significantly limit their 
therapeutic use, especially in chronic conditions like OA [Hochberg, 2005]. Despite 
their side effects, NSAIDs are recommended by EULAR and OARSI treatment 
guidelines committee recommends NSAIDs for management of hip and knee OA 
[McAlindon et al., 2014]. 
Opioid analgesics, such as tramadol, are useful alternatives in patients in whom 
NSAIDs, including COX2-selective inhibitors, are contraindicated, ineffective and/or 
poorly tolerated. The increased risk of adverse side effects, particularly in the elderly, 
has to be taken seriously [Nuesch et al., 2009; Wieland et al., 2005]. Finally, the 
treatment with glucocorticoids is one of the last pharmacological lines of OA treatment 
and could be used as alternatives for pain relief in patients who cannot use or do not 
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respond to other first line therapies [Towheed et al., 2006]. However, they can bring 
about adverse effects, including mild ones as constipation, nausea and itching, and 
more serious, as respiratory depression, and addiction [Nuesch et al., 2009]. 
In addition to the types of medications mentioned above, there is a heterogeneous 
group of medications that, unlike the COX-2 inhibitors, do not inhibit prostaglandin 
synthesis. This group includes hyaluronic acid (HA), D-glucosamine sulphate (GlcN), 
chondroitin sulphate (CS), and diacerhein. These medications are collectively called 
Symptomatic Slow Acting Drugs for Osteoarthritis (SYSADOA), and have been 
recommended by EULAR for the treatment of pain in OA [Zhang and Doherty, 2006]. 
Nevertheless, their usefulness is controversial, being considered as treatments of 
“uncertain appropriateness” by OARSI on the last update of Knee OA management 
guidelines [McAlindon et al., 2014]. This heterogeneous group of compounds was the 
first to be linked to structure-modifying effects in the disease with several evidences 
showing that these drugs slow the radiographical progression of knee OA [Zhang et al., 
2008]. Their activities can range from inhibition of inflammation to a potential alteration 
of the viscoelastic properties of cartilaginous tissue [Hochberg et al., 2012; Michael et 
al., 2010; Towheed and Anastassiades, 2007]. Several studies have shown that they 
have a slow onset of action improving OA symptoms after a couple of weeks, benefits 
that last for a long period after the end of treatment [Volpi, 2004; Volpi, 2006]. In a 
randomized, controlled, double-blind trial, patients with knee OA treated with intra-
articular injection of hyaluronic acid had significantly less pain and better function for up 
to three weeks afterward the end of treatment with no severe side effects reported 
[Petrella and Petrella, 2006]. On the other hand, several studies reported opposite 
effects regarding the efficacy of CS, GlcN and HA. Among the studies that compare 
glucosamine with placebo for OA treatment, one review found no statistically significant 
benefit of glucosamine for pain [Wandel et al., 2010] and the other found a positive 
effect for pain that did not reach statistical significance [Towheed et al., 2005]. For HA 
there is only a small effect in the treatment of knee OA compared with placebo injection 
[Bannuru et al., 2011; McAlindon et al., 2014; Rutjes et al., 2012] and for CS, results 
differed regarding symptom relief, with some reviews finding no significant benefit over 
placebo for pain and others finding large effect sizes in favor of chondroitin [Hochberg 
et al., 2008].  
Diacerhein is also a SYSADOA with anti-inflammatory properties used in OA treatment. 
It works by blocking the action of IL-1β, and is a potent inhibitor of IL-1β-induced NF-κB 
activation and NO production in chondrocytes [Mendes et al., 2002b; Pelletier et al., 
1998]. Several evidences show that diacerhein is slightly, but significantly, more 
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effective than placebo in improving pain and slowing the progress of hip OA [Bartels et 
al., 2009; Fidelix et al., 2006]. However the Pharmacovigilance Risk Assessment 
Committee (PRAC) of the European Medicines Agency (EMA) recommended the 
suspension of diacerhein-containing medicines across the European Union, in 
November 2013, due to concerns over gastro-intestinal side effects (diarrhea) and liver 
toxicity that outweigh the benefits for treating OA. 
Despite all the claims of pharmacotherapeutic efficacy of SYSADOAs, to date, none 
have shown a significant structure modifying effect in placebo-controlled, clinical 
studies. So, their use in OA treatment is so far debatable [Chard and Dieppe, 2001; 
McAlindon et al., 2014; Wieland et al., 2005]. 
 
Figure 1.8 Represent the current treatment options for osteoarthritis as issued by the 
American college of Rheumatology and OARSI. In addition to non-pharmaceutical 
measures such as weight loss and physical exercise they include only symptomatic 
treatment of limited efficacy with analgesics, non-steroidal anti-inflammatory agents, 
SYSADOAs or intra-articular administration of corticosteroids or hyaluronic acid. None 
of them present effective disease modifiable effects 
 
More recently, the first steps on anti-cytokine therapy for OA were taken. These 
therapies are based on the importance of the inflammatory component of OA, 
especially the increased expression and activity of several secreted proinflammatory 
cytokines, namely IL-1β and TNF-α, in joint tissues and their importance not only in the 
inflammatory, but in the degenerative processes of the cartilage. Despite the clear 
evidence on the role of TNF-α and IL-1β in the pathophysiology of OA, only a few 
experimental trials have investigated the efficacy of blocking these pro-inflammatory 
cytokine in the treatment of OA. The currently available biological anti-cytokine 
therapies are the antibodies against TNF-α, Adalimumab, Infliximab and Etanercept, 
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which were initially approved for RA treatment [van der Bijl et al., 2008]. For OA, in 
humans, a case report described the successful treatment of inflammatory knee OA 
using Adalimumab [Grunke and Schulze-Koops, 2006] with improvement not only in 
the symptoms, but also on MRI findings with an important reduction of synovitis and 
synovial effusion. However, the results of the open label study with this drug in 12 
patients with erosive OA of the hands revealed only a modest improvement in the 
number of swollen joints, disability score, pain score, and physician global assessment 
[Magnano et al., 2007]. 
 
1.4.2 Disease Modifying OA Treatment 
 
Given the high disability burden among patients, the social-economic impact generated 
by OA and the limitations of the existing non-pharmacologic/protective measures and 
pharmacological agents, new treatments for OA are urgently needed. In particular, 
disease-modifying OA drugs (DMOADs), capable of slowing or halting the structural 
changes in joint tissues occurring in OA, are crucial to significantly reduce pain and 
restore the joint function.  
Cytokine cascades, nitric oxide, proteinase release and activation, senescence, 
apoptosis, etc., are all processes or mediators affecting all the cells of the joint, 
whether they are located in the synovium, bone or in the articular cartilage [Qvist et al., 
2008], that can be considered important targets for DMOADs. 
In theory, replacing the balance between those processes would stop the progression 
and eventually favor the reparative process which are the main focus of the DMOADs 
principals [Alcaraz et al., 2010]. The development of DMOADs presents many 
challenges that include, firstly, the complexity of the disease, namely the involvement 
of several joint structures (cartilage, synovium and bone…) the complex 
etiopathogenesis, the heterogeneity of clinical presentations and the slow progression 
of OA, which create a complex environment for therapeutic development with disease-
modifying objectives [Hunter, 2011]. The second one seems to be the lack of sensitive 
biomarkers and measurable clinical endpoints that help to connect the structural 
changes to the patient response and assess the efficacy of new formulations. For 
instance, the determination of joint space narrowing could be an important radiograph 
measure of cartilage loss, however, its use as single endpoint considered for the 
evaluation of the efficacy of a new drug could be critical. The space between the two 
bones in a joint, in a radiograph view represents the overall thickness of the joint 
cartilage surfaces of each opposing bone as they articulate, or come into contact with 
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one another. In conditions like arthritis, the joint space gets narrow because of cartilage 
degradation. Although this parameter can be relevant on the late phases of OA were 
the cartilage degradation and loss is obvious, in early stages this parameter is not that 
relevant as could be, for instance, the presence of inflammatory mediators [Qvist et al., 
2008; Sokolove and Lepus, 2013]. 
Strategies for development of DMOADs include anti-catabolic agents, aiming at 
slowing or halting OA progression and anabolic agents aiming at inducing cartilage 
regeneration. Anti-catabolic agents would target: 1) direct inhibition of MMP expression 
and activity [Clutterbuck et al., 2009], as these proteinases are intrinsically involved in 
cartilage breakdown. 2) Prevention of excessive proinflammatory cytokine production, 
especially IL-1β and TNF-α but also IL-6, IL-8, and IL-17, also implicated in OA 
pathophysiology [Goldring, 2001; Rudolphi et al., 2003] and/or 3) prevention of the 
activation of major signalling pathways that drive inflammatory and catabolic 
responses, as those of NF-κB [Costa et al., 2012; Marcu et al., 2010] and MAPKs 
[Khalife and Zafarullah, 2011], since their activation by stress-related stimuli regulates 
the expression of many cytokines, chemokines, adhesion molecules, inflammatory 
mediators, and several matrix-degrading enzymes related with joint damage [Goldring, 
2006]. On the other hand, pro-anabolic therapeutic agents, such as growth factors, 
could be used to target several receptors and signalling pathways that[Pelletier, 2004]  
increase chondrocyte anabolism [Pelletier, 2004]. 
Highly specific drugs, small interfering RNAs (siRNAs), or other biological inhibitors are 
under the focus of current OA research [Mobasheri, 2013], but despite the large 
number of active research and drug discovery programs to identify structure-modifying 
approaches to inhibit joint destruction in OA, none has been conclusive or showed 
significant efficacy as a DMOAD and to date, no DMOADs are approved by the Food 
and Drug Administration (FDA) or the EMA. Oral administration of PG-116800, a MMP 
inhibitor effective against MMP-2, -3, -8, -9, -11, -13, and -14 was associated with 
severe musculoskeletal adverse effects without clear benefits for knee OA [Krzeski et 
al., 2007]. Similarly, other non-selective MMP inhibitors evaluated for oncology were 
associated with arthralgia, stiffness and joint swelling, as well as with other severe 
musculoskeletal complications [Bissett et al., 2005; King et al., 2003; Leff et al., 2003]. 
Nevertheless, the MMP inhibitor, doxycycline, has demonstrated potential efficacy for 
disease modification [Brandt et al., 2005; Maher et al., 2013]. Development of more 
selective MMP inhibitors could potentially improve the balance between benefit and 
side effects in patients with OA. 
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Similarly, despite the clear role of inflammation in OA, no anti-inflammatory therapies 
were found, and those under test, including use of biologic agents to inhibit TNFα and 
IL-1β, all proved to be disappointing [Hunter, 2008]. IL-1 or IL-1R inhibitors have been 
tested in preclinical and clinical trials of RA, however only a few of these have been 
investigated in OA, e.g. Anakinra (IL-1R antagonist) and AMG-108 (anti-IL-1 human 
antibody, anti-IL-1 huMAb). Their beneficial effects on symptoms and signs in knee OA 
are still controversial [Chevalier et al., 2005; Yang et al., 2008]. 
Other DMOADs are under investigation namely the iNOS inhibitor, SD-6010, by Pfizer 
which rationale for development rests on the inhibition of pro-catabolic and pro-
inflammatory effects of effects of NO generated by the upregulation of the synthetic 
activity of enzyme, iNOS [Abramson, 2008] and the COX-inhibiting NO-donating 
compound naproxcinod (formerly HCT 3012), from NiCox. Naproxcinod is a derivative 
of naproxen and is the first compound in the COX-inhibiting NO-donating class, which 
integrates the anti-inflammatory effects of the NSAID with the potential beneficial 
effects of NO on the cardiovascular system. It is in phase III trial for the treatment of 
OA [Anonimous, 2007; Qvist et al., 2008]. 
Since ever, natural products, as plants, are a source of compounds with 
pharmacological properties. In the last decades, a great percentage of the new drug 
entities registered have a natural origin or are inspired in a natural compound which 
proves them as a believable source of new compounds with pharmacological 
properties[Newman and Cragg, 2007]. Accordingly, research on OA therapy has 
focused on these sources to found new compounds with disease modifying properties 
with very promising results [Henrotin et al., 2013; Khalife and Zafarullah, 2011; 
Mobasheri, 2012; Seidl, 2002; Shakibaei et al., 2012; Shakibaei et al., 2011; Shakibaei 
et al., 2005], However, none has yet proceed to clinical development. 
The biodiversity of the Portuguese flora opens wide possibilities for identification of 
compounds to be studied in the context of chronic inflammatory diseases and 
specifically in OA. From the panoply of compounds that can be obtained from plants, 
literature and preliminary studies showed that small volatile and hydrophobic plant 
metabolites can modulate inflammatory signalling pathways [Neves et al., 2009]. A 
huge amount of compounds with such characteristics can be found in essential oils 
which are typical extracts from aromatic plants, generally obtained by distillation. 
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1.5 OBJECTIVES AND ORGANIZATION OF THE THESIS 
 
OA and DM are age-related diseases whose prevalence is increasing exponentially. 
Several studies showed that OA is a heterogeneous disease and that the multiple risk 
factors associated with it are responsible for a multiplicity of OA phenotypes. Diabetes 
mellitus, especially type 2, has been considered an independent risk factor for the 
development and progression of OA in several epidemiological studies which indicate 
that OA is more prevalent, more severe, has an earlier onset and progresses more 
rapidly in diabetic- than in non-diabetic patients [King et al., 2013; Martinez-Huedo et 
al., 2013; Nieves-Plaza et al., 2013; Schett et al., 2012a]. These evidences, as well as 
in vitro and in vivo data, including studies by our own group [Rosa et al., 2009; Rosa et 
al., 2011b], strongly suggest the existence of a specific DM-associated OA phenotype 
[Berenbaum, 2011]. A better understanding of particular underlying physiological and 
pathological mechanisms is essential for the design and development of new and 
better targeted therapeutic strategies effective to halt OA progression, its growing 
incidence and its associated huge socio-economic costs [Kaplan et al., 2013]. We 
addressed this issue by hypothesizing that hyperglycemia, a hallmark of DM and other 
conditions associated with glucose imbalance, is a major effector of chondrocyte 
damage, accelerating age-related changes that favor OA development. In this context, 
previous studies from our group [Rosa et al., 2009; Rosa et al., 2011b] showed that 
hyperglycemia-like glucose concentrations induce catabolic responses and impair the 
ability of chondrocytes to respond to anabolic agents. Thus, one of the objectives of 
this thesis was to identify mechanisms by which chondrocytes sense and regulate 
glucose transport which is the first rate limiting step for glucose utilization and thus can 
be a target for preventing deleterious effects caused by hyperglycemia. Moreover, and 
to further identify potential therapeutic targets, we also investigated the role of 
hyperglycemia in modulating inflammatory responses in chondrocytes. The results 
obtained and their discussion are presented in chapters 3 and 4. 
Since every factor, including hyperglycemia as we demonstrate in chapter 4, that shifts 
chondrocyte homeostasis towards a pro-catabolic state, induces an inflammatory 
response in chondrocytes and this is a major effector mechanism of cartilage 
destruction in OA, our last objective was to identify compounds that can halt 
inflammation and catabolic responses in chondrocytes. Identification of such 
compounds is crucial for the development of effective disease-modifying anti-
osteoarthritic drugs. For this, we evaluated a series of essential oils and their 
compounds for their ability to inhibit the inflammatory and catabolic processes in 
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human chondrocytes, focusing on the major signalling pathways activated in 
osteoarthritic joints, namely NF-κB and the MAPKs. The results obtained are reported 
and discussed in chapters 5 to 7. 
Finally, even though OA involves the whole joint, cartilage degradation, a multi-faceted 
and complex process that characterizes all forms of OA, is the hallmark of the 
progression and irreversibility of the disease reason why this work was specifically 
focused on this tissue. 
The last chapter of this thesis presents a general and integrated overview of the results 
reported, matching them with the major objectives defined and identifying new 
questions and future perspectives elicited by this work. 
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CHAPTER 2.  
MATERIAL AND METHODS 
 
2.1 Cartilage Samples 
 
Human knee cartilage was collected, within 12 h of death, from the distal femoral 
condyles of multi-organ donors or with informed consent from patients undergoing total 
knee replacement surgery at the Orthopaedics Department of the University Hospital of 
Coimbra (HUC). The Ethics Committee of HUC approved all procedures. Where 
considered relevant for the work goals the samples were classified according to the 
degree of macroscopic damage, using the classification of Outerbridge (1961). Group 
0-1 includes cartilage samples with no macroscopic signs of degradation (score 0) or 
presenting only a softened surface (score 1); Group 2-3 includes fibrillated or fissured 
cartilage samples without evident signs of surface erosion (scores 2 and 3); and Group 
4 comprises severely damaged cartilage samples, with areas of extensive full thickness 
erosion that exposed the subchondral bone, corresponding to advanced OA. 
 
2.2 Chondrocyte Isolation and Culture 
 
Chondrocytes were isolated by enzymatic digestion from non-pooled cartilage samples. 
Briefly, cartilage slices underwent sequential digestion with Pronase (Roche, 
Indianapolis, IN, USA), a non-specific protease for 1h30min and collagenase A (Roche) 
overnight. To avoid chondrocyte dedifferentiation, non-proliferating monolayer cultures 
were setup by plating 1x106 chondrocytes/ml in Ham : F-12 medium containing 3% 
antibiotic/antimycotic solution and 5% Fetal Bovine Serum (Invitrogen, Life 
technologies, Carlsbad, CA) and allowed to recover for 24 h at 37ºC in a humidified 
atmosphere supplemented with 5% CO2.  
Cells from the human chondrocytic cell line, C28/I2, kindly provided by Prof. Mary 
Goldring (currently at the Hospital for Special Surgery, New York) and Harvard 
University, were cultured in DMEM/ Ham’s F-12 (1:1, v/v) and passaged every 
four days, as recommended. For the experiments 0,5x106 chondrocytes/mL were 
plated and allowed to recover for 24h in similar conditions to that of primary human 
chondrocytes. 
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Prior to any treatments, the cells were serum-starved overnight and thereafter 
maintained in culture medium with 1% antibiotic/antimycotic solution, without serum. 
The specific treatments conditions are indicated in figure legends. 
 
2.3 Assessment of Cell Viability 
 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT; Sigma) reduction assay, 
a quantitative colorimetric method based on the reduction of the MTT salt by the 
mitochondrial enzymes of viable cells [Mosmann, 1983], was used to determine the 
cytotoxicity and to select non-cytotoxic concentrations of each of the compounds under 
test. Briefly, the cells were incubated with each compound in different concentrations 
for 24h h after what the culture medium was replaced by fresh medium containing 5 
μg/mL MTT and the cells further incubated for 30 min. The resulting dark blue crystals 
of formazan were then dissolved in acidified isopropanol and the absorbance of the 
corresponding solution, directly proportional to the number of living cells, was 
measured in an automatic plate reader (SLT, Austria) set at a test wavelength of 570 
nm and a reference wavelength of 620 nm. The absence of cytotoxic effects in each 
cell model was defined as the concentration of tested compounds eliciting an 
absorbance reading of at least 80% of the value measured in the cells treated with IL-
1β alone for same time period. 
 
2.4 Western Blot 
 
Total, cytoplasmatic and nuclear cell extracts were prepared and subjected to western 
blot. Briefly, 25 µg of protein were separated by SDS/PAGE [10% (v/v)] and transferred 
onto PVDF membranes by electroblotting. The membranes were blocked with 5% skim 
milk for 2 hours in Tris-buffered saline-Tween (TBS-T, 20mM Tris-HCl, 150mM NaCl, 
0,1% Tween 20) and probed with the antibodies presented on Table 2.1 and with anti-
rabbit, anti-mouse, anti-goat alkaline phosphatase-conjugated secondary antibodies 
(GE Healthcare, Chalfont St Giles, UK). β-tubulin, actin and lamin B1 antibodies were 
used to detect those proteins as loading controls. Immune complexes were detected 
with the Enhanced ChemiFluorescence reagent (GE Healthcare) and the bands were 
analyzed using ImageQuant™TL (version 7.0, GE Healthcare). The results were 
normalized by calculating the ratio between the intensities of the bands corresponding 
to the protein of interest and the protein used as loading control. 
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Table 2.1 Antibodies used for western blot and immunohistochemistry analysis 
Protein   Source  Purification  MW (KDa)  Purchasing Company 
Kir 6.1  Goat  Polyclonal  51  Santa Cruz BioTech, Inc. 
Kir6.2  Rabbit  Polyclonal  40  Santa Cruz BioTech, Inc. 
SUR 1  Mouse  Monoclonal  37  Abcam® 
SUR 2A  Goat  Polyclonal  140  Santa Cruz BioTech, Inc. 
SUR2B  Goat  Polyclonal  140  Santa Cruz BioTech, Inc. 
iNOS  Mouse  Monoclonal  135  R&D systems 
GLUT-1  Rabbit  Polyclonal  54  Millipore 
GLUT-3  Rabbit  Polyclonal  54  Millipore 
p-IκBα  Mouse  Polyclonal  40  Cell Signalling Tech., Inc. 
IκBα  Rabbit  Polyclonal  39  Cell Signalling Tech., Inc. 
p-JNK  Rabbit  Monoclonal  54  Cell Signalling Tech., Inc. 
p-p38  Rabbit  Polyclonal  43  Cell Signalling Tech., Inc. 
p-ERK 1/2  Rabbit  Polyclonal  42/44  Cell Signalling Tech., Inc. 
p65  Rabbit  Polyclonal  65  Abcam® 
β-Tubulin  Mouse  Monoclonal  55  Sigma-Aldrich® 
Actin  Mouse  Monoclonal  43  Millipore 
Lamin B1  Rabbit  Polyclonal  68  Abcam® 
 
2.5 Immunohistochemistry 
 
Five millimetres diameter full thickness cartilage cylinders were collected from the distal 
femoral condyles of multi-organ donors, immersed in OCT embedding compound 
(TAAB Laboratories, UK) and immediately frozen at -80 ºC. Cryostat sections, 10 µm 
thick, were fixed in acetone at -20 ºC for 10 min and incubated with the primary 
antibodies against Kir6.1, Kir6.2, SUR1, SUR2A and SUR2B presented on Table 2.1. 
Secondary antibodies used were Alexa fluor 488-conjugated goat anti-rabbit, Alexa 
fluor 488-conjugated goat anti-mouse (Molecular Probes, Eugene, OR) and FITC-
conjugated rabbit anti-goat (Serotech Laboratories; Toronto, Canada). Counterstaining 
was performed with DAPI (Sigma-Aldrich) to allow nucleus visualization. Specificity 
was assessed by omitting the first antibody (negative control). Images of cartilage 
sections were acquired in a confocal laser scanning microscope (Zeiss LSM 710; Carl 
Zeiss Co, Germany) using an excitation filter of 500 nm and an emission filter of 520 
nm. The acquisition settings were maintained throughout the work. 
 
2.6 Total RNA Extraction and Quantitative Real-Time PCR (qRT-PCR) 
 
Total RNA was extracted from primary chondrocyte cultures using TRIzol® Reagent 
(Invitrogen, Life Technologies, Co; Paisley, UK) and quantified using a NanoDrop ND-
1000 spectrophotometer at 260nm. RNA purity was assessed as the 240/260 and 
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280/260 ratios. The cDNA was reverse transcribed using the iScript Select cDNA 
Synthesis Kit (Bio-Rad), beginning with 1 µg of RNA. Specific sets of primers used 
throughout the work, including housekeeping genes and summarized in Table 2.2 were 
designed using Beacon Designer software (PREMIER Biosoft International, Palo Alto, 
CA). PCR reactions were performed using 25 g/mL of transcribed cDNA in a final 
volume of 20 µL. 
The efficiency of the amplification reaction for each gene was calculated using a 
standard curve of a series of diluted cDNA samples, and the specificity of the 
amplification products was assessed by analyzing the melting curve generated in the 
process. 
Gene expression changes were analyzed using the built-in iQ5 Optical system software 
v2, which enables the analysis of the results with the Pfaffl method, a variation of the 
ΔΔCT method corrected for gene-specific efficiencies [Nolan et al., 2006]. 
The results for each gene of interest were normalized against HPRT-1 or against 18S 
ribosomal protein, the housekeeping genes found to be the most stable under the 
different experimental conditions used. 
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Table 2.2 Oligonucleotide Primer Pairs Used for qRT-PCR 
Gene Name 
Genbank 
Accession number 
Sequence 
GLUT-1 NM_006516.2 
F:5’-CGTCTTCATCATCTTCACTG-3’ 
R: 5’-CTCCTCGGGTGTCTTATC-3’ 
GLUT-3 NM_006931.2 
F:5’-CGGCTTCCTCATTACCTTC-3’ 
R: 5’-GGCACGACTTAGACATTGG-3’ 
Kir6.1 NM_000352 
F:5’-CAACTGCTGTGTCCAGAT-3’ 
R: 5’-ATACGAATGGTGATGTTGGA-3’ 
Kir6.2 NM_ 000525 
F:5’-CATAGGCATTAGTGTAGT-3’ 
R: 5’-TTATAGAAGAGGCAACTG-3’ 
SUR 1 NM_000352 
F:5’- CAACTGCTGTGTCCAGAT-3’ 
R: 5’-ATACGAATGGTGATGTTGGA-3’ 
SUR 2A NM_005691 
F:5’-AAGCATTCGGTCATTGTAG-3’ 
R: 5’-GCCACATAGTAGGTCTGA-3’ 
SUR 2B NM_020297 
F:5’-TGGAGAGGATGTGGAGAA-3’ 
R: 5’-CTGTAAGAATGGTGAATGTGAT-3’ 
iNOS NM_000625.4 
F:5’-AATCCAGATAAGTGACATAAG-3’ 
R: 5’-CTCCACATTGTTGTTGAT-3’ 
MMP-1 NM_001145938.1 
F:5’-GAGTCTCCCATTCTACTG-3’ 
R:5’-TTATAGCATCAAAGGTTAGC-3’ 
MMP-13 NM_002422.3 
F:5’-GTTTCCTATCTACACCTACAC-3’ 
R: 5’-CTCGGAGACTGGTAATGG-3’ 
TIMP-1 NM_003254.2 
F:5’-TGTTGCTGTGGCTGATAG-3’ 
R: 5’-CTGGTATAAGGTGGTCTGG-3’ 
TIMP-3 NM_000362.4 
F: 5'-CCATACACTATCCAC -3' 
R: 5'-TAACAGCATTGAACA -3' 
Aggrecan NM_001135 
F: 5’-CCTGGTGTGGCTGCTGTC-3’ 
R: 5’- CTGGCTCGGTGGTGAACTC-3’ 
Collagen II NM_001844.4 
F:5’-GGCAGAGGTATAATGATAAGG-3’ 
R: 5’-ATTATGTCGTCGCAGAGG-3’ 
Collagen I NM_000088.3 
F:5’GGAGGAGAGTCAGGA-3’ 
R: 5’-GCAACACAGTTACAC-3’ 
HPRT-1 NM_000194.2 
F:5’-TGACACTGGCAAAACAAT-3’ 
R: 5’-GGCTTATATCCAACACTTCG-3’ 
18S rRNA NM_022551 
F:5’-GAAGATATGCTCATGTGGTGTTG-3’ 
R: 5’-CTTGTACTGGCGTGGATTCTG-3’ 
RPL13A NM_012423 
F:5’-GGAAGAGCAACCAGTTACTATGAG-3’ 
R: 5’-CAGAGTATATGACCAGGTGGAAAG-3’ 
GAPDH NM_002046 
F:5’-ACAGTCAGCCGCATCTTC-3’ 
R: 5’-GCCCAATACGACCAAATCC-3’ 
F: Forward sequence; R: Reverse sequence 
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2.7 2-Deoxy-D-Glucose uptake Assay 
 
Glucose transport was determined by measuring the net uptake of a non-metabolizable 
analogue of glucose, 2-deoxy-D-glucose (2-DG). Briefly, chondrocytes were pre-
incubated for 18 hours with Glibenclamide (10, 20, 100 nM and 20 M) and then 
incubated for 30 minutes at 37oC in glucose-free DMEM containing 0.5 mM 2-DG and 
0.5 Ci/mL of [2,6-3H]-2-DG. Cytochalasin B, a glucose transporter inhibitor (10 M), 
was used to determine the non-specific uptake. For each sample, the non-specific 
uptake was subtracted from the total uptake, before normalization to the respective 
protein concentration. 
 
2.8 Nitric Oxide Production 
 
NO production was evaluated as the concentration of nitrite accumulated in the 
supernatants of primary chondrocyte cultures treated with IL-1β in the presence or 
absence of the test compounds, as indicated in figures and figure legends. Nitrite 
concentration was measured using the spectrophotometric method based on the 
Griess reaction [Green et al., 1982]. 
 
2.9 NF-κB Transcription Factor Assay 
 
A colorimetric ELISA-based assay (NoShift Transcription Factor Assay kit, Novagen, 
La Jolla, CA) was used to evaluate the presence of active NF-κB dimers, capable of 
binding to the cognate consensus DNA sequence. For this purpose, nuclear extracts 
from C-28/I2 cells were incubated with a biotinylated consensus NF-κB oligonucleotide 
(NoShift NF-κB Reagents; Novagen) and the assay performed according to the 
manufacturerʼs instructions. The absorbance intensity in each sample is directly 
proportional to the amount of NF-κB-DNA complexes formed and, thus, to the amount 
of active NF-κB dimers present in each sample. In parallel, the specificity of the 
reaction was confirmed in competition assays where addition of a 10-fold molar excess 
of non-biotinylated wild-type or mutant oligonucleotides (NoShift NF-κB Reagents; 
Novagen) to binding reactions containing nuclear extracts from IL-1β treated cells 
abrogated or did not affect, respectively, the formation of NF-κB-DNA complexes. 
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2.10 Essential oil identification, Fractionation and Analysis 
 
EOs from the aerial parts of Eryngium duriaei subsp. juresianum (M. Laínz) M. Laínz 
(Apiaceae), from the aerial parts of Laserpitium eliasii subsp. thalictrifolium Sennen & 
Pau (Apiaceae), from leaves and flowers of Lavandula luisieri (Rozeira) Rivas-Martínez 
(Lamiaceae), from the aerial parts of Othantus maritimus (L.) Hoff. & Link (Asteraceae) 
and from the aerial parts of Thapsia villosa L. (Apiaceae) were picked from the 
collection of plant extracts of the Faculty of Pharmacy, Univ. Coimbra. Voucher 
specimens of plant material are deposited at the Herbarium of the Botanic Garden, 
Univ. Coimbra (COI) or at the Herbarium of the Faculty of Pharmacy, Univ. Coimbra. 
All EOs were prepared at laboratory by water distillation using a Clevenger-type 
apparatus (EDQM, 2007) (+)-α-Pinene (≥98% purity) was purchased from Sigma 
Chemical Co. (St. Louis, MO, US). 
The composition of each essential oil was established following a combined 
methodology of GC and GC/MS. Analytical GC was performed in a Hewlett-Packard 
6890 (Agilent Technologies, Palo Alto, CA, US) gas chromatograph with a HP GC 
ChemStation Rev. A.05.04 data handling system, equipped with a single injector and 
two flame ionization detectors (FID). A graphpak divider (Agilent Technologies, part no. 
5021-7148) was used for simultaneous sampling to two Supelco (Supelco, Bellefonte, 
PA, US) fused silica capillary columns with different stationary phases: SPB-1 
(polydimethylsiloxane 30 m × 0.20 mm i.d., film thickness 0.20 μm), and SupelcoWax-
10 (polyethyleneglycol 30 m × 0.20 mm i.d., film thickness 0.20 μm). Oven temperature 
program: 70–220°C (3°C/min), 220°C (15 min); injector temperature: 250°C; carrier 
gas: helium adjusted to a linear velocity of 30 cm/s; split ratio 1:40; detectors 
temperature: 250°C. GC-MS was performed in a Hewlett-Packard 6890 gas 
chromatograph fitted with a HP1 fused silica column (polydimethylsiloxane 30 m × 0.25 
mm i.d., film thickness 0.25 μm), interfaced with an Hewlett-Packard mass selective 
detector 5973 (Agilent Technologies) operated by HP Enhanced ChemStation 
software, version A.03.00. GC parameters were as described above; interface 
temperature: 250°C; MS source temperature: 230°C; MS quadrupole temperature: 
150°C; ionization energy: 70 eV; ionization current: 60 μA; scan range: 35 – 350 units; 
scans/s: 4.51. 
The essential oils of E. duriaei subsp. juresianum and L. luisieri were fractionated by 
flash chromatography on silica gel 63-200 m (Merck) using a 2 cm x 40 cm Omnifit 
(Sigma-Aldrich) glass columns. Elution was made in step gradients from 100% of n-
pentane, n-pentane / ethyl ether mixtures, till a final concentration of 100% ethyl ether. 
CHAPTER 2 
 
64 
 
Collected fractions were analysed by gas chromatography-mass spectroscopy 
(GC/MS) and combined if having similar composition. Analysis were performed  using a 
Hewlett-Packard 6890 gas chromatograph fitted with a HP1 fused silica column 
(polydimethylsiloxane 30 m × 0.25 mm i.d., film thickness 0.25 m), interfaced with an 
Hewlett-Packard mass selective detector 5973 (Agilent Technologies) operated by HP 
Enhanced ChemStation software, version A.03.00. GC-MS parameters: oven 
temperature program: 70–220 C (3 C.min-1), 220 C (15 min); injector temperature: 
250 C; carrier gas: helium, adjusted to a linear velocity of 30 cm.s-1; splitting ratio 1:40; 
interface temperature: 250 C; MS source temperature: 230 C; MS quadrupole 
temperature: 150 C; ionization energy: 70 eV; ionization current: 60 A; scan range: 
35–350 units; scans.s-1: 4.51.  
Components of each EO and fraction were identified considering their retention indices 
(RIs) on both SPB-1 and SupelcoWax-10 columns and their mass spectra. RIs, 
calculated by linear interpolation relative to retention times of C8–C23 n-alkanes 
(Vandendool & Kratz, 1963), were compared with those of authentic samples, 
laboratory database (CEF / Faculty of Pharmacy, University of Coimbra) data available 
in digital banks (Linstrom, 2013; El-Sayed, 2012; Acree, 2004 and/ or literature data.. 
Acquired mass spectra were compared with reference spectra from the laboratory 
database, Wiley / NIST library[McLafferty, 2009]  Wiley / NIST database (EDQM, 2007) 
and literature data [Adams, 1995; Cavaleiro et al., 2011; Joulain, 1998; Videira et al., 
2013] (Adams, 1995; Joulain, 1998). Relative amounts of individual components were 
calculated based on GC raw data without further correction. Table 5.1 summarizes the 
major components found in each EO and table 7.1 summarizes the major components 
found in each fraction of the Eryngium duriaei subsp. juresianum and Lavandula luisieri 
essential oils 
For cell assays, the EOs and isolated compounds were diluted in Dimethylsulfoxide 
(DMSO) and then dispersed in the culture medium to achieve final concentrations of 
10-200 µg/mL. The final DMSO concentration did not exceed 0.1% (v/v). 
 
2.11 Statistical Analysis 
 
Results are presented as mean ± SEM. Statistical analysis was performed using 
GraphPad Prism (version 5.00). SPSS software (version 17.0) was used to assess the 
normality (Kolmogorov Smirnov test) and homogeneity of variances to determine 
whether the conditions required to apply parametric tests were satisfied. As in all cases 
such conditions were observed, the statistical analysis was performed using the paired 
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Student t-test for comparison of each condition with its respective positive (IL-1β 
treated) or negative (untreated cells) control. Results were considered statistically 
significant at P <0.05. 
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ABSTRACT 
 
ATP-sensitive potassium [K(ATP)] channels sense intracellular ATP/ADP levels, being 
essential components of a glucose-sensing apparatus in various cells that couples 
glucose metabolism, intracellular ATP/ADP levels and membrane potential. These 
channels are present in human chondrocytes, but their subunit composition and 
functions are unknown. This study aimed at elucidating the subunit composition of 
K(ATP) channels expressed in human chondrocytes and determining whether they play 
a role in regulating the abundance of major glucose transporters, GLUT-1 and GLUT-3, 
and glucose transport capacity. The results obtained show that human chondrocytes 
express the pore forming subunits, Kir6.1 and Kir6.2, at the mRNA and protein levels 
and the regulatory sulfonylurea receptor (SUR) subunits, SUR2A and SUR2B, but not 
SUR1. The expression of these subunits was no affected by culture under 
hyperglycemia-like conditions. Functional impairment of the channel activity, using a 
SUR blocker (glibenclamide 10 or 20 nM), reduced the protein levels of GLUT-1 and 
GLUT-3 by approximately 30% in normal chondrocytes, while in cells from cartilage 
with increasing osteoarthritic (OA) grade no changes were observed. Glucose transport 
capacity, however, was not affected in normal or OA chondrocytes. These results show 
that K(ATP) channel activity regulates the abundance of GLUT-1 and GLUT-3, 
although other mechanisms are involved in regulating the overall glucose transport 
capacity of human chondrocytes. Therefore, K(ATP) channels are potential 
components of a broad glucose sensing apparatus that modulates glucose transporters 
and allows human chondrocytes to adjust to varying extracellular glucose 
concentrations. This function of K(ATP) channels seems to be impaired in OA 
chondrocytes. 
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3.1 INTRODUCTION 
 
Glucose serves an important anabolic function in chondrocytes, being required for the 
synthesis of matrix components. Due to the avascular nature of cartilage, chondrocytes 
are physiologically exposed to low oxygen tensions [Grimshaw and Mason, 2000; Kay 
et al., 2011; Zhou et al., 2004b], using glycolysis as the main energy source [Rajpurohit 
et al., 1996], even when exposed to normoxia [Schneider et al., 2007]. The supply of 
glucose to chondrocytes depends on diffusion from the synovial fluid [Maroudas, 1970] 
which is facilitated by joint motion and fluid flow in the extracellular matrix (ECM). The 
synovial fluid glucose concentration is identical to that in the plasma both in normal 
conditions and in non-inflammatory and inflammatory types of arthritis, except in septic 
arthritis where it is usually significantly reduced [Brannan and Jerrard, 2006]. Several 
members of the facilitative glucose transporter family – the GLUT/SLC2A transporters 
– are expressed in chondrocytes and optimize its uptake [Mobasheri et al., 2008]. 
GLUT-1 is especially important as both anabolic and catabolic stimuli increase its 
expression, while others, like GLUT-3, which is also highly expressed constitutively, 
does not seem to be regulated by those stimuli [Mobasheri et al., 2008; Phillips et al., 
2005; Richardson et al., 2003; Shikhman et al., 2004]. 
On the other hand, extracellular glucose concentrations both below and above 
physiologic levels, have been predicted and shown to alter the pattern of gene 
expression [Mobasheri et al., 2002a; Rosa et al., 2011b], as well as the availability of 
GLUT-1 protein [Rosa et al., 2009] in chondrocytes. Indeed, glucose deprivation 
increases the expression of GLUT-1, whereas a supra-physiologic glucose 
concentration has the opposite effect, decreasing GLUT-1 content and glucose uptake 
in young/healthy chondrocytes, but has no effect on those isolated from osteoarthritic 
(OA) cartilage [Rosa et al., 2009]. Therefore, normal chondrocytes seem to be able to 
adjust to the extracellular glucose concentration by modulating the abundance of 
GLUT-1 and the total glucose transport capacity. Nonetheless, this ability seems to be 
compromised in OA chondrocytes in vitro, leading to intracellular glucose 
accumulation, increased production of reactive oxygen species [Rosa et al., 2009] and 
expression of matrix degrading enzymes [Rosa et al., 2011b] when these cells are 
exposed to supra-physiologic glucose concentrations, as those occurring in diabetes 
mellitus, metabolic syndrome and other conditions characterized by impaired glucose 
metabolism. These conditions are increasingly recognized as independent risk factors 
for OA development and progression [Berenbaum, 2011; Del Rosso et al., 2006; Hart 
et al., 1995; Katz et al., 2010; Schett et al., 2012b; Sturmer et al., 2001; Velasquez and 
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Katz, 2010]. OA is the major musculoskeletal disorder - or most likely, a set of 
disorders with distinct etiological and clinical characteristics [Berenbaum, 2011; Zhuo et 
al., 2012] and a main cause of physical disability [Goldring and Marcu, 2009; Martel-
Pelletier et al., 2008]. Understanding how human chondrocytes sense extracellular 
glucose and intracellular ATP concentrations and adjust their substrate uptake to 
match the cell’s needs and whether such mechanisms remain functional in OA 
chondrocytes is, thus, critical to elucidate the mechanisms by which conditions 
associated with impaired glucose metabolism contribute to the development and/or 
progression of OA. 
ATP-sensitive potassium [K(ATP)] channels are weak inwardly rectifying potassium 
channels that act as metabolic sensors in a number of cell types, coupling metabolic 
activity to the membrane potential and to secretory activity, primarily by sensing 
intracellular ATP levels [Burke et al., 2008; McTaggart et al., 2010; Miki et al., 2002; 
Minami et al., 2004]. In pancreatic β-cells [Burke et al., 2008] and in subpopulations of 
mediobasal hypothalamic neurons [Acosta-Martinez and Levine, 2007], for instance, 
K(ATP) channels have been identified as an essential component of a glucose-sensing 
mechanism, wherein uptake and metabolism of glucose leads to increased intracellular 
ATP/ADP levels, closure of the channels, and increase in insulin secretion and 
neuronal excitability, respectively. 
Structurally, K(ATP) channels are heteromultimers of four ATP-binding cassette (ABC) 
proteins that form the sulfonylurea receptor (SUR), surrounding four pore forming 
potassium channel subunits (Kir6) [Babenko et al., 1998]. Kir6 and SUR have two 
isoforms each, Kir6.1 and Kir6.2 and SUR1 and SUR2, respectively. SUR2 has two 
major splice variants, SUR2A and SUR2B [Burke et al., 2008; Hibino et al., 2010]. ATP 
binds to the SUR subunits inducing a conformational change of the Kir6 subunits that 
results in channel closure, cessation of K+ efflux and cell membrane depolarization. In 
contrast, decreased intracellular ATP availability allows ADP binding and channel 
opening with the consequent K+ efflux and hyperpolarization [Babenko et al., 1998; Shi 
et al., 2005] 
The subunit composition of K(ATP) channels determines their sensitivity to intracellular 
ATP and to pharmacological modulators, eliciting the functional diversity of these 
channels [Acosta-Martinez and Levine, 2007; Babenko et al., 1998; Inagaki and Seino, 
1998]. Kir6.1 and Kir6.2 have similar sensitivities to nucleotides (ATP and ADP), so the 
differences found are believed to be due to the SUR subtype existing in each channel 
or to the combination of different SUR subunits in the same channel [Chan et al., 2008; 
Shi et al., 2005]. K(ATP) channels involved in coupling glucose sensing with insulin 
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secretion in pancreatic β-cells are composed of Kir6.2 and SUR1 [Nielsen et al., 2007], 
whereas channels containing Kir6.2 and SUR2A, found in cardiomyocytes, and 
channels composed of Kir6.2 or Kir6.1 and SUR2B, occurring in vascular cells, 
regulate the duration of the action potential and vasodilatation [Aguilar-Bryan and 
Bryan, 1999; Burke et al., 2008; Chan et al., 2008; Gribble and Ashcroft, 2000; Hibino 
et al., 2010]. 
Information regarding the subunit composition and function of K(ATP) channels 
expressed in non-excitable cells is much scarcer. Functional K(ATP) channels have 
been demonstrated in equine chondrocytes and Kir6.1 was detected in normal and OA 
human cartilage [Mobasheri et al., 2007], but their subunit composition and 
physiological roles in cartilage are not yet understood, even though these channels are 
highly likely to be important for regulation of cartilage metabolism and sensing ATP 
levels within the cell [Barrett-Jolley et al., 2010; Mobasheri et al., 2012]. We 
hypothesize that K(ATP) channels, by responding to ATP levels, may indirectly act as 
components of the glucose sensing apparatus in chondrocytes, generating signals that 
allow the cell to adjust to varying extracellular glucose concentrations by regulating the 
availability of its facilitative glucose transporters and hence net glucose transport 
capacity. Therefore, this work was aimed at i) elucidating the subunit composition of 
K(ATP) channels expressed in human chondrocytes and ii) determining whether 
K(ATP) channels play a role in regulating the abundance of two major glucose 
transporters in chondrocytes, GLUT-1 and GLUT-3, and the glucose transport capacity 
of human chondrocytes exposed to hyperglycemia-like conditions. Furthermore, these 
processes were evaluated in chondrocytes isolated from cartilage samples with 
different degradation grades to determine whether they are impaired in OA. 
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3.2 RESULTS 
 
3.2.1 Characterization of the subunit composition of (KATP) channels 
expression in human chondrocytes 
 
To determine the subunit composition of K(ATP) channels present in human 
chondrocytes, we evaluated the expression of the different Kir and SUR subunits, both 
at the protein and mRNA levels, by western blot and qRT-PCR, respectively. The 
results obtained show that all the pore-forming and regulatory subunits that can 
compose K (ATP) channels are expressed in human chondrocytes, although with 
different intensities and inter-individual variability (Fig. 3.1). Kir6.1, SUR1, SUR2A and 
SUR2B are expressed both at the protein and mRNA levels (Fig. 3.1). Kir6.2 is 
apparently the most abundant of the pore-forming subunits at the protein level, but its 
mRNA is absent or, at least, is expressed at very low levels, which may simply indicate 
that this protein has a low turnover. On the other hand, even though the mRNAs of all 
the regulatory SUR subunits were detected in human chondrocytes (Fig. 3.1C), SUR2B 
seems to be expressed at the protein level more intensely than SUR2A, while SUR1 
was only detected at very low levels (Fig. 3.1A). Nonetheless, the apparently different 
intensities of those subunits may simply be accounted for by limitations of the western 
blot technique and distinct affinities of the antibodies used. Even though it was not 
possible to gather a sufficient number of cartilage samples of each OA grade to allow 
an adequate statistical analysis of the expression of each Kir6 and SUR subunit among 
the three experimental groups defined, the western blot images shown in Fig. 3.1B 
suggest that OA grade does not affect the protein levels of each subunit. 
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A 
K(ATP) channel subunits protein level in human chondrocytes  
  
Control 
 
HG 
    
Subunits 
 
Mean ± SED 
 
Mean ± SED 
 
P value 
 
N 
Kir6.1 
 
0.341±0.054 
 
0.382±0.073 
 
0.4322 
 
8 
Kir6.2 
 
2.304±0.239 
 
2.775±0.348 
 
0.2056 
 
6 
SUR -1 
 
0.099±0.025 
 
0.084±0.020 
 
0.201 
 
8 
SUR- 2A 
 
0,295±0.061 
 
0,260±0.059 
 
0.6151 
 
6 
SUR- 2B 
 
0.890±0.044 
 
0.842±0.058 
 
0.6513 
 
6 
 
B 
 
 
 
 
 
 
 
 
 
 
 
  C 
K(ATP) channel subunits mRNA levels (ΔΔCt relative to 18S rRNA)  
  
Control 
 
HG 
    
Gene Name 
 
Mean ± SEM 
 
Mean ± SEM 
 
P value 
 
N 
Kir6.1 
 
1.078±0.175 
 
1.030±0.168 
 
0.877 
 
5 
Kir6.2 
 
0.004±0.002 
 
0.028±0.009* 
 
0.004 
 
5 
SUR -1 
 
0.655±0.314 
 
0.370±0.199 
 
0.239 
 
5 
SUR-2A 
 
1.694±0.252 
 
0.968±0.188* 
 
0.015 
 
5 
SUR- 2B 
 
2.503±0.641 
 
1.975±0.652 
 
0.476 
 
5 
 
 
Figure 3.1 Protein and mRNA levels of K(ATP) channel subunits expressed in human 
chondrocytes A) Protein content of each Kir6 and SUR subunit in whole cell extracts 
from human chondrocytes exposed to high glucose (HG) (30 mM) for 18 h or left 
untreated (control). The protein content of each subunit was evaluated by Western 
blotting and normalized to the respective β‐tubulin band. B) Western blot images 
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representative of the protein content of each Kir6 and SUR subunit expressed in 
human chondrocytes according to OA grade, as defined in Materials and Methods 
Section. MW, molecular weight protein marker. C) mRNA content of each Kir6 and 
SUR subunit in human chondrocytes exposed to high glucose (HG) (30 mM) for 18 h or 
left untreated (control). The mRNA content of each subunit was evaluated by qRT‐PCR 
and normalized to the respective 18S rRNA content. 
 
3.2.2 Immunofluorescence staining of K(ATP) channels expressed in human 
chondrocytes 
 
To further confirm the results obtained in isolated chondrocytes (Fig. 3.1), the presence 
of each subunit in full depth normal (grade 0-1) cartilage samples was assessed by 
immunofluorescence.  
Fig. 3.2 shows the presence of chondrocytes staining positively for Kir6.1, Kir6.2, 
SUR2A and SUR2B scattered throughout the cartilage sections and in the midst of 
non-stained chondrocytes. No cells staining positively for SUR1 could be detected in 
any of the cartilage sections analysed. Although no quantitative analysis of the 
immunofluorescence images was performed, these results are in agreement with those 
obtained in cell extracts of isolated chondrocytes where SUR1 was detected at very 
low levels by western blot, while Kir6.2 and SUR2B seem to be more abundant. 
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Figure 3.2 In situ immunofluorescence staining of K(ATP) channel subunits in normal 
(OA grades 0–1) human cartilage. Each section was stained with an antibody specific 
for the subunit (green) identified in the upper right corner of the representative image 
and counterstained with DAPI (blue) to allow visualization of nuclei. Negative controls 
(column on the right) were obtained by omitting the primary antibody for each subunit. 
Cartilage sections were viewed and images captured at 100X and 400X (insets) 
magnifications.  
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3.2.3 Role of exposure to high glucose on K(ATP) channel subunit protein and 
mRNA expression 
 
To elucidate whether exposure to a hyperglycemia-like glucose concentration 
influences the subunit composition of K(ATP) channels, chondrocytes, classified 
according to OA grade, were treated with 30 mM glucose for 18 h and the protein and 
mRNA levels of each subunit were analysed by western blot and qRT-PCR, 
respectively. No differences in MTT reduction capacity were found between 
chondrocytes of either OA grade, exposed or not to high glucose for 18 h (data not 
shown), thus showing that exposure to high glucose did not affect chondrocyte viability. 
The results presented in Fig. 3.1 show that exposure to high glucose did not 
significantly affect the protein levels of SUR1, SUR2A, SUR2B, Kir6.1 or Kir6.2 relative 
to chondrocytes maintained in regular culture medium containing 10 mM glucose. 
However, as shown in Fig. 3.1C, a small, but statistically significant difference was 
found in the mRNA level of SUR2A between cells treated with 30 mM glucose 
(0.97±0.19) and control cells maintained in regular medium (10 mM glucose) 
(1.69±0.25). On the other hand, the mRNA levels of Kir6.2 were approximately 6.5 fold 
higher in cells cultured in high glucose for 18 h (0.028±0.009) than in those kept in 
regular medium (0.004±0.002), although the absolute levels in either condition were 
very low. 
 
3.2.4 Regulation of GLUT-1 and GLUT-3 protein levels by the K(ATP) channel 
blocker Glibenclamide 
 
To determine whether the activity of K(ATP) channels is involved in the regulation of 
glucose transporters in human chondrocytes, the cells were treated for 18 h with 
glibenclamide, a widely used SUR inhibitor that blocks K(ATP) channels [Burke et al., 
2008], in concentrations ranging from 10 nM to 20 µM. 
Data presented on Table 3.1 show that there are no significant differences in the basal 
protein levels of GLUT-1 and GLUT3 among the three groups defined according to the 
macroscopic OA grade, as defined in Materials and Methods. 
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Table 3.1 Basal protein levels of GLUTs-1 and -3 in human chondrocytes according to 
OA grade 
OA grade 
 
0 - 1 
 
2 - 3 
 
4 
    
 
Mean ± SEM 
 
Mean ± SEM 
 
Mean ± SEM 
 
P value 
 
N 
GLUT-1 0.58± 0.097 
 
0.70± 0.29 
 
0.66± 0.21 
 
0.919 
 
6 
GLUT-3 1.85± 0.58 
 
1.75± 0.14 
 
1.49± 0.34 
 
0.766 
 
5 
 
GLUT-1 protein levels were significantly decreased by treatment of grade 0-1 
chondrocytes with glibenclamide 10 nM (71.24 ± 6.59%, P=0.0009, n=7) and 20 nM 
(76.55± 9.47%, P=0.029, n=7), whereas only 10 nM was effective in decreasing GLUT-
1 protein levels in chondrocytes of OA grades 2-3 (82.16±4.27, P= 0.0024, n=7) and 4 
(76.3 ± 8.0, P=0.025, n=7) (Fig. 3.3A).  
Fig. 3.3B represents the results obtained for GLUT 3. It shows that a significant 
decrease of GLUT-3 occurs only in chondrocytes from groups with OA grade 0-1 and 
2-3 treated with 10 nM glibenclamide (64.17± 5.89, P=0.0038; n=3 and 79.77±7.38, 
P=0.0265; n=5, respectively), while no significant differences were found in OA grade 4 
chondrocytes with any of the glibenclamide concentrations tested. 
Regardless of the OA grade, glibenclamide concentrations above 20 nM had no effect 
either on GLUT-1 or -3 protein content, although for each OA grade the variability 
between chondrocytes isolated from different cartilage samples was higher than 
observed by treatment with 10 nM glibenclamide. 
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Figure 3.3 Regulation of total GLUT-1 and GLUT-3 protein content by glibenclamide in 
chondrocytes from different OA grades. A: Relative GLUT-1 protein levels normalized 
to the respective β-tubulin band, in whole cell extracts from human chondrocytes of OA 
grades 0–1 (n=7), 2–3 (n=7), and 4 (n=6) treated with the indicated concentrations of 
glibenclamide for 18 h. B: Relative GLUT-3 protein levels normalized to the respective 
β-tubulin band, in whole cell extracts from human chondrocytes of OA grades 0–1 
(n=3), 2–3 (n=5), and 4 (n=6) treated with the indicated concentrations of glibenclamide 
for 18 h. Results are expressed in percentage relative to control untreated cells of the 
same OA grade ***P <0.005; **P <0.01; *P <0.05 relative to the respective control 
cells. MW, molecular weight protein marker. C: GLUT-1 and -3 mRNA levels in 
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chondrocytes grades 0–1 treated with 10 nM glibenclamide for the time periods 
indicated, relative to untreated chondrocytes of the same OA grade. 
 
3.2.5 Role of Glibenclamide in regulating GLUT-1 and GLUT-3 mRNA levels in 
OA grade 0-1 chondrocytes 
 
To determine whether the decrease in the protein levels of GLUT-1 and GLUT-3 was 
due to glibenclamide effects at the transcriptional level, we analyzed the mRNA levels 
of both glucose transporters by qRT-PCR. Fig. 3.3C shows that there were no 
statistically significant differences in the mRNA levels of either glucose transporter in 
glibenclamide-treated groups compared to the control group at any treatment period 
considered. 
 
3.2.6 Role of glibenclamide in regulating cellular glucose transport 
 
To determine whether the effects of glibenclamide on GLUT-1 and -3 protein levels had 
functional consequences in terms of glucose transport capacity by chondrocytes of 
various OA grades, the uptake of [3H]2-DG was measured after treatment with 
glibenclamide for 18 h. The results obtained (Table 3.2) show no significant differences 
in 2-DG uptake by cells treated with any of the glibenclamide concentrations tested, 
compared with the corresponding control untreated chondrocytes of the same OA 
grade. 
 
 
  
Table 3.2 : Relative 2-DG uptake (% of untreated cells) 
Glibenclamide 
(nM) 
 
OA grade 0-1 
 
OA grade 2-3 
 
OA grade 4 
 
Mean±SEM P value N 
 
Mean±SEM P value N 
 
Mean±SEM P value N 
10 
 
92.63±9.79 0.4962 6 
 
106.9±5.98 0.2979 5 
 
94.03±3.14 0.2466 3 
20 
 
97.92±1.53 0.2347 6 
 
108.6±8.73 0.3777 4 
 
100.7±4.53 0.8422 3 
100 
 
93.95±5.36 0.3322 6 
 
102.2±8.03 0.7749 5 
 
87.33±5.37 0.1629 3 
20000 
 
100.6±3.24 0.8203 6 
 
113.7±8.10 0.1785 4 
 
91.41±8.36 0.4120 3 
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3.3 DISCUSSION 
 
Although the presence of Kir6.1 in human and equine chondrocytes has already been 
demonstrated [Mobasheri et al., 2007], this study represents the first comprehensive 
analysis of Kir6.x and SUR subunits expressed in human articular chondrocytes, both 
at the protein and mRNA levels. The results obtained (Figs. 3.1 and 3.2) suggest that 
Kir6.2 and SUR2B are major K(ATP) channel subunits expressed in human 
chondrocytes, while Kir6.1 and SUR2A are likely present at much lower levels and 
SUR1 is barely detectable or even undetectable. How the various Kir and SUR 
subunits expressed in human chondrocytes assemble to form functional K(ATP) 
channels is beyond the scope of this study and was not investigated. Nonetheless, it is 
possible that K(ATP) channels containing more than one SUR subtype co-exist with 
others containing only one SUR isoform. The relative abundance of each channel type 
would depend on the expression level of each subunit, as observed in other cells [Chan 
et al., 2008; Wheeler et al., 2008]. Since Kir 6.2 and SUR2B seem to be more 
abundant than the other Kir6 and SUR subunits, it seems likely that K(ATP) channels 
containing these subunits, namely octamers composed of Kir6.2 and SUR2B, 
predominate in human articular chondrocytes, although all other possible combinations 
of Kir6 and SUR subunits can also be present. Even though the scarcity of human 
cartilage samples did not allow us to determine the influence of the OA grade on the 
subunit composition of K(ATP) channels in human chondrocytes, the results presented 
in Fig. 3.1 suggest that none of the Kir6 or SUR subunits is affected at the protein level. 
The composition of those channels, at least at the protein level, was not significantly 
affected by culture under a supra-physiologic glucose concentration (30 mM), unlike 
demonstrated at the mRNA level in other cells, namely mediobasal hypothalamic 
neurons [Acosta-Martinez and Levine, 2007] and pancreatic β-cells [Moritz et al., 
2001]. 
The nucleotide binding affinity of SUR2B is much higher than that of SUR2A, but lower 
than that of SUR1, although its channel gating activity is similar to that of SUR1 
[Matsuo et al., 2000]. Therefore, SUR2B-containing K(ATP) channels are functionally 
very similar to those that contain SUR1, namely those expressed in pancreatic -cells 
[Burke et al., 2008] and in mediobasal hypothalamic neurons [Acosta-Martinez and 
Levine, 2007] that readily bind ATP in response to augmented glucose availability. To 
test the hypothesis that K(ATP) channels expressed in human chondrocytes behave 
similarly, we attempted to measure changes in membrane potential induced by culture 
under a supra-physiologic glucose concentration (30 mM) which is in the range of 
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plasma glucose concentrations found in diabetic patients. For this, we loaded the cells 
with the potential-sensitive fluorescence dye, bis-(1,3-dibutylbarbituric acid)trimethine 
oxonol [DiBAC 4 (3)] that becomes fluorescent upon depolarization. Unfortunately, we 
were unable to detect any changes using fluorescence spectroscopy, probably 
because changes in membrane potential occur in a very dynamic and fast manner. 
Possibly, in vivo fluorescence imaging may be required to detect such fast and 
transient changes. Therefore, we were unable to directly demonstrate whether glucose 
availability affects the chondrocyte membrane potential.  
To further test the hypothesis that K(ATP) channels function as metabolic sensors in 
human chondrocytes playing a role in the modulation of glucose transport capacity, we 
used glibenclamide, a widely used SUR inhibitor, to block these channels and 
measured the whole cell content of major glucose transporters, GLUT-1 and GLUT-3. 
Glibenclamide displays differential selectivity towards distinct SUR subunits, being 
moderately selective for SUR1 [Burke et al., 2008]. The sensitivity of equine 
chondrocytes to glibenclamide is lower than that found in cells expressing SUR1 and in 
the same range of that presented by cells in which K(ATP) channels contain SUR2B 
[Mobasheri et al., 2007] which further suggests that K(ATP) channels containing this 
subunit are relevant in human chondrocytes. Nevertheless, as K(ATP) channels 
composed of other subunits may also exist in human chondrocytes, we used 
glibenclamide concentrations ranging from 10 nM to 200 M in order to cover the whole 
range of channel sensitivities to this SUR inhibitor. Interestingly, only the lowest 
concentration was effective in reducing GLUT-1 protein content in chondrocytes from 
all OA grades, whereas 20 nM was effective only in grade 0-1 OA chondrocytes (Fig. 
3.3A). GLUT-3 content, however, was only reduced by treatment of grades 0-1 and 2-
3, but not grade 4 OA chondrocytes with glibenclamide 10 nM (Fig. 3.3B). These 
results indicate that closing K(ATP) channels, at least partially, is sufficient to reduce 
the cell protein content of two major glucose transporters, GLUT-1 and GLUT-3, 
without affecting their mRNA levels, in normal human chondrocytes, in a way similar to 
the reduction induced by exposure to 30 mM glucose [Rosa et al., 2009].  
The inability of OA chondrocytes to downregulate the protein levels of GLUT-1 and 
GLUT-3 in response to glibenclamide (Fig. 3.3), mimicking their inability to adjust to 
high extracellular glucose concentrations [Rosa et al., 2009], further indicates that 
either K(ATP) channels are functionally defective or some other downstream 
component or process is impaired in OA chondrocytes. Nonetheless, the possibility that 
ATP production may simultaneously be impaired in advanced OA chondrocytes cannot 
be excluded. 
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Another intriguing question arises from the observation that the response to 
glibenclamide in terms of GLUT-1 and GLUT-3 protein content, occurred only with the 
lowest glibenclamide concentrations tested. In equine chondrocytes, similar 
glibenclamide concentrations (10-20 nM) elicited a partial reduction in current 
amplitude, while much higher concentrations in the range of 100-300 nM were required 
to completely block K(ATP) channel activity [Mobasheri et al., 2007]. Therefore, it is 
possible that different ranges of channel activity elicit distinct changes in membrane 
potential that operate diverse signalling pathways and cell responses. This is further 
supported by the observation that K(ATP) channels with distinct subunit compositions 
and therefore with different glibenclamide and nucleotide sensitivities, may coexist in 
human chondrocytes (Figs. 3.1 and 3.2). 
Nonetheless, glibenclamide-induced changes in the total protein content of GLUT-1 
and GLUT-3 were not accompanied by corresponding decreases in glucose transport 
capacity by chondrocytes of any OA grade (Table 3.2). This suggests that even though 
K(ATP) channel activity regulates the availability of GLUT-1 and GLUT-3, other 
mechanisms are involved in the regulation of the overall glucose transport capacity of 
human chondrocytes. On one hand, other glucose transporters known to be expressed 
in chondrocytes [Mobasheri et al., 2008] may not be regulated by K(ATP) channels and 
compensate for changes in GLUT-1 and -3. On the other hand, GLUT-1 has been 
shown to exist in a dynamic equilibrium involving the plasma membrane, intracellular 
storage in the trans Golgi network and lysosomal degradation [Ortiz et al., 1992]. Our 
previous study indicated that high glucose-induced GLUT-1 downregulation involved 
lysosomal degradation [Rosa et al., 2009]. Thus, it is possible that K(ATP) channel 
activity affects total GLUT-1 and possibly GLUT-3 protein content by increasing 
lysosomal degradation of intracellular stores, in agreement with studies in other cells 
suggesting that GLUT-1 degradation and functional membrane expression may be 
regulated through independent pathways [Ortiz et al., 1992]. 
In summary, this study contributes to elucidate the subunit composition of K(ATP) 
channels expressed in human chondrocytes and establishes a role for these channels 
as components of the glucose sensing apparatus in these cells by demonstrating that 
their activity influences the abundance of two major glucose transporters, GLUT-1 and 
GLUT-3. Nonetheless, since glucose transport was not similarly affected, additional 
mechanisms must be involved in the adaptation of human chondrocytes to high 
extracellular glucose concentrations. Moreover, this study also shows that 
chondrocytes isolated from cartilage of increasing OA grade are less responsive to 
changes in K(ATP) channel activity, which may contribute to the inability of OA 
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chondrocytes to downregulate glucose transporters and avoid the deleterious effects of 
high extracellular glucose concentrations that we have previously observed [Rosa et 
al., 2009; Rosa et al., 2011b]. Taken together, the results presented highlight the 
importance of K(ATP) channels as metabolic sensors and potential components of a 
broad glucose sensing apparatus that allows human chondrocytes to adjust to varying 
extracellular glucose concentrations. 
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ABSTRACT 
 
Objective: This work aimed at determining whether high glucose induces inflammatory 
responses in human chondrocytes. Since hyperinsulinemia often accompanies DM 
type 2, we also evaluated the ability of insulin to modulate inflammatory responses 
induced by high glucose. 
Method: We analyzed IL-1β, TNF-α and inducible nitric oxide synthase (iNOS) 
expression by qRT-PCR and nuclear NF-κB p65 accumulation by western blot in 
human chondrocytes cultured in medium containing 10 or 30 mM glucose.  
Results: Culture in high glucose (30 mM) for 24h increased iNOS mRNA and protein 
levels and NO production by 61% (P=0.0017), 148% (P=0.0089) and 70% (P=0.049), 
respectively, relative to human chondrocytes maintained in 10 mM glucose. Similarly, 
IL-1β and TNF-α mRNA levels increased by 97 (P=0.0066) and 85% (P=0.0045), 
respectively. NF-κB p65 nuclear levels increased in a time-dependent manner, peaking 
at 1h. Treatment with 100 nM insulin also increased nuclear p65 levels, independently 
of the glucose concentration. 
Conclusion: This study shows that hyperglycemia and hyperinsulinemia induce 
inflammatory responses in human chondrocytes. This can be a relevant mechanism by 
which DM type 2, obesity, the metabolic syndrome and other conditions associated 
with impaired glucose and insulin homeostasis contribute to the development and 
progression of OA. 
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4.1 INTRODUCTION 
 
Aging is the major risk factor for osteoarthritis (OA), but other factors have been 
recognized [Berenbaum, 2011; Zhang and Jordan, 2010], including diabetes mellitus 
(DM), especially type 2, and impaired glucose homeostasis  Recent epidemiologic 
studies demonstrated that DM is an independent risk factor for OA development and 
progression [Nieves-Plaza et al., 2013; Schett et al., 2012a], supporting the notion of a 
specific diabetes-induced OA phenotype [Berenbaum, 2011; Zhang and Jordan, 2010]. 
How DM and impaired glucose homeostasis contribute to cartilage and joint destruction 
is largely unknown. 
Chronic low grade inflammation is a major OA driver, being associated with other 
mechanisms involved in OA pathogenesis, including cell senescence, oxidative stress, 
mitochondrial dysfunction and impaired autophagy, which together contribute to cell 
depletion and imbalanced anabolic and catabolic responses, especially in 
chondrocytes [Lotz and Carames, 2011]. 
All the above mechanisms, including inflammation, have been associated with the 
effects of hyperglycemia and have been implicated in DM pathogenesis and its 
complications [Donath and Shoelson, 2011]. 
Only a few studies have been conducted so far to identify direct effects of glucose in 
articular chondrocytes, collectively indicating that hyperglycemia-like glucose 
concentrations favor catabolic processes and impair anabolic responses. Our previous 
studies showed that exposure to high glucose causes oxidative stress and induces 
catabolic responses in human chondrocytes, especially from OA/aged articular 
cartilage [Rosa et al., 2009; Rosa et al., 2011a]. 
Given the role of inflammation in OA and in mediating hyperglycemia-induced effects in 
other cells, this study aimed at determining whether high glucose induces inflammatory 
responses in human chondrocytes. Since hyperinsulinemia often accompanies DM 
type 2, we also evaluated the ability of insulin to modulate inflammatory responses 
induced by high glucose. 
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4.2 RESULTS 
 
4.2.1 Induction of pro-inflammatory cytokines, iNOS expression and NO 
production by high glucose 
 
Figure 4.1 shows that culture of human chondrocytes in medium containing 30 mM 
glucose for 24 h is sufficient to increase IL-1β and TNF-α mRNA levels relative to those 
found in chondrocytes maintained in 10 mM glucose medium. Moreover, 30 mM 
glucose also induced iNOS expression, both at the mRNA and protein levels, and 
activity as shown by the augmented NO production. 
 
Figure 4.1 Role of high glucose in modulating pro-inflammatory cytokines, iNOS 
expression and NO production. mRNA levels of iNOS, IL-1β and TNF-α (A), protein 
levels of iNOS (B) and NO production (C) were measured in human chondrocytes 
cultured for 24 (A) or 72 h (B, C) in medium containing 10 or 30 mM glucose. The 
results represent the means and 95% confidence intervals relative to cells in 10 mM 
glucose. 
 
4.2.2 High glucose induces NF-κB p65 translocation to the nucleus 
 
As human cartilage samples are limited and a large number of cells was required, the 
human chondrocytic cell line, C-28/I2, was used to evaluate the ability of high glucose 
to induce NF-κB activation. This requires the phosphorylation and subsequent 
ubiquitination and proteassomal degradation of an inhibitory protein, IκB-α (NF-κB 
Inhibitor-α), which, in basal conditions, retains NF-κB dimers in the cytoplasm. Once 
IκB-α is degraded, the NF-κB dimers translocate to the nucleus promoting the 
transcription of target genes. Therefore, activation of this transcription factor leads to its 
nuclear translocation that can be detected as the nuclear levels of p65 (Rel A), a major 
component of NF-κB dimers found in chondrocytes [Mendes et al., 2002c]. 
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Figure 2A shows that nuclear p65 levels gradually increased during culture in 30 mM 
glucose, peaking at 1h. After 2h, nuclear levels of p65 were identical to those found in 
cells maintained in 10 mM glucose and remained as such until up to, at least, 24h. Co-
treatment with the specific IκB-α phosphorylation inhibitor, Bay-11-7082, completely 
reversed the high glucose-induced effect. 
To rule out osmotic effects, 20 mM mannitol, a non-absorbable polysaccharide, were 
added to the medium containing 10 mM glucose. No significant changes were 
observed in cells cultured in this medium for 1h (mean=80.5, 95% CI: 61.0-100.0, 
P=0.348) relative to those cultured in 10 mM glucose, indicating that the effects 
detected with 30 mM glucose are not due to osmotic stimulation. 
 
 
Figure 4.2 Role of glucose and insulin concentrations on nuclear NF-κB p65 levels. A) 
C28/I2 cells were cultured in 10 or 30 mM glucose, with or without 5 μM Bay-11782, a 
specific IκB-α phosphorylation inhibitor, for the indicated time periods. B) Insulin, 10 or 
100 nM, was added to C28-I2 cultures in medium with 10 or 30 mM glucose for 1h. The 
results represent the means and 95% confidence intervals relative to cells in 10 mM 
glucose. 
 
4.2.3 High Insulin modulates NF-κB translocation to the nucleus 
 
To determine whether insulin modulates the inflammatory state induced by high 
glucose, we evaluated the effect of physiologic (10 nM) and supraphysiologic (100 nM) 
insulin concentrations on p65 nuclear levels in C28-I2 cells cultured in 10 or 30 mM 
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glucose. Figure 4.2B shows that treatment of cells in 10 mM glucose medium with 100 
nM insulin increased nuclear p65 levels to the same extent as 30 mM glucose. 
Simultaneous treatment with high glucose (30 mM) and 100 nM insulin did not further 
increase nuclear p65 levels. On the other hand, 10 mM insulin did not affect p65 
nuclear levels, regardless of the glucose concentration in the medium. 
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4.3 DISCUSSION 
 
The present study aimed at determining whether high, hyperglycemia-like, glucose 
concentrations induce inflammatory responses in human chondrocytes and thus, 
contribute to unveil pathological mechanisms by which DM and impaired glucose 
homeostasis can favor OA initiation and progression. For this purpose, we exposed 
human chondrocytes to culture medium containing 10 or 30 mM glucose and compared 
the expression of pro-inflammatory mediators known to be relevant in OA 
pathogenesis, namely the pro-inflammatory and pro-catabolic cytokines, IL-1β and 
TNF-α, and iNOS, the enzyme responsible for the production of large amounts of NO 
[Stadler et al., 1991] To further elucidate the mechanisms involved, we also evaluated 
the ability of high glucose (30 mM) to activate the transcription factor, Nuclear Factor-
κB (NF-κB), which plays a central role in inducing inflammatory and catabolic gene 
expression, including IL-1β, TNF-α and iNOS, in chondrocytes [Rosa et al., 2008]. 
The results obtained show that culture under high glucose is sufficient to induce NF-κB 
activation and the expression of IL-1β, TNF-α and iNOS. These observations, along 
with the pro-catabolic and anti-anabolic effects that we reported previously [Rosa et al., 
2009; Rosa et al., 2011a], support the hypothesis that hyperglycemia can drive 
cartilage damage and, thus, OA. 
These results are consistent with several reports that demonstrated the induction of 
exacerbated inflammatory responses by hyperglycemia in various human tissues and 
cells [Donath and Shoelson, 2011; Jia et al., 2013]. 
iNOS mRNA and protein levels were similarly upregulated by high glucose, suggesting 
that this effect occurs at the transcriptional level, since it is the major mechanism of 
iNOS regulation. Nonetheless, upregulated iNOS mRNA levels were detected upon 
culture in high glucose for 24h, whereas measurable amounts of the protein and NO 
were detected after 72h and required culture periods longer than, at least, 48h. 
Moreover, NF-κB activation was maximal after exposure to high glucose for 1h and by 
2h the effect had returned to levels found in the control. This kinetics is similar to NF-κB 
activation by other stimuli, like IL-1β, which on the contrary allows iNOS protein to be 
detected much earlier than observed here with high glucose [Mendes et al., 2002c]. 
This suggests that other mechanisms may contribute to induce iNOS expression in 
response to high glucose. One possibility is that high glucose-induced IL-1β and TNF-
α, which are potent iNOS inducers in chondrocytes [Stadler et al., 1991] are required to 
mediate iNOS expression. On the other hand, since we did not evaluate the protein 
levels of those cytokines, we cannot exclude the possibility that unknown mechanisms 
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lead to a large gap between mRNA transcription of the three genes and synthesis of 
the corresponding proteins. 
The rapid nuclear translocation of p65 induced by high glucose, suggests a direct effect 
on the NF-κB signalling pathway in chondrocytes. This is further supported by the 
finding that the IκB-α phosphorylation inhibitor, Bay 11-7082, completely abolished high 
glucose-induced nuclear p65 accumulation. This suggests that IκB-α phosphorylation 
or another upstream event on the NF-κB activation pathway is sensitive to high 
glucose. 
Insulin, especially in supraphysiologic concentrations, was shown to induce anabolic 
and inhibit catabolic responses in adult chondrocytes and cartilage explant cultures 
from various species [Kellner et al., 2001; Rosa et al., 2011a]. Thus, we hypothesized 
that insulin might counteract the deleterious pro-inflammatory effects of high glucose 
that we observed in chondrocytes. Surprisingly, 100 nM insulin were sufficient to 
induce nuclear p65 accumulation, either alone or in combination with high glucose, 
whereas 10 nM insulin, which is at the upper physiologic limit had no effect. These 
results are in agreement with a recent study showing that insulin, in concentrations 
similar to those we used, induced NF-κB activation and synergized with TNF-α in 
cardiac myoblasts [Madonna et al., 2014]. Moreover, accumulating evidence is 
unravelling a role for hyperinsulinemia in driving or at least contributing to the low-
grade inflammation characteristic of metabolic disorders, from obesity and DM type 2 to 
the metabolic syndrome and their complications [Guo, 2014]. The results presented 
here also point to the possibility that hyperinsulinemia can induce inflammatory 
responses in chondrocytes by activating NF-κB. Nonetheless, further studies are 
required to confirm the proinflammatory effects of hyperinsulinemia in primary human 
chondrocytes. 
In summary, this study shows for the first time that hyperglycemia and 
hyperinsulinemia can induce inflammatory responses in human chondrocytes. This can 
be a relevant mechanism by which DM type 2, obesity, the metabolic syndrome and 
other conditions associated with impaired glucose and insulin homeostasis contribute 
to the development and progression of OA. 
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ABSTRACT 
 
Context: Effective drugs to treat osteoarthritis (OA) and inflammatory bowel disease 
(IBD) are needed. 
Objective: To identify essential oils (EOs) with anti-inflammatory activity in cell models 
of OA and IBD. 
Material and methods: EOs from Eryngium duriaei subsp. juresianum (M. Laínz) M. 
Laínz (Apiaceae), Laserpitium eliasii subsp. thalictrifolium Sennen & Pau (Apiaceae), 
Lavandula luisieri (Rozeira) Rivas-Martínez (Lamiaceae), Othantus maritimus (L.) Hoff. 
& Link (Asteraceae) and Thapsia villosa L. (Apiaceae) were analyzed by GC and 
GC/MS. The anti-inflammatory activity of the EOs (5-200 μg/mL) was evaluated by 
measuring iNOS and NF-κB activation (total and phosphorylated IκB-α), in primary 
human chondrocytes and the intestinal cell line, C2BBe1, stimulated with IL-1β or IFN-
γ, IL-1β and TNF-α, respectively. 
Results: The EO of L. luisieri significantly reduced iNOS (by 54.9 and 81.0%, 
respectively) and phosphorylated IκB-α (by 87.4% and 62.3%, respectively), in both cell 
models. The EO of E. duriaei subsp. juresianum caused similar effects in human 
chondrocytes, but was inactive in intestinal cells, even at higher concentrations. The 
EOs of L. eliasii subsp. thalictrifolium and O. maritimus decreased iNOS expression by 
45.28.7% and 45.26.2%, respectively, in C2BBe1 cells and were inactive in 
chondrocytes. The EO of T. villosa was inactive in both cell types. 
Discussion and conclusion: This is the first study showing anti-inflammatory effects of 
the EOs of L. luisieri and E. duriaei subsp. juresianum. These effects are cell type-
specific and may be valuable to develop new therapies or as sources of active 
compounds with improved efficacy and selectivity towards OA and IBD. 
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5.1 INTRODUCTION 
 
An increasing number of reports describes anti-inflammatory properties of many natural 
products and compounds. Nonetheless, very few studies have been dedicated to 
evaluate their therapeutic potential on chronic inflammatory diseases. These remain 
important therapeutic targets due to their high prevalence and lack of effective 
therapies. Indeed, most studies concerning anti-inflammatory properties of natural 
products have been performed in cell or animal models of acute inflammation. These 
models do not entirely reflect pathological mechanisms and cells involved in chronic 
inflammatory diseases. 
Among natural products, essential oils (EOs) are particularly interesting to look for 
compounds with pharmacological activities, since they are complex mixtures of a huge 
diversity of low molecular weight (<300 Da) lipophilic compounds. These characteristics 
may represent favorable pharmacokinetic properties [Miguel, 2010]. 
Recent reviews on the anti-inflammatory potential of EOs fully highlight that these plant 
extracts and some of their components are useful therapeutic alternatives, modulating 
several molecular targets of the acute inflammation cascades, namely in cells of the 
immune system, like monocytes and macrophages [Adorjan and Buchbauer, 2010; 
Miguel, 2010]. There is also an evident lack of information on the potential of EOs as 
modulators of chronic inflammatory diseases, especially involving cells unrelated to the 
immune system. Exceptions are two reports from our group [Neves et al., 2009; Rufino 
et al., 2014] describing anti-inflammatory effects of the EO of Juniperus oxycedrus L. 
subsp. oxycedrus (Cupressaceae) and -pinene in a cell model of osteoarthritis (OA). 
Chronic inflammatory diseases, in general, lead to the up-regulation of a series of 
enzymes and signalling molecules that bring about the characteristic inflammation and 
tissue destruction. Likewise, OA and Inflammatory Bowel Disease (IBD) share many 
features and mechanisms and are largely driven and perpetuated by pro-inflammatory 
cytokines, such as Interleukin-1β (IL-1β), Tumor necrosis factor-α (TNF-α) and 
Interferon- (IFN-) [Goldring and Otero, 2011; Goldring et al., 2008; Jobin and Sartor, 
2000; Wielockx et al., 2004]. In chronic inflammatory diseases, the onset and 
perpetuation of inflammatory responses and tissue destruction are primarily dependent 
on the transcription factor, Nuclear Factor-κB (NF-κB) [Tak and Firestein, 2001]. This 
promotes the expression of inflammation-related genes, including cytokines (IL-1β, 
TNF-α, IL-6, etc.) and enzymes. One of these, the inducible nitric oxide synthase 
(iNOS), produces large amounts of nitric oxide (NO), a potent and destructive 
inflammatory mediator that plays an important role in the development and progression 
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of OA and IBD. For instance, our previous study showed that iNOS expression, NO 
production and NF-κB activity are spontaneously increased in chondrocytes isolated 
from OA patients compared to those isolated from non-affected human cartilage [Rosa 
et al., 2008]. Increased mucosal and plasma NO concentrations associated with 
augmented iNOS activity have also been demonstrated in active IBD [Quenon et al., 
2012]. Moreover, NF-κB promotes the expression of specific proteases that degrade 
the extracellular matrix, causing the characteristic tissue destruction of OA and IBD 
[Goldring and Otero, 2011; Jobin and Sartor, 2000; Wielockx et al., 2004]. 
Therefore, this transcription factor constitutes an attractive target for anti-inflammatory 
therapeutic interventions both in OA and IBD [Berenbaum, 2004; Goldring and Otero, 
2011; Jobin and Sartor, 2000; Marcu et al., 2010]. Hence, we proposed to study the 
ability of EOs to inhibit NF-κB activation in cell models of these diseases. 
To address this purpose, EOs to be screened were selected considering two major 
criteria: i) to collectively ensure the highest diversity of compounds from the chemical 
classes usually found in EOs; and ii) availability of etnopharmacological information or 
previous evidence of anti-inflammatory activity. For this, several EOs, isolated at 
laboratory from native or endemic species of the Iberian flora, were first fully 
characterized by identification and quantification of their components. Upon 
composition elucidation, the EOs were assayed in cellular models relevant for the study 
of OA and IBD [Csaki et al., 2009; Megias et al., 2007]. Since we found previously that 
α-pinene inhibits inflammatory and catabolic responses in human chondrocytes, 
namely IL-1β-induced NF-κB activation [Neves et al., 2009; Rufino et al., 2014], we 
also tested this compound in the cellular model of IBD. 
Primary human chondrocyte cultures stimulated with IL-1β were used as an in vitro 
cartilage degradation model that emulates the damage seen in OA and cultures of the 
human colorectal adenocarcinoma cell line, C2BBe1, stimulated with a mixture of pro-
inflammatory cytokines composed of IFN-γ, TNF-α and IL-1β, were used as a model of 
IBD. 
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5.2 RESULTS 
 
5.2.1 Composition of the essential oils 
 
Chemical characterization of the EOs of L. luisieri, E. duriaei subsp. juresianum, O. 
maritimus, L. eliasii and T villosa allowed the identification and quantification of 94, 25, 
30, 42 and 14 compounds, respectively, comprising at least 85% of the respective 
composition. Table 5.1 summarizes the composition of each EO, indicating the relative 
amounts of grouped components and the most representative compounds (≥ 2%). 
Thirty-eight compounds, comprising seven monoterpene hydrocarbons, twelve oxygen-
containing monoterpenes, including four necrodane derivatives, eight sesquiterpene 
hydrocarbons, nine oxygen-containing sesquiterpenes, the phenylpropanoid, 
methyleugenol, and the aliphatic, n-nonane, were found in concentrations over 2.0% in, 
at least, one EO. 
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Table 5.1 Classes of compounds and major constituents of the essential oils tested 
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5.2.2 Evaluation of cytotoxicity and selection of non cytotoxic concentrations 
of the essential oils 
 
Neither the EOs nor α-pinene were cytotoxic to C2BBe1 cells in concentrations up to 
200 µg/mL, either in the presence or absence of the pro-inflammatory cytokine mixture 
(Fig. 5.1C and D). On the contrary, in human chondrocytes, only the EO of T. villosa 
had no significant cytotoxic effects at that concentration (Fig. 5.1A and B). In 
concentrations up to 50 μg/mL for 24 h, the EOs of E. duriaei subsp. juresianum, L. 
eliasii and L. luisieri did not affect chondrocyte viability either in the presence or 
absence of IL-1β. The EO of O. maritimus showed no cytotoxicity at concentrations up 
to 100 μg/mL (Fig. 5.1A and B). Therefore, subsequent experiments were performed 
using the non-cytotoxic concentrations identified for each EO in each cell model, as 
shown in Fig. 5.1. 
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Figure 5.1 Viability of human chondrocytes (A and B) and C2BBe1 cells (C and D) 
treated with the EOs for 24 h in the absence (A and C) or presence (B and D) of the 
respective pro-inflammatory stimulus. Each column represents, at least, 4 independent 
experiments. The dotted line represents the limit below which cell viability is impaired. 
§P <0.05, §§P <0.01 relative to the respective control (untreated) cells. 
 
5.2.3 Effect of the EO’s on cytokine induced iNOS expression and NO 
production 
 
Treatment of human chondrocytes (Fig. 5.2) and C2BBe1 cells (Fig. 5.3) with IL-1β or 
CytMix, respectively, for 24 h, strongly induced the expression of iNOS. Accordingly, 
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human chondrocytes stimulated with IL-1β produced almost six-fold more NO than 
control cells, as shown by the concentration of nitrite accumulated in the respective 
culture medium (15.6 ± 1.9 µM and 2.7 ± 0.8 µM, respectively, P<0.001, Fig. 5.4). 
 
Figure 5.2 Effect of the EOs on iNOS protein expression in human chondrocytes left 
untreated (Ctrl) or treated with IL-1β, 10 ng/mL, for 24 h, after pre-treatment with each 
EO. The images shown are representative of, at least, 3 independent experiments. 
**P<0.01, ***P<0.001 relative to cells treated with IL-1β. #P<0.05 and ##P<0.01 
between different concentrations of the same essential oil (one-way ANOVA). 
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Surprisingly, no differences in nitrite concentration were detected in C2BBe1 cell 
cultures treated with the CytMix for various periods (6-48 h) in comparison with 
untreated cells (data not shown). As measurement of NO production was used just as 
a rapid screening assay and iNOS protein was readily identified, no other methods 
were used to detect NO production in C2BBe1 cells. 
Figure 5.3 Effect of the EOs on iNOS protein expression in C2BBe1 cells left untreated 
(Ctrl) or treated with CytMix, for 24 h, after pre-treatment with each EO. The images 
shown are representative of, at least, 3 independent experiments. *P< 0.05, **P<0.01, 
***P<0.001 relative to cells treated with CytMix. 
Of the EOs tested, only those of L. luisieri and E. duriaei subsp. juresianum were 
effective in decreasing iNOS expression (Fig. 5.2) and the subsequent NO production 
(Fig. 5.4) in human chondrocytes. The EOs of L. eliasii and O. maritimus produced a 
statistically significant, but very modest decrease of NO production (Fig. 5.4), even 
though no significant effects were detected on iNOS protein levels (Fig. 5.2). The EO of 
T. villosa had no significant effects, either on iNOS protein levels (Fig. 5.2) or NO 
production (Fig. 5.4). 
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Figure 5.4 Effect of the EOs on IL-1β-induced NO production in human chondrocytes 
left untreated (Ctrl) or treated with IL-1β, 10 ng/mL, for 24h, after pre-treatment with 
each EO. Each column represents, at least, 4 independent experiments. *P<0.05, and 
***P<0.001 relative to IL-1β-treated cells. 
 
In C2BBe1 cells, the EO of L. luisieri, at a concentration of 200 μg/mL, achieved the 
highest inhibition of iNOS expression (81.0 ± 5.2%). At a concentration of 50 μg/mL, 
iNOS levels were similarly reduced in C2BBe1 cells and in chondrocytes (Fig. 5.3). The 
EOs of L. eliasii and O. maritimus significantly reduced iNOS protein levels (by 45.2 ± 
8.7% and 45.2 ± 6.2%, respectively) in C2BBe1 cells, but were much less effective 
than the EO of L. luisieri (Fig. 5.3). Noticeably in these cells, the EO of E. duriaei 
subsp. juresianum had no significant effect on iNOS expression (Fig. 5.3), even at a 
concentration of 100 μg/mL which is several fold higher than those tested in human 
chondrocytes. Neither the EO of T. villosa nor α-pinene had any significant effect (Fig. 
5.3). 
 
5.2.4 Effect of the EO’s of Lavandula luisieri and Eryngium duriaei subsp. 
juresianum on NF-κB activation 
 
In response to appropriate stimuli, the NF-κB inhibitory protein, IκB-α, is 
phosphorylated and subsequently degraded, which releases NF-κB and allows its 
translocation to the nucleus to induce the expression of target genes [Hayden and 
Ghosh, 2008a; O'Dea and Hoffmann, 2009]. To assess NF-κB activation, we evaluated 
the cytoplasmic levels of phosphorylated and total IκB-α. 
The EOs more effective in inhibiting iNOS expression and NO production were 
selected to evaluate their ability to inhibit IL-1β-induced NF-κB activation in human 
chondrocytes and C2BBe1 cells. 
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In human chondrocytes, the EOs of L. luisieri and E. duriaei subsp. juresianum, at the 
concentration of 200 µg/mL, completely inhibited IL-1β-induced IκB-α phosphorylation, 
achieving an effect similar (P=0.82 and P=0.25, respectively) to that elicited by Bay 11-
7082, a specific inhibitor of IκBα-phosphorylation [Mendes Sdos et al., 2009] used as a 
positive control (Fig. 5.5). Total IκB-α levels relative to those in control cells increased 
from 4.3 ± 1.5% (n=4) in IL-1β-treated chondrocytes to 47.9 ± 10.7% (n=4) and 55.6 ± 
9.9% (n=4) in cells treated with 200 μg/mL of the EOs of L. luisieri and E. duriaei 
subsp. juresianum, respectively. Moreover, total IκB-α levels in chondrocytes treated 
with 200 μg/mL of the EO of E. duriaei subsp. juresianum were not significantly 
different from those observed in control cells, indicating that this concentration 
completely prevented the response induced by IL-1β. 
 
Figure 5.5 Effect of the EOs of L. luisieri and E. duriaei subsp. juresianum on IL-1β-
induced IκB-α phosphorylation and degradation in chondrocytes left untreated (Ctrl) or 
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treated with IL-1β, 10 ng/mL, for 5 (A) or 30 min (B) after pre-treatment with the EOs or 
Bay 11-7082 (5 µM). The images shown are representative of, at least, 4 independent 
experiments. *P<0.05, and ***P<0.001 relative to IL-1β-treated cells. §P<0.05, and 
§§§P<0.001 relative to Ctrl. 
 
In C2BBe1 cells, the EO of L. luisieri, at concentrations of 50 and 200 µg/mL, 
significantly reduced IκB-α phosphorylation to 77.3 ± 8.7% (n=7) and to 37.7 ± 3.0% 
(n=7), respectively, of the CytMix-induced response (Fig. 5.6). Total IκB-α levels 
increased from 11.7 ± 1.2% in CytMix-treated cells to 30.4 ± 4.3% (n=8) in L. luisieri-
treated cells relative to the control, indicating that the EO effectively decreased CytMix-
induced NF-κB activation. Moreover, 200 μg/mL of this EO inhibited IκB-α 
phosphorylation to even a larger extent than the positive control, Bay 11-7082 
(P=0.028), while IκB-α degradation was similarly inhibited (P=0.31). 
 
Figure 5.6 Effect of the EO of L. luisieri on CytMix-induced IκB-α phosphorylation and 
degradation in intestinal C2BBe1 cells left untreated (Ctrl) or treated with CytMix for 5 
min (A) or 30 min (B) after pre-treatment with the EO or Bay 11-7082 (5 µM). The 
images shown are representative of, at least, 4 independent experiments. *P<0.05, 
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**P<0.01 and ***P<0.001 relative to CytMix-treated cells. §§§P<0.001 relative to Ctrl and 
###P<0.001 between different concentrations of the same essential oil (one-way 
ANOVA)  
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5.3 DISCUSSION 
 
The results presented show clear differences in the ability of the EOs tested to inhibit 
relevant mediators of inflammation in the two cell models of OA and IBD used. Such 
differences are evident among distinct EOs, as well as comparing each one in the two 
cell models. Indeed, only the EO of L. luisieri was capable of significantly inhibiting 
inflammatory markers (iNOS expression and NF-κB activation) both in human 
chondrocytes and intestinal C2BBe1 cells. These results confirm our previous 
observation that this EO inhibits IL-1β-induced NO production in human chondrocytes 
[Neves et al., 2009]. On the other hand, the EO of E. duriaei subsp. juresianum did not 
significantly inhibit iNOS expression in intestinal cells over a wide range of 
concentrations, but was effective in human chondrocytes, even at much lower 
concentrations. Conversely, the EOs of O. maritimus and L. eliasii showed some 
activity in intestinal cells, but were inactive in chondrocytes. These results indicate that 
the EOs of L. luisieri and E. duriaei subsp. juresianum have cell type-specific anti-
inflammatory effects.  
To our knowledge, this is the first study showing anti-inflammatory effects of the EOs of 
L. luisieri and E. duriaei subsp. juresianum. Indeed, EOs from Lavandula ssp, namely 
L. angustifolia L. stoechas, L. multifida and L. viridis, have demonstrated antibacterial, 
antifungal, analgesic and anti-inflammatory effects [Amira et al., 2012; Ghelardini et al., 
1999; Kirmizibekmez et al., 2009; Zuzarte et al., 2011a; Zuzarte et al., 2011b], while 
the EO of L. luisieri has only been reported to have antifungal effects [Zuzarte et al., 
2012]. On the other hand, EOs from Eryngium ssp, including E. duriaei subsp. 
juresianum, have been shown to have anti-fungal and anti-bacterial properties 
[Cavaleiro et al., 2011; Celik et al., 2011], whereas anti-inflammatory effects were only 
reported for aqueous or alcoholic extracts from Eryngium species [Dawilai et al., 2013; 
Kupeli et al., 2006]  not including E. duriaei subsp. juresianum. 
α-Pinene from a commercial source (purity ≥ 98%) was unable to decrease iNOS 
expression in intestinal cells, while our previous studies showed that both commercial 
α-pinene[Rufino et al., 2014] and the EO of J. oxycedrus subsp. oxycedrus (76.4% α-
pinene) and one of its fractions (93% α-pinene) [Neves et al., 2009], were effective in 
human chondrocytes. Interestingly, the EOs of L. luisieri, O. maritimus and L. eliasii, 
the only ones containing significant amounts of α-pinene (2.3%, 6.7% and 30.5%, 
respectively), were all effective in intestinal cells, but only that of L. luisieri was also 
effective in human chondrocytes, even though it presents the lowest α-pinene content. 
Taken together, these results suggest that α-pinene is unlikely the compound 
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responsible for the inhibitory activities of the EOs of L. luisieri, O. maritimus and L. 
eliasii observed in this study. 
Similar considerations can be made about other compounds present in two or more of 
the EOs tested. Limonene, for instance, represents 58.8% of the EO of T. villosa, but 
only 2.7% of the EO of L. eliasii. Nevertheless, this EO was effective in intestinal cells 
while that of T. villosa was inactive in both cell types.  
On the other hand, the EOs of L. luisieri and E. duriaei subsp. juresianum have distinct 
compositions, the first being rich in oxygenated monoterpenes, while the second is 
mainly composed of oxygenated and non-oxygenated sesquiterpenes. Nonetheless, 
they were both effective in reducing markers of inflammation in human chondrocytes, 
suggesting that distinct compounds are involved in the observed activities of these 
EOs.  
Moreover, we cannot discard the possibility that different components of the EOs act in 
synergy or in antagonism to modulate their overall activity, contributing to the apparent 
discrepancies described above. This possibility is even more plausible as some of 
these compounds, like limonene [Chi et al., 2012], have been shown to exert anti-
inflammatory effects in various cell and animal models. 
Taken together, the results presented indicate that two of the EOs studied, those of L. 
luisieri and E. duriaei subsp. juresianum, have significant cell type-specific anti-
inflammatory effects that can be useful for the development of tissue-selective anti-
inflammatory therapies. 
The results obtained also show that the EOs of L. luisieri and E. duriaei subsp. 
juresianum which were the most effective in inhibiting iNOS expression in human 
chondrocytes and/or intestinal epithelial cells, also decreased cytokine-induced NF-κB 
activation. Since NF-κB is essential for iNOS expression [Taylor et al., 1998], these 
results strongly suggest that the observed inhibition of iNOS is mediated, at least in 
part, by the inhibitory effects of these EOs on NF-κB activation. The concentrations of 
the EOs of L. luisieri and E. duriaei subsp. juresianum effective in inhibiting 
IL-1β-induced NF-κB activation in human chondrocytes were substantially higher than 
those that inhibited iNOS expression and NO production, suggesting that other 
mechanisms may contribute to the inhibitory activity of these EOs, at least in human 
chondrocytes. Since none of the EOs showed NO scavenging activity (data not 
shown), this can be discarded as a potential contributing mechanism. Other 
possibilities include direct inhibition of iNOS activity and inhibition of other signalling 
pathways that are required for iNOS expression in human chondrocytes [Mendes et al., 
2002c]. More studies are required to identify the specific molecular targets of the EOs 
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of L. luisieri and E. duriaei subsp. juresianum. On the other hand, since EOs are 
complex mixtures of chemically diverse compounds, it is possible that distinct 
components have different targets, so that the effects observed result from the 
combined actions of individual compounds. Future work will be directed at fractionating 
each of these EOs and elucidating the chemical composition and pharmacological 
activity of each fraction in order to identify the active compound(s) and their specific 
molecular targets, as well as potential pharmacological interactions. 
In summary, this study shows for the first time that the EOs of L. luisieri and E. duriaei 
subsp. juresianum efficiently inhibit NF-κB activation and the expression of its target 
genes, namely iNOS, in cells unrelated to the immune system. Moreover, these EOs 
display differential effects in relevant cell models of OA and IBD and in response to 
distinct inflammatory stimuli. These properties may be of great value in the 
development of new therapies with improved efficacy and selectivity towards distinct 
chronic inflammatory diseases, namely OA and IBD. 
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ANTI-INFLAMMATORY AND CHONDROPROTECTIVE ACTIVITY OF (+)-Α-PINENE: 
STRUCTURAL AND ENANTIOMERIC SELECTIVITY 
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ABSTRACT 
 
Previous studies have suggested that α-pinene, a common volatile plant metabolite, 
may have anti-inflammatory effects in human chondrocytes, thus exhibiting potential 
anti-osteoarthritic activity. The objective of this study was to further characterize the 
potential anti-osteoarthritic activity of selected pinene derivatives by evaluating their 
ability to modulate inflammation and extracellular matrix remodelling in human 
chondrocytes and to correlate the biological and chemical properties by determining 
whether the effects are isomer- and/or enantiomer-selective. To further elucidate 
chemicopharmacological interactions, the activities of other naturally occurring 
monoterpenes with the pinane nucleus were also investigated. At non-cytotoxic 
concentrations, (+)-α-pinene (1) elicited the most potent inhibition of the IL-1β-induced 
inflammatory and catabolic pathways, namely, NF-κB and JNK activation and the 
expression of the inflammatory (iNOS) and catabolic (MMP-1 and -13) genes. (−)-α-
Pinene (2) was less active than the (+)-enantiomer (1), and β-pinene (3) was inactive. 
E-Pinane (4) and oxygenated pinane-derived compounds, pinocarveol (5), myrtenal 
(6), (E)-myrtanol (7), myrtenol (8), and (Z)-verbenol (9), were less effective or even 
completely inactive and more cytotoxic than the pinenes tested (1−3). The data 
obtained show isomer- and enantiomer-selective anti-inflammatory and anti-catabolic 
effects of α-pinene in human chondrocytes, (+)-α-pinene (1) being the most promising 
for further studies to determine its potential value as an anti-osteoarthritic drug. 
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6.1 INTRODUCTION 
 
Osteoarthritis (OA) is estimated to affect 10−15% of the world population, being the 
leading cause worldwide of chronic disability in the elderly and also in those in the 
working age range.[Kaplan et al., 2013; Zhang and Jordan, 2010] OA is a multifactorial 
joint disease characterized by a progressive loss of the articular cartilage extracellular 
matrix and local inflammation that lead to cartilage destruction, loss of joint function, 
and pain.[Goldring and Otero, 2011] The huge socioeconomic burden of the disease 
and the absence of effective disease-modifying OA drugs have led to its inclusion in a 
group of priority diseases selected in the World Health Organization report “Priority 
Medicines for Europe and the World”, as commissioned by the European 
Commission.[Kaplan et al., 2013] In view of this, our previous study identified the 
essential oil from the leaves of Juniperus oxycedrus L. subsp. oxycedrus 
(Cupressaceae) as a promising source of compounds with potential anti-osteoarthritic 
activity. In particular, it was found that two fractions of this essential oil, one rich in α-
pinene (93%) and the other containing oxygenated mono- and sesquiterpenes, 
effectively inhibited nuclear factor-κB activation and the production of nitric oxide 
(NO),[Neves et al., 2009] which play major roles in promoting the inflammatory and 
catabolic responses in human articular chondrocytes that drive OA development and 
progression.[Fernandes et al., 2002; Goldring and Otero, 2011; Goldring et al., 2008] 
Several studies have attributed biological properties to α- pinene, including 
antimicrobial, anti-inflammatory,[Zhou et al., 2004a] apoptotic, and anti-metastatic 
effects,[Matsuo et al., 2011] but information concerning the activities of its enantiomers, 
as well as of the β-isomer, is scarce. To our knowledge, this is restricted to 
antibacterial, antifungal,[da Silva et al., 2012] and insecticide[Michaelakis et al., 2009] 
activities. Therefore, this study aimed to confirm that the previously described inhibitory 
effects of the essential oil of J. oxycedrus L. subsp. oxycedrus in human chondrocytes 
are due primarily to α- pinene and especially to determine whether those effects are 
enantio- and/or isomer-selective. For this purpose, (+)-α- pinene (1), (−)-α-pinene (2), 
the racemic α-pinene (1 and 2) OA,[Akhtar and Haqqi, 2011; Csaki et al., 2009] 
consisting of human articular chondrocytes treated with the pro-inflammatory and pro-
catabolic cytokine interleukin-1β (IL-1β).[Fernandes et al., 2002; Goldring and Otero, 
2011; Goldring et al., 2008] To further elucidate possible relationships between 
chemical structure and potential anti-osteoarthritic activity, other naturally occurring 
pinane derivative compounds were also included in this study, namely, (E)-pinane (4), 
pinocarveol (5), myrtenal (6), (E)-myrtanol (7), myrtenol (8), and (Z)-verbenol (9). Some 
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of these pinane derivatives were chosen since they are present in the oxygenated 
monoterpene containing fraction of J. oxycedrus subsp. oxycedrus essential oil found 
to be active on human chondrocytes.[Neves et al., 2009] 
Finally, and to further assess the potential anti-osteoarthritic activity of the test 
compound(s) found to be more active, their ability to modulate signalling pathways that 
lead to inflammation and articular cartilage degradation was evaluated. Given their 
central role in those pathways, nuclear factor-κB (NF-κB) and the mitogen-activated 
protein kinases (MAPKs), JNK, p38, and ERK, are attractive targets for the 
development of new drugs to effectively block OA progression.[Berenbaum, 2004; 
Goldring and Otero, 2011] Likewise, we evaluated the ability of the most active test 
compound to modulate the activity of these mediators and the expression of genes 
relevant in OA pathogenesis. The genes studied included inflammatory (inducible nitric 
oxide synthase, iNOS), catabolic (matrix metalloproteases, MMP-1 and -13), and 
anticatabolic mediators (tissue inhibitor of metalloproteases, TIMP-1) and extracellular 
matrix components (collagens I and II). 
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6.2 RESULTS AND DISCUSSION 
 
Since NO is a major inflammatory mediator and plays an important role in OA 
pathogenesis, while simultaneously representing a final end point of NF-κB 
activation,[Abramson, 2008; Berenbaum, 2004; Marcu et al., 2010] inhibition of its 
production in human chondrocytes is a facile screening method for the identification of 
NF-κB inhibitors with potential antiosteoarthritic activity. Thus, inhibition of IL- 1β-
induced NO production was used to discriminate active compounds at noncytotoxic 
concentrations as defined by evaluation of cell viability with the MTT reduction assay 
(Supporting Information).  
Supporting Information Figure. Chondrocyte viability in human chondrocytes 
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Chondrocyte treatment with 10 ng/mL IL-1β increased NO production significantly from 
10.6 ± 0.8 μg/mL in untreated control cells to 40.9 ± 3.6 μg/mL (n = 11; p < 0.0001). 
Treatment of the chondrocyte cultures with noncytotoxic concentrations (Supporting 
Information) of the test compounds revealed that only myrtenol (8) and (Z)-verbenol (9) 
had no effect on IL-1β-induced NO production, while the other compounds decreased 
NO production to a varying degree, at least, at the highest concentration tested (Figure 
6.1A). (+)-α-Pinene (1) decreased NO production in a concentration- dependent 
manner (p = 0.015 between the two concentrations tested), eliciting the highest 
inhibition of NO production at a concentration of 200 μg/mL, with a decrease to 31.5 ± 
2.6% (n = 10, p < 0.0001) relative to cells treated with IL-1β alone. At the same 
concentration, racemic α-pinene (3) decreased NO production to only 40.6 ± 1.9% (p = 
0.0011).  
 
Figure 6.1 Effect of α–pinene (1), β-pinene (2) and other pinane derivatives (3 – 9) on 
IL-1β-induced NO production (A) and effect of the active test compounds on iNOS 
protein (B) and mRNA (C) expression levels in primary human chondrocytes. Human 
chondrocyte cultures were left untreated (control, Ctrl) or treated with IL-1-β, 10 ng/mL, 
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for 24 h (A and B) or 6h (C), following pre-treatment for 30 min with the indicated 
concentrations of the test compounds or DMSO. Each column represents the mean ± 
SEM of at least, four independent experiments. *p <0.05, **p <0.01, ***p <0.001 relative 
to IL-1β-treated cells; §p <0.05, §§p <0.01, §§§p <0.001 relative to Ctrl; #p <0.05, ##p 
<0.01 between the conditions indicated. 
 
However, these results were not statistically different and are in the same range 
reported for the α-pinene-rich fraction of the essential oil from the leaves of J. 
oxycedrus subsp. oxycedrus. [Neves et al., 2009] 
On the other hand, (−)-α-pinene (2) and the racemic β- pinene (3) were active only at 
the highest concentrations tested (200 μg/mL), with much lower inhibitions (to 58.1 ± 
4.9%, p = 0.0001 and 76.8 ± 2.3%, p = 0.0098) than those elicited by either racemic α-
pinene (1 and 2) or its (+) enantiomer (1) at the same concentration. In contrast, (E)-
pinane (4), pinocarveol (5), myrtenal (6), and (E)-myrtanol (7), at the highest non-
cytotoxic concentration, elicited only relatively small decreases of IL-1β-induced NO 
production.  
These results show clear differences in activity among the compounds tested (Figure 
6.1A). In particular, it is noticeable that α-pinene is the most active, showing not only 
selectivity concerning the β-isomer (3), almost devoid of activity, but also enantiomeric 
selectivity, as (+)-α-pinene (1) was found to be more effective than the (−) enantiomer 
(2). 
To confirm these results and further elucidate the mechanism of action of the 
compounds that more effectively reduced NO production, the α-pinene enantiomers (1 
and 2) and (E) - pinane (4), effects on iNOS protein levels induced by IL-1β were 
evaluated. Paralleling the results relative to NO production, Figure 6.1B shows that at 
200 μg/mL (+)-α-pinene (1) elicited the greatest inhibition, decreasing iNOS protein 
levels to 24.4 ± 14.9% (p < 0.0001) relative to those found in cells treated with IL-1β 
alone. The highest concentrations tested of (−)-α-pinene (2) and (E)-pinane (4) elicited 
a smaller, but statistically significant, decrease of iNOS protein levels. (+)-α-Pinene (1) 
also extensively decreased IL-1β- induced iNOS mRNA levels (Figure 6.1C), indicating 
that reduction of iNOS protein and enzymatic activity likely occur through effects at or 
upstream of gene transcription.  
As human cartilage samples are limited, both in number and quantity, and a large 
number of cells is required, the human chondrocytic cell line, C-28/I2, was used to 
evaluate the ability of α-pinene enantiomers to inhibit IL-1β-induced NF-κB activation. 
This requires the phosphorylation and subsequent ubiquitination and proteassomal 
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degradation of an inhibitory protein, IκB-α (NF-κB inhibitor-α), which, in basal 
conditions, retains NF-κB dimers in the cytoplasm. Once IκB-α is degraded, the freed 
NF-κB dimers translocate to the nucleus and bind to specific sequences in the 
promoter region of target genes promoting their transcription.[Hayden and Ghosh, 
2008a] Treatment of the cells with 10 ng/mL IL-1β, for 5 min, induced a pronounced 
phosphorylation of IκB-α, indicating the activation of NF-κB, which, as expected, is 
barely detected in the untreated control cells (Figure 6.2A). 
 
Figure 6.2 Effect of α–pinene enantiomers (1 and 2) on IL-1β-induced NF-κB 
activation, evaluated as the levels of phosphorylated IκB-α (A) and NF-κB–DNA 
complexes (B). C28-I2 chondrocytic cells were left untreated (control, Ctrl) or treated 
with 10 ng/mL IL-1β, for 5 (A) or 30 min (B), following pre-treatment with or without 200 
µg/mL of the test compounds for another 30 min. Each column represents the mean ± 
SEM of three (A) or four (B) independent experiments. *p <0.05, **p <0.01, ***p <0.001 
relative to IL-1β-treated cells and §§p <0.01, §§§p <0.001 relative to Ctrl cells. 
 
The results presented in Figure 6.2A show that treatment with (+)-(1) and (−)-α-pinene 
(2) reduced IL-1β-induced IκB-α phosphorylation to 33.6 ± 3.1% (p = 0.002) and 58.4 ± 
5.4% (p = 0.017), respectively, relative to cells treated with IL-1β alone. Interestingly, 
each enantiomer inhibited IκB-α phosphorylation to approximately the same extent as 
iNOS expression and NO production, further corroborating that these two events are 
dependent on NF-κB activation and that the (+)-α enantiomer (1) is the most effective. 
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To confirm that inhibition of IκB-α phosphorylation by (+)-α-pinene (1) results in 
decreased NF-κB activity, the formation of specific NF-κB−DNA complexes was 
evaluated by an ELISA assay, as described in the Experimental Section. The results 
obtained indicated that this process suffers a dramatic increase upon stimulation with 
10 ng/mL IL-1β for 30 min (Figure 6.2B) and is effectively reduced by pre-treatment 
with 200 μg/mL (+)-α-pinene (1) (p = 0.0081). 
As other transcription factors, namely, AP-1,17,18 and signalling intermediates, such 
as JNK and p38 MAPKs,[Kristof et al., 2001; Marks-Konczalik et al., 1998; Mendes et 
al., 2002c] can be involved in the expression of iNOS, MMPs, and other genes relevant 
in OA pathogenesis,[Berenbaum, 2004; Han et al., 2001; Mengshol et al., 2000] the 
possibility that such pathways are also modulated by α-pinene enantiomers was 
investigated. For this, both compounds (1 and 2) were tested for their capacity to 
modulate IL-1β-induced JNK and p38 MAPK phosphorylation. The results obtained 
show that only the highest concentration of the α-pinene enantiomers (1 and 2) elicited 
a statistically significant decrease of IL-1β-induced JNK phosphorylation (51.3 ± 6.3%; 
p = 0.0015 and 65.8 ± 12.9%, p = 0.0452) (Figure 6.3A), while none of them affected 
p38 phosphorylation (Figure 6.3B). 
 
 
Figure 6.3 Effect of the α–pinene enantiomers on IL-1-induced JNK (A) and p38 MAPK 
(B) phosphorylation. Primary chondrocytes were left untreated (control, Ctrl) or were 
treated with 10 ng/mL IL-1β, for 5 min, following pre-treatment with or without the 
indicated concentrations of the α-pinene enantiomers. Each column represents the 
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mean ± SEM of four independent experiments. *p <0.05, **p <0.01, ***p <0.001 relative 
to IL-1β-treated cells. 
 
Since (+)-α-pinene (1) demonstrated the highest ability to inhibit IL-1β-induced NF-κB 
and JNK activation, which are required for the expression of MMPs-1 and -13 induced 
by IL- 1β,[Han et al., 2001; Mendes et al., 2002c] its ability to decrease these effects 
was also evaluated. As expected the expression of both genes increased significantly 
in response to IL-1β and was completely abolished by pre-treatment with 200 μg/mL 
(+)-α-pinene (1) (Figure 6.4A). 
To further investigate its potential anti-osteoarthritic activity, the effect of (+)-α-pinene 
(1) was also evaluated on the expression of TIMP-1, collagen I, and collagen II genes. 
Treatment of chondrocytes with 10 ng/mL IL-1β significantly decreased TIMP-1 (Figure 
6.4B) and collagen II (Figure 6.4C) mRNA levels to 59.5 ± 7.0% and 32.2 ± 3.8%, 
respectively, relative to untreated control cells, while the mRNA levels of the non-
cartilage specific collagen I were significantly increased to 378.39 ± 82.9% (Figure 
6.4C). Treatment with 200 μg/mL (+)-α-pinene (1) did not affect the expression of any 
of these genes, significantly (Figure 6.4B and C). Nevertheless, the mean mRNA levels 
of TIMP-1 and collagen I showed a tendency to reach control levels on (+)-α- pinene 
(1) treatment (Figure 6.4B and C). 
Several studies suggest that inhibition of MMP expression is sufficient to prevent the 
release of matrix components, like collagen II, and thus retard OA progression.[Piecha 
et al., 2010; Sabatini et al., 2005] Therefore, the ability of (+)-α-pinene (1) to decrease 
MMP-1 and -13 expression, even if not increasing TIMP-1 and collagen II expression, 
suggests that this compound can be effective in blocking cartilage destruction and, 
thus, OA progression. To determine further whether (+)-α-pinene (1) can restore the 
ability of chondrocytes to produce and maintain a normal articular cartilage matrix, the 
ratio of collagen II/collagen I mRNA levels was calculated as an index of chondrocyte 
differentiation, where the higher the ratio value, the more differentiated the 
phenotype.[Marlovits et al., 2004; Martin et al., 2001] Even though treatment with this 
compound increased the ratio 2.6-fold, indicating a tendency toward a more 
differentiated phenotype in (+)-α- pinene (1)-treated cells, the difference relative to the 
same ratio in cells treated with IL-1β alone did not reach statistical significance. 
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Figure 6.4 Effect of (+)-α-pinene (1) on IL-1β-induced changes in gene expression. 
mRNA levels of (A) MMP-1 and -13, (B) TIMP-1 and (C) collagen I and collagen II were 
evaluated by RT-PCR. Each column represents the mean ± SEM of, at least, four 
independent experiments in which human chondrocytes were left untreated (control, 
Ctrl) or treated for 12 h (A) or 24 h (B and C) with 10 ng/mL IL-1β, in the presence or 
absence of 200 µg/mL (+)-α-pinene (1). *p <0.05, **p <0.01, ***p <0.001 relative to IL-1β-
treated cells; §§p <0.01 and §§§p <0.001 relative to Ctrl cells. 
 
In summary, the results reported in this study showed enantiomeric-selective anti-
inflammatory and anticatabolic effects of (+)-α-pinene and derivatives in human 
chondrocytes. Of the compounds tested, (+)-α-pinene (1) showed the greatest efficacy 
to inhibit IL-1β-induced inflammatory and catabolic pathways, namely, NF-κB and JNK 
activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and -13) 
genes. Thus, (+)-α-pinene (1) deserves to be further investigated, namely, by 
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evaluating its pharmacokinetic and pharmacodynamic in vivo properties, in order to 
determine its potential as an antiosteoarthritic drug. Moreover, this study also shows 
that oxygenated pinane-derived compounds, namely, pinocarveol (5), myrtenal (6), (E)-
myrtanol (7), myrtenol (8), and (Z)-verbenol (9), are less effective or even completely 
inactive and more cytotoxic than the non-oxygenated counterparts tested. 
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CHAPTER 7.  
 
EVALUATION OF THE ANTI-INFLAMMATORY, ANTI-CATABOLIC AND PRO-
ANABOLIC EFFECTS OF E-CARYOPHYLLENE, MYRCENE AND LIMONENE IN A 
CELL MODEL OF OSTEOARTHRITIS 
 
 
 
 
Figure 7.0 Graphical Abstract 
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ABSTRACT 
The essential oils of Eryngium duriaei subsp. juresianum and Lavandula luisieri 
demonstrated anti-inflammatory properties in human chondrocytes. This study aimed at 
identifying active compounds and characterizing their antiosteoarthritic properties. E-
caryophyllene (1), myrcene (2) and limonene (3), present in the active fractions of 
these essential oils, were evaluated for their ability to modulate inflammatory, catabolic 
and anabolic processes in human chondrocytes. Myrcene (2) (IC50=37.3 μg/mL) and 
limonene (3) (IC50=85.3 µg/mL) inhibited IL-1β-induced nitric oxide production, but E-
caryophyllene was inactive. Myrcene, and limonene to a lesser extent, also decreased 
IL-1β-induced NF-κB, JNK and p38 activation and the expression of inflammatory 
(iNOS) and catabolic (MMP-1 and MMP-13) genes, while increasing the expression of 
anti-catabolic genes [TIMP-1 and -3 by myrcene (2) and TIMP-1 by limonene (3)]. 
Neither myrcene (2) nor limonene (3) increased the expression of cartilage-specific 
genes (collagen II and aggrecan), but both compounds prevented the increase in the 
non-cartilage specific, collagen I. Limonene (3) increased ERK1/2 activation by 30% 
which may be unfavorable, while myrcene (2) decreased it by 26%, relative to IL-1β-
treated cells. 
These data show that myrcene (2) has significant anti-inflammatory and anti-catabolic 
effects and, thus, may halt or, at least, slow down cartilage destruction and 
osteoarthritis progression. 
 
  
CHAPTER 7 
 
125 
 
7.1 INTRODUCTION 
 
Osteoarthritis (OA) is a multifactorial degenerative joint disease characterized by 
inflammation and progressive loss of the articular cartilage. It affects 10-15% of the 
world population and is a major cause of disability in the elderly, as well as in the 
workforce population.[Zhang and Jordan, 2010] Existing therapeutic approaches are 
mainly symptomatic, thus novel drugs with disease-modifying and chondroprotective 
properties are required to halt disease progression and decrease its huge socio-
economic impact.[Goldring and Goldring, 2007; Kaplan et al., 2013] 
Plant-derived compounds show important biological properties that can be explored 
in the context of OA for identification of compounds with potential anti-osteoarthritic 
activity.[Calixto et al., 2004; Khalife and Zafarullah, 2011] Among compounds of plant 
origin, those found in essential oils present favorable pharmacokinetic properties, 
namely lipophilicity and low molecular weight.[Miguel, 2010] Our previous studies have 
been focused in identifying essential oils with anti-inflammatory and anti-catabolic 
properties in human chondrocytes to be used as sources of compounds with potential 
anti-osteoarthritic activitya[Neves et al., 2009] In this context, we identified the essential 
oils of Eryngium duriaei subsp. juresianum and Lavandula luisieri as possessing anti-
inflammatory properties in human chondrocytes.a The current study aims at identifying 
the active compounds of these essential oils and further characterizing their 
pharmacological properties in human chondrocytes.  
For this, mechanisms relevant as pharmacological targets for the development of 
anti-osteoarthritic drugs need to be addressed. Although OA etiology is not yet 
completely understood, pro-inflammatory cytokines, like interleukin-1β (IL-1β), play a 
central role in disease development and progression by inducing the expression of 
cartilage matrix-degrading enzymes and impairing anabolic and anti-catabolic 
responses.[Goldring et al., 2008] The consequent upregulated degradative process, 
together with impaired reparative responses, results in progressive cartilage loss, the 
hallmark of OA, accompanied by alterations in other joint tissues. 
                                                     
a Rufino, A. T.; Ferreira, I. V.; Judas, F.; Salgueiro, L.; Lopes, M. C.; Cavaleiro, C.; Mendes, A. 
F. (submitted at Journal of Natural products _ Chapter 5). 
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Matrix metalloproteases (MMPs) and aggrecanases are the main enzymes responsible 
for hydrolyzing the major articular cartilage-specific matrix components, collagen II and 
aggrecan. This is accompanied by impaired reparative responses involving 
downregulation of the natural MMP inhibitors, the tissue inhibitor of metalloproteases 
(TIMP) family, and decreased synthesis of collagen II and aggrecan.[Troeberg and 
Nagase, 2012] Moreover, increased production of pro-inflammatory and pro-catabolic 
mediators, like nitric oxide (NO), amplifies and perpetuates cartilage 
destruction.[Boileau et al., 2002; Rosa et al., 2008; Sasaki et al., 1998] The 
transcription factor, Nuclear Factor-κB (NF-κB), and the family of mitogen-activated 
protein kinases (MAPK) play a central role in modulating the expression of those 
catabolic and inflammatory mediators [Goldring and Otero, 2011] and, thus, agents that 
suppress their activity have the potential to effectively decrease cartilage destruction 
and, therefore, OA progression.[Berenbaum, 2004] Furthermore, compounds that can 
also restore anabolic and anti-catabolic gene expression have the potential to promote 
cartilage repair. 
Therefore, we used primary human chondrocyte cultures stimulated with IL-1β as an in 
vitro cartilage degradation model that emulates the damage seen in OA. Using this 
model, we evaluated the inhibition of IL-1β-induced NO production as a simple 
screening assay to rapidly identify active fractions and compounds of the essential oils 
of E. duriaei subsp. juresianum and L. luisieri. Moreover and to further assess the anti-
osteoarthritic potential of the active compounds identified, we evaluated their ability to 
modulate IL-1β-induced signaling pathways involved in the expression of inflammatory 
and catabolic genes, namely activation of NF-κB and the MAPK family members, Jun 
terminal Kinase (JNK), p38 and Extracellular signal-Regulated Kinase 1/2 (ERK1/2). 
Then, we evaluated the ability of those compounds to counteract the effects of IL-1β on 
the expression of those genes, including inflammatory (iNOS), catabolic (MMP-1 and -
13), anti-catabolic (TIMP-1 and -3) and extracellular matrix (collagen I, and the 
cartilage matrix-specific, collagen II and aggrecan) genes in human articular 
chondrocytes. 
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7.2 RESULTS AND DISCUSSION 
 
In the current study, various fractions of the essential oils of E. duriaei subsp. 
juresianum and L. luisieri, whose full chemical compositions we previously reported, a 
were separated in amounts sufficient for pharmacological characterization. The 
composition of these fractions was fully elucidated and is reported in table 7.1. 
The fractions obtained were then tested at non-cytotoxic concentrations (Supporting 
Information) ranging from 10-50 μg/mL. The results (Figure 7.1A) show that the 
hydrocarbon-containing fractions (F1 and FA) of both essential oils decreased IL-1β-
induced NO production in a concentration-dependent manner, the highest 
concentrations achieving an inhibition of 55 and 75%, respectively, relative to cells 
treated with IL-1β alone. The other three fractions of the essential oil of L. luisieri also 
showed some inhibitory activity which, nonetheless, did not exceed 35% relative to IL-
1β-treated cells. Fractions F2.4 and F2.5 of the essential oil of E. duriaei subsp. 
juresianum were only tested at a concentration of 10 µg/mL, as higher concentrations 
were found to be cytotoxic (Supporting Information). These fractions, as well as fraction 
F2.7 at a concentration of 50 µg/mL, also significantly inhibited IL-1β-induced NO 
production, although to a lesser extent than found with F1. No significant effects were 
obtained with F2.3 at any of the concentrations tested. Therefore, the hydrocarbon-
containing fractions (F1 and FA) of both essential oils were considered the most 
promising for selection of compounds for further studies. 
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Supporting Information Figure: Effect of the fractions isolated from the essential oils 
of Eryngium duriaei subsp. juresianum and Lavandula luisieri (A) and of the isolated 
compounds E-Caryophyllene (1), myrcene (2) and limonene (3) (B) on human 
chondrocyte viability. Each column represents the mean ± SEM of at least four 
independent experiments where chondrocytes were treated with the indicated 
concentrations of the test compounds for 24 h together with IL-1β (10ng/mL) and cell 
viability accessed as described above. §P<0.05, §§P<0.01 relative to untreated control 
cells (Ctrl). 
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Table 7.1 Composition of E.duriaei subsp juresianum and L. luisieri Essential Oils Fractions 
 
E. duriaei subsp 
juresianum 
% 
 
 Lavandula luisieri % 
F1 
E- caryophyllene  29.5 
FA 
3.5-Dimethylene-1.4.4-
trimethylcyclopentene 
10.4 
α-neocallitropsene 50.2 α-pinene 26.9 
germacrene D 2.7 -pinene 3.5 
β- selinene 2.7 -3-carene 5.2 
Bicyclogermacrene 6.3 Limonene 3.0 
Limonene 0.1 E--ocimene 1.6 
Myrcene T Cyclosativene 2.0 
F2.3 
Octanal 9.3 -copaene 2.2 
caryophyllene oxide  31.6 E-caryophyllene 3.9 
isocaryophyllene-14-al 44.4 Alloaromadendrene 1.2 
F2.4 
unknown 1 22.8 -selinene 2.9 
Spathulenol 9.8 -selinene 3.5 
14-hydroxy-β-
caryophyllene 
38.0 -cadinene 6.7 
unknown 2 6.6 selina-3.7(11)-diene 4.5 
F2.5 
unknown 1 8.8 
FB 
trans-α-necrodyl acetate 30.5 
Spathulenol 21.4 lavandulyl acetate 8.2 
14-hydroxy-β-
caryophyllene 
45.2 cis-α-necrodyl acetate 3.8 
unknown 2 2.9 1.8-cineole 32.4 
unknown 3 3.7 lyratyl acetate 2.4 
F2.7 
caprylic acid 8.1 
FC 
1.10-di-epi-cubenol 4.8 
buthyhidroxytoluene 
(solvent contaminant) 
8.6 
 
2.3.4.4-tetramethyl-5-methylene-cyclopent-
2-enone 
8.6 
tetradecanoic acid 40.5 Linalool 11.9 
hexadecanoic acid 8.5 epi-cubenol 1.3 
 
trans-α-Necrodol 20.1 
Lavandulol 2.2 
viridiflorol  8.2 
T-cadinol 2.4 
T-muurolol 4.4 
cis-linalool oxide (THP) 3.2 
unkown (C10H16O) 2.3 
1.1.2.3-tetramethyl-4-hidroxymethyl-2-
ciclopentene 
7.2 
14-norcadin-5-ene-4-one (Isomer) 4.3 
FD 
trans- linalool oxide (THF) 12.6 
-terpineol 7.1 
Verbenone 2.5 
α-muurolol 1.3 
trans-verbenol 3.1 
globulol  2.5 
-cadinol 48.7 
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Figure 7.1 Effect of the fractions isolated from the essential oils of Eryngium duriaei 
subsp. juresianum and Lavandula luisieri (A) and of the isolated compounds E-
caryophyllene (1), myrcene (2) and limonene (3) (B) on IL-1β-induced NO production. 
Human chondrocytes were left untreated (Control, Ctrl) or treated with IL-1-β, 10ng/mL, 
for 24 h, following pre-treatment for 30 min with the indicated concentrations of each 
fraction or compound. Each column represents the mean ± SEM of, at least, four 
independent experiments. *p <0.05, **p <0.01, ***p <0.001 relative to IL-1β-treated cells; 
§p <0.05, §§p <0.01, §§§p <0.001 relative to Control cells; ##p <0.01, ###p <0.001 between 
the conditions indicated. 
 
As shown in table 7.1, these fractions (FA and F1) are composed of monoterpene and 
sesquiterpene hydrocarbons, chiefly α-pinene and 3,5-dimethylene-1,4,4-
trimethylcyclopentene, and E-caryophyllene (1), -neocallitropsene, germacrene D, -
selinene and bicyclogermacrene, respectively. Of these compounds, only α-pinene and 
E-caryophyllene (1) are readily available from commercial sources and we have 
recently reported the differential activity of α-pinene enantiomers as inhibitors of pro-
inflammatory and catabolic pathways in human chondrocytes.[Rufino et al., 2014] 
Nonetheless, both essential oils have other minor components in common, namely the 
monoterpene hydrocarbons, myrcene (2) and limonene (3), which were thus selected 
for pharmacological evaluation and comparison with the effects of α-pinene previously 
reported.[Rufino et al., 2014] Thus, E-caryophyllene (1), myrcene (2) and limonene (3), 
obtained from commercial sources, were screened for their ability to inhibit IL-1β-
induced NO production. 
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The results obtained (Figure 7.1B) show that, at non-cytotoxic concentrations 
(Supporting Information), myrcene (2) and limonene (3) effectively inhibited IL-1β-
induced NO production, while E-caryophyllene (1) had no significant effect at any of the 
concentrations tested. This finding was somewhat unexpected as this compound has 
been reported to exert anti-inflammatory effects by activating cannabinoid CB2 
receptors,[Bento et al., 2011; Medeiros et al., 2007] while endogenous and synthetic 
cannabinoids have been reported to decrease inflammation in animal models of 
arthritis[Sumariwalla et al., 2004] and to inhibit IL-1-induced NO production in bovine 
chondrocytes.[Mbvundula et al., 2005] 
Since myrcene (2) and limonene (3) showed inhibitory activity towards IL-1β-induced 
NO production, various non-cytotoxic concentrations were then tested to determine the 
respective concentration required to inhibit NO production by 50% (IC50) and thus, to 
compare their relative potencies. We found that myrcene (2) has an IC50 value (37.3  
1.1 μg/mL) lower than that of limonene (3) (IC50 = 85.3  1.2 µg/mL), thus indicating a 
higher potency. 
To determine whether the observed inhibition of NO production by myrcene (2) and 
limonene (3) is due to inhibition of iNOS expression, its mRNA (Figure 7.2A) and 
protein (Figure 7.2B) levels were evaluated. Treatment with myrcene (2), 50 µg/mL, 
significantly diminished IL-1β-induced iNOS mRNA and protein levels by 78% and 
69%, respectively, while inhibition by limonene (3), even at a concentration four fold 
higher, did not exceed 39% and 60%, respectively, further confirming the higher 
potency of myrcene (2). 
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Figure 7.2 Effect of myrcene (2) and limonene (3) on IL-1β-induced iNOS protein (A) 
and mRNA (B) levels in human chondrocytes left untreated (Control, Ctrl) or treated 
with IL-1-β, 10 ng/mL, for 24 h (A) or 6 h (B), following pre-treatment for 30 min with the 
indicated concentrations of the test compounds. Each column represents the mean ± 
SEM of, at least, four independent experiments. A representative image is shown. *p 
<0.05, ***p <0.001 relative to IL-1β-treated cells; §p <0.05, §§p <0.01 relative to Control 
cells. 
 
To further elucidate the mechanisms by which the two compounds (2 and 3) inhibit 
iNOS expression and to evaluate their potential as anti-osteoarthritic drugs, their ability 
to inhibit IL-1β-induced NF-κB activation was determined. NF-κB activation requires the 
phosphorylation, ubiquitination and proteassomal degradation of its natural inhibitor, 
NF-κB Inhibitor-α (IκB-α), which, in unstimulated cells, retains NF-κB dimers in the 
cytoplasm. Once IκB-α is degraded, the freed NF-κB dimers translocate to the nucleus 
and bind to specific sequences in the promoter region of target genes promoting their 
transcription.[Hayden and Ghosh, 2008b] Thus, we evaluated the protein levels of 
phosphorylated and total IκB-α by western blot and the binding of the freed NF-κB 
dimers to a specific DNA sequence by ELISA. 
Since human cartilage samples are scarce and a large number of cells is required, the 
ability of the test compounds to inhibit IL-1β-induced NF-κB-DNA binding was 
evaluated in the human chondrocytic cell line, C-28/I2, while the levels of 
phosphorylated and total IκBα were evaluated in primary human chondrocytes. The 
results show that treatment with IL-1β dramatically increased IκB-α phosphorylation 
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(Figure 7.3A) and decreased total IκB-α levels, reflecting its almost complete 
degradation (Figure 7.3B), followed by increased NF-κB-DNA binding (Figure 7.3C). 
Treatment with Bay 11-7082 (Bay), a specific NF-κB inhibitor that selectively prevents 
IκB-α phosphorylation, or with the test compounds markedly reduced IL-1β-induced 
IκB-α phosphorylation (Figure 7.3A) and degradation (Figure 7.3B), as well as NF-κB–
DNA binding (Figure 7.3C). Interestingly, although the degree of inhibition of IκB-α 
phosphorylation and of NF-κB-DNA binding achieved with Bay was significantly higher 
than that obtained with myrcene (2) and limonene (3), IκB-α degradation was similarly 
decreased by the three compounds. 
 
Figure 7.3 Effect of myrcene (2) and limonene (3), on IL-1β-induced NF-κB activation, 
evaluated as the levels of phosphorylated (A) and total (B) IκB-α and NF-κB–DNA 
complexes (C). C28-I2 cells were left untreated (Control, Ctrl) or treated with IL-1β, 10 
ng/mL, for 5 min (A) or 30 min (B and C) following pre-treatment with or without the test 
compounds or the specific NF-κB inhibitor, Bay 11-7082 (Bay, 5 µM). Each column 
represents the mean ± SEM of three to five independent experiments. *p <0.05, **p 
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<0.01 ***p <0.001 relative to IL-1β-treated cells; §p <0.05, §§§p <0.001 relative to Control 
cells. 
 
Together with NF-κB activation, signalling pathways involving MAPK activation also 
play an important role in the proteolytic cartilage degradation process, namely in the 
expression of MMPs.[Mengshol et al., 2000] Thus, the ability of the test compounds (2 
and 3) to inhibit IL-1-induced MAPK activation was assessed by evaluating their 
phosphorylation levels.  
Myrcene (2) and limonene (3) showed quite distinct effects on IL-1β-induced JNK 
(Figure 7.4A), p38 (Figure 7.4B) and ERK1/2 (Figure 7.4C) phosphorylation. Myrcene 
(2) significantly reduced IL-1β-induced phosphorylation of the three MAPKs by 
approximately 33%, 26% and 26%, respectively, while limonene (3) effectively reduced 
the phosphorylation of p38 by near 39%, but increased that of ERK1/2 by 30% and had 
no significant effect on JNK phosphorylation. 
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Figure 7.4 Effects of myrcene (2) and limonene (3) on IL-1β- induced activation of 
JNK, p38 and ERK1/2 in human chondrocytes. Phosphorylated levels of JNK (A), p38 
(B) and ERK (1/2) (C) were analyzed in total cell extracts of human chondrocytes left 
untreated (Control, Ctrl) or treated for 5 min with IL-1β, 10 ng/mL, following a pre-
treatment for 30 min with the indicated concentrations of myrcene, limonene or a 
specific inhibitor of each MAPK. Each column represents the mean ± SEM of, at least, 
four independent experiments. Representative images are shown. **p <0.01, ***p <0.001 
relative to IL-1β-treated cells and §§§p <0.001 relative to Control cells. iJNK: SP600125 
(20 µM); ip38: SB203580 (20 µM); iERK: U0126 (10 µM). 
 
Reports on pharmacological properties of limonene (2) are scarce, but it has been 
shown to have antimicrobial properties [Bevilacqua et al., 2010] and anti-inflammatory 
effects in a mouse model of LPS-induced acute lung injury by suppressing MAPK and 
NF-κB pathways[Chi et al., 2012]. The results presented here only partially agree with 
this study, since limonene (3) inhibited NF-κB and p38 activation, but did not affect IL-
1β-induced JNK and actually potentiated ERK1/2 activation, suggesting that this 
compound (3) has cell and/or stimulus specific effects. On the other hand, ERK1/2 is 
required for a number of cellular processes, including activation of c-fos expression 
which, among other functions, is involved in cell survival.[Karin et al., 1997; Shaulian 
and Karin, 2002] Whether increased activation of ERK1/2 by limonene (3) contributes 
to enhance chondrocyte survival was not addressed in this study, but is an interesting 
possibility to study further, as increased chondrocyte death is a relevant feature of 
OA.[Johnson et al., 2008] Nonetheless, since ERK1/2 has also been shown to inhibit 
proteoglycan synthesis and promote inflammatory responses in chondrocytes,[Scherle 
et al., 1997] the net effect resulting from its induction by limonene (3) is likely 
undesirable, compromising its potential utility as a therapeutic agent in OA. 
Then, we evaluated the ability of the compounds tested (2 and 3) to counteract the 
effects of IL-1β on the expression of catabolic, anti-catabolic and extracellular matrix 
genes, which, at least in part, are mediated by NF-κB and the MAPKs.[Goldring and 
Otero, 2011] As expected, treatment of human chondrocytes with IL-1β (10 ng/mL) 
increased MMP-1 and -13 mRNA levels by nearly 9- and 5-fold, respectively (Figure 
7.5A), while decreasing TIMP-1 and -3 expression (Figure 7.5B). Myrcene (2) 
decreased the mRNA levels of both MMPs by nearly 60%, relative to IL-1β, while 
limonene (3) reduced MMP-1 and -13 levels by 51% and 39%, respectively. 
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Nevertheless, the reduction of MMP-13 levels elicited by limonene (3) did not reach 
statistical significance. 
On the other hand, limonene (3) did not significantly change the inhibitory effect of IL-
1β on TIMP-1 and -3 mRNA levels, even though it showed a tendency to increase 
TIMP-1 levels that did not reach statistical significance. On the contrary, myrcene (2) 
not only completely reversed the inhibitory effect exerted by IL-1β, as it effectively 
increased TIMP-1 and -3 levels approximately 2- and 1.3-fold above those in untreated 
control cells, respectively, which correspond to even larger increases if compared to 
TIMP-1 and -3 mRNA levels in cells treated with IL-1β alone. 
 
Figure 7.5 Effect of myrcene (2) and limonene (3) on IL-1β-induced changes in the 
expression of catabolic and anti-catabolic genes. mRNA levels of MMP-1 and -13 (A) 
and TIMP-1 and -3 (B) were evaluated by RT-PCR. Each bar represents the mean ± 
SEM of, at least, four independent experiments in which human chondrocytes were left 
untreated (Control, Ctrl) or treated for 12 h (A) or 24 h (B) with IL-1β, 10 ng/mL, in the 
presence or absence the indicated compounds. *p <0.05, **p <0.01, ***p <0.001  relative 
to IL-1β-treated cells and §p <0.05, §§p <0.01, §§§p <0.001 relative to Control cells. 
 
To assess the potential ability of the test compounds to inhibit the deleterious effects of 
IL-1β in anabolic responses that are essential for repair of damaged articular cartilage, 
the expression of collagen II and aggrecan was evaluated. Furthermore, the ability of 
the test compounds to decrease the expression of the non-cartilage specific, collagen I 
gene, induced by IL-1β, was also evaluated. Chondrocyte treatment with 10 ng/mL IL-
1β, for 24 h, significantly increased collagen I mRNA levels, while decreasing those of 
collagen II and aggrecan, relative to untreated control cells (Figure 7.6). Treatment of 
human chondrocytes with myrcene (2) or limonene (3) caused no significant changes 
CHAPTER 7 
 
137 
 
on collagen II (Figure 7.6A) and aggrecan (Figure 7.6B) mRNA levels compared to 
those in cells treated with IL-1β alone. Nonetheless, both treatments were able to 
completely abolish or even reverse the increase in collagen I mRNA levels induced by 
IL-1β. 
 
Figure 7.6 Effect of myrcene (2) and limonene (3) on IL-1β-induced changes in the 
expression of extracellular matrix genes. mRNA levels of collagen I and collagen II (A) 
and aggrecan (B) were evaluated by RT-PCR. Each bar represents the mean ± SEM 
of, at least, four independent experiments in which human chondrocytes were left 
untreated (Control, Ctrl) or treated for 24 h with IL-1β, 10 ng/mL, in the presence or 
absence of the indicated compounds. *p <0.05, ***p <0.001 relative to IL-1β-treated cells 
and §§p <0.01, §§§p <0.001 relative to Control cells. 
 
Taken together, the results presented indicate that myrcene (2) is more effective than 
limonene (3) in preventing inflammatory and catabolic responses, namely iNOS 
expression and NO production, and MMP-1 and -13 expression, induced by IL-1β in 
human chondrocytes, likely reflecting, at least in part, the stronger inhibition of NF-κB 
and the three MAPKs. These findings are in agreement with another study that 
reported anti-inflammatory properties of myrcene (2) in a mouse model of pleurisy 
induced by zymosan and bacterial lipopolysaccharide where it inhibited the production 
of NO and inflammatory cytokines.[Souza et al., 2003] Moreover, myrcene (2), but not 
limonene (3), caused a net increase in the expression of the anti-catabolic genes, 
TIMP-1 and -3, which in combination with the decrease in MMP-1 and -13 expression 
can cause a significant reduction of the catabolic milieu characteristic of OA.  
On the other hand, myrcene (2), unlike limonene (3), also completely prevented the 
increase in collagen I induced by IL-1β. Collagen I is not normally found in articular 
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cartilage and its expression is associated with chondrocyte dedifferentiation, a process 
that involves several alterations of chondrocyte gene expression and morphology and 
leads to the formation of fibrocartilage, increasing in OA.[Martin et al., 2001] Therefore, 
even though it did not increase the specific anabolic responses of human 
chondrocytes, myrcene (2) may be effective in preventing chondrocyte dedifferentiation 
associated with increased collagen I expression, while decreasing inflammatory and 
catabolic processes directly involved in cartilage destruction. 
In comparison with (+)-α-pinene,[Rufino et al., 2014] myrcene (2) shows potential 
advantages as, besides inhibiting iNOS expression and activity and NF-κB and JNK 
activation to a similar extent, this compound can further decrease ERK1/2 and p38 
activation and increase anti-catabolic responses, namely TIMP-1 and -3 expression, 
while promoting the maintenance of the differentiated chondrocyte phenotype, as it 
also decreased collagen I expression. Nonetheless, none of the compounds tested (2 
and 3), nor (+)-α-pinene, seem effective in promoting the expression of articular 
cartilage matrix-specific genes. 
In summary, the results presented suggest that myrcene (2) may be useful to halt or, at 
least, slow down cartilage destruction and, thus, OA progression, although it is unlike to 
promote the repair of areas already damaged. 
. 
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CHAPTER 8.  
DISCUSSION AND CONCLUSION 
 
8.1 GENERAL DISCUSSION 
 
Research on osteoarthritis in the last few years have been focused in particular 
mechanisms underlying the course of the disease that can be related to particular risk 
factors or events. This is essential for a better understanding of the intrinsic 
mechanisms of specific phenotypes and, in that way, to enable the development of new 
drugs targeted to the deregulated molecular processes responsible for disease onset 
and progression that can prevent or halt OA and, consequently, reduce its individual 
and socio-economic costs. 
The association between Diabetes and the development and progression of OA is 
increasingly clear. Independently of the glucose requirements for the plastic and 
metabolic needs of chondrocytes, hyperglycemia has been shown to induce 
deleterious effects in human chondrocytes. In diabetes, especially in uncontrolled type 
2 diabetes, chronic hyperglycemia is the major hallmark and has been shown to 
directly lead to diabetic complications, including those with inflammatory characteristics 
as retinopathy, atherosclerosis or β-cell deterioration. The inflammatory process also 
plays a central role in OA pathogenesis since the deregulated pro-inflammatory 
mediators and, in particular, cytokine activities likely contribute to the disruption of the 
balance between anabolic and catabolic processes of chondrocytes that lead to the 
joint destruction characteristic of OA.  
In this context, this work aimed to contribute to elucidate how extracellular glucose 
levels are sensed by human chondrocytes, in particular by determining the role of 
potassium channels in this process, and to further understand the mechanisms by 
which hyperglycemia induces cartilage damage, unraveling in that way possible 
pathological mechanisms and potential pharmacological targets of DM-associated OA. 
Moreover, molecules, from plant origin were studied to assess their anti-inflammatory 
and chondroprotective activities that can be explored for development of new drugs 
with disease-modifying osteoarthritis properties. 
In general, the results presented in chapters 3 and 4 show that: 
 Human chondrocytes of any OA grade present heterogeneous K(ATP) 
channels, with Kir6.2 and SUR2B being the major subunits expressed. 
 The activity of K(ATP) channels influences the abundance of the major glucose 
transporters, GLUT-1 and GLUT-3, in normal chondrocytes, but did not affected 
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glucose transport, suggesting that these channels participate in a glucose 
sensing apparatus that regulates GLUT levels which, by themselves, are not 
sufficient to adjust glucose transport capacity. 
 Chondrocytes of increasing OA grade are less responsive to changes in K(ATP) 
channel activity.  
 Exposure of human chondrocytes to high, hyperglycemia-like glucose 
concentrations induces the expression of pro-inflammatory mediators, namely 
IL-1β, TNF-α and iNOS, accompanied by increased NO production, in a 
mechanism, at least partially, mediated by NF-κB. 
 Insulin, not only does not prevent the pro-inflammatory effects of hyperglycemia 
in human chondrocytes, as, in supraphysiologic concentrations, it can induce 
NF-κB activation by itself  
Finally, the results presented in chapters 5, 6 and 7 show that: 
 The essential oils of Lavandula luisieri and Eryngium duriaei subsp. juresianum 
display important anti-inflammatory properties, namely, significant inhibition of 
IL-1β induced iNOS expression, NO production and NF-κB activation in human 
chondrocytes. Likewise, these essential oils may be of great value in the 
development of new therapies or as sources of active compounds for the 
treatment of chronic inflammatory diseases, like OA. 
 (+)-α-pinene, showed the most potent chondroprotective and anti-inflammatory 
activities among its isomers, enantiomers and other naturally occurring 
compounds derived from the pinane nucleus, by significantly inhibiting IL-1β-
induced inflammatory and catabolic pathways, namely, NF-κB and JNK 
activation and the expression of inflammatory (iNOS) and catabolic (MMP-1 and 
-13) genes. 
 Limonene and especially Myrcene, natural compounds found in the essential 
oils of Eryngium duriaei subsp juresianum and Lavandula luisieri, showed 
interesting anti-inflammatory and anti-catabolic properties, namely inhibition of 
IL-1β-induced expression of pro-inflammatory and catabolic mediators, namely 
NO, iNOS, MMP-1 and -13, and pathways as NF-κB and p38 MAPK.  
 Myrcene further inhibits the phosphorylation of JNK and ERK MAPKs which 
possibly contributes to the inhibition of pro-inflammatory, pro-catabolic and 
chondrocyte dedifferentiation genes, namely the expression of collagen type I, 
as well as to relieve the inhibition of TIMP-1 and -3 expression caused by IL-1β. 
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Considering the objectives proposed, the findings that either hyperglycemia or 
hyperinsulinemia, as well as the two combined, activate NF-κB, the major pro-
inflammatory signalling pathway, are by themselves main mechanisms that can shift 
the chondrocyte homeostasis towards the catabolic program leading to OA 
development and/or progression. Among the specific molecular events that may 
underlie this response, the results obtained demonstrate that K(ATP) channels are 
involved in glucose sensing, playing a role in the regulation of glucose transporter 
availability in human chondrocytes which, nonetheless, is not sufficient to adjust 
glucose transport in response to changes in its extracellular concentration. Thus, the 
observed lack of response of chondrocytes of increasing age/OA grade to modulators 
of K(ATP) channel activity, namely glibenclamide, a sulfonylurea drug used in DM 2 
therapy as an insulin secretagogue, implies that in patients under this kind of therapy, 
chondrocytes may still be susceptible to the deleterious effects caused not only by 
hyperglycemia episodes, even occurring sporadically, as by hyperinsulinemia. 
Nonetheless, glibenclamide has also been shown to decrease high glucose-induced IL-
1β production in pancreatic β cells [Zhou et al., 2010] which, if also occurring in 
chondrocytes, may counteract the pro-inflammatory effects of hyperglycemia and 
hyperinsulinemia. More studies are clearly required to elucidate the effects of anti-
diabetic drugs in human chondrocytes, which will contribute to fully assess their 
risk/benefit and inform the rationale therapy of both conditions. 
On the other hand and even though the specific molecular events were not elucidated 
in this work, several other mechanisms may regulate glucose transport and metabolism 
and mediate the effects of hyperglycemia in chondrocytes. Such mechanisms deserve 
to be further investigated as they may disclose relevant targets both for prevention and 
treatment of DM-associated OA. Among those potential mechanisms, AMP-activated 
protein kinase (AMPK) and Silent Information Regulator 2 type 1 or sirtuin 1 (SirT1) 
may play important roles. 
AMPK is a metabolic sensor in a wide variety of cells that becomes activated during 
metabolic stress. At least in pancreatic β cells, K(ATP) channels and AMPK cooperate 
to regulate the energetic status [Lim et al., 2009]. Moreover, AMPK also seems to play 
an important role in regulating the mechanisms involved in glucose transport in 
response to hyper or hypoglycemic conditions [Lim et al., 2009; McCrimmon et al., 
2004; Ning et al., 2011]. Activation of AMPK has been shown to increase glucose 
transport in various cells by promoting the recruitment of GLUT-4 [Li et al., 2004] or 
GLUT-1 [Xi et al., 2001] to the plasma membrane. AMPK is expressed and 
constitutively active in normal, but is decreased in human OA knee articular 
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chondrocytes and cartilage [Terkeltaub et al., 2011]. So, it is possible that AMPK 
participates in the glucose sensing apparatus in chondrocytes that also includes 
K(ATP) channels, regulating, at least in part, GLUT trafficking to the plasma membrane 
and glucose uptake. Further studies will be necessary to elucidate the role of AMPK in 
the regulation of glucose transport in chondrocytes in normal and osteoarthritic 
conditions and whether modulation of its activity can have beneficial effects on 
chondrocyte functions under hyperglycemia. 
SirT1 is a deacetylase that fine tunes many cellular biochemical processes through its 
capacity to interact and modify various histone and non-histone proteins, playing 
important roles in the coordination of the response to low calorie intake and in cellular 
survival. On the other hand, under high glucose conditions, SirT1 expression and 
activity are decreased in many cells, contributing to cell senescence and dysfunction 
[Ceolotto et al., 2014; Servillo et al., 2013]. Accordingly, SirT1 has been associated 
with metabolic and aging-related diseases, including DM 2 [Donath, 2014] and OA 
[Dvir-Ginzberg and Steinmeyer, 2013]. SirT1 has been shown to promote cartilage 
extracellular matrix synthesis [Dvir-Ginzberg et al., 2011] and chondrocyte survival 
[Gabay et al., 2012], even under pro-inflammatory stress conditions. Furthermore, 
SirT1 has been associated with anti-inflammatory effects induced by various stimuli, 
including high glucose, in many cells through its ability to inhibit NF-κB [Kauppinen et 
al., 2013; Liu and McCall, 2013]. Recent studies showed that the same mechanism is 
also relevant in cell and animal models of OA [Lim et al., 2012] and inflammatory 
arthritis [Wang et al., 2014]. Inhibition of NF-κB by SirT1 seems to occur through, at 
least, two distinct mechanisms. The first is deacetylation of the p65 subunit of NF-kB 
directly by active SirT1 while the second involves activation of other intermediates, 
namely AMPK, PPAR-α and PGC-1α, which stimulate oxidative energy production and 
also inhibit NF-κB activity [Kauppinen et al., 2013]. Thus, by impairing SirT1 expression 
and activity, high glucose can induce NF-κB and the subsequent expression of pro-
inflammatory genes, like IL-1β and TNF-α, as we observed. Nonetheless, other 
mechanisms are also likely involved as SirT1 impairment may not be sufficient to 
explain the inability of OA/aged chondrocytes to downregulate glucose transport and 
prevent its intracellular accumulation when exposed to hyperglycemia-like conditions. 
Nonetheless, the role of SirT1 and its downstream effectors, namely AMPK, in the 
adaptation of chondrocytes to high glucose deserves to be further investigated as it can 
disclose an important therapeutic target for DM-associated OA. 
From another point of view, our results show that the inflammatory response induced 
by high glucose in human chondrocytes is not distinct from that induced by other 
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stimuli, from ageing of chondrocytes to abnormal mechanical forces [Goldring and 
Otero, 2011], that play significant roles in OA pathophysiology. These triggering factors 
not only contribute to irreversible joint damage (progression), but importantly, also to 
the initiation/onset phase, wherein the homeostatic balance between anabolic and 
catabolic functions becomes disrupted. Our work thus points to pro-inflammatory 
cytokines, namely IL-1β and TNF-α, as common mediators of DM-associated OA.  
Given their central role in OA development and progression, these mediators and the 
signalling pathways that they initiate are likely main targets for the development of new 
drugs with disease-modifying properties for OA treatment. Therefore, we used IL-1β to 
imitate those processes in vitro, so as to evaluate the anti-inflammatory, anti-catabolic 
and pro-anabolic effects of compounds of plant origin. 
The initial screening assays showed that essential oils have interesting anti-
inflammatory effects and thus can be important sources of compounds with anti-
osteoarthritic properties. Among the essential oils tested, those of Lavandula luisieri 
and Eryngium duriaei subsp. juresianum presented the best properties, reason why 
they were further studied. Screening of fractions of these essential oils containing 
distinct families of compounds showed that in both cases, the most active fractions are 
composed of mono- and sesquiterpene hydrocarbons, respectively, while fractions 
containing oxygenated mono- and sesquiterpenes were less or completely inactive. 
Finally, the screening of some commercially available compounds found in the active 
fractions, allowed to identify myrcene and limonene as potential anti-inflammatory and 
anti-catabolic compounds in human chondrocytes. Also (+)-α-pinene was shown to 
have anti-inflammatory properties in human chondrocytes being the active enantiomer 
of the α-pinene racemic mixture, previously presented by our group as showing anti-
inflammatory properties in this cells [Neves et al., 2009].  
Among those compounds, myrcene showed to be the most promising as a lead 
candidate for further development of new drugs that can halt OA progression. Even 
though the 3 compounds showed ability to significantly reduce some of the major pro-
inflammatory and pro-catabolic mediators (NO, iNOS, MMP-1 and MMP-13) and 
pathways (NF-κB) involved in the pro-inflammatory stress-related responses of 
chondrocytes that contribute to OA onset and progression, myrcene was additionally 
able to increase the anti-catabolic expression of the MMP inhibitors, TIMP-1 and -3, 
and to further decrease the activation of the MAPK pathways (p38 and ERK1/2 in 
relation to (+)α-pinene and JNK and ERK1/2 in relation to limonene)deeply involved in 
the expression of catabolic mediators. 
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Moreover, even though none of the compounds seemed to be effective in restoring the 
synthesis of ECM components, myrcene may contribute to the maintenance of the 
differentiated chondrocyte phenotype and to prevent the formation of fibrocartilage by 
decreasing the expression of type I collagen. Further studies are needed to determine 
if the effects observed result from the action of those compounds on a common single 
molecular target upstream of all the signalling pathways evaluated or, on the other 
hand, if they result from the combined action on various components of those signalling 
pathways. Moreover, it will also be interesting to understand whether these 
compounds, belonging to the same broad class of organic compounds, the terpenes, 
act on the same molecular target or not. Future work can also involve the evaluation of 
the observed myrcene properties in vivo using appropriate animal models of OA, as the 
model induced by intra-articular injection of mono-iodoacetate in rats or the surgical 
induction by transecting the anterior cruciate ligament [Bendele, 2001]. 
Furthermore, to establish a proof of concept for the efficacy of myrcene in Diabetes-
associated OA, it would also be interesting to induce OA in a model of non-obese type 
2 diabetes, as the Goto-Kakizaki rat model which presents mild hyperglycemia, insulin 
resistance and hyperinsulinemia [Akash et al., 2013], and evaluate the ability of the 
compound to prevent OA development and/or to stop its progression. 
In summary, a comprehensive view of the results suggests that if, on one hand, altered 
glucose sensing mechanisms and high glucose exposure lead to an increased 
expression of inflammatory mediators and pathways in chondrocytes, establishing a 
new link between DM and OA and supporting the existence of a DM-induced OA 
phenotype, on the other hand, those inflammatory and catabolic mediators and 
signalling pathways are major targets for the development of new drugs with disease-
modifying OA properties, myrcene being an interesting lead compound for that 
purpose. 
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